|
US6908744B1
(en)
*
|
2000-03-14 |
2005-06-21 |
Regeneron Pharmaceuticals, Inc. |
Methods of stimulating cartilage formation
|
|
US6596541B2
(en)
|
2000-10-31 |
2003-07-22 |
Regeneron Pharmaceuticals, Inc. |
Methods of modifying eukaryotic cells
|
|
US20050144655A1
(en)
|
2000-10-31 |
2005-06-30 |
Economides Aris N. |
Methods of modifying eukaryotic cells
|
|
GB0115256D0
(en)
|
2001-06-21 |
2001-08-15 |
Babraham Inst |
Mouse light chain locus
|
|
EP3269235B1
(en)
|
2001-11-30 |
2022-01-26 |
Amgen Fremont Inc. |
Transgenic mice bearing human ig lambda light chain genes
|
|
JP2006506317A
(ja)
|
2002-01-11 |
2006-02-23 |
バイオマリン ファーマシューティカル インコーポレイテッド |
治療用リソソーム酵素の送達のための酵素送達系としてのｐ９７の使用
|
|
ATE548461T1
(de)
*
|
2002-01-18 |
2012-03-15 |
Morphotek Inc |
Verfahren zur erzeugung manipulierter zellen zur locus-spezifischen genregulation und analyse
|
|
USRE47770E1
(en)
|
2002-07-18 |
2019-12-17 |
Merus N.V. |
Recombinant production of mixtures of antibodies
|
|
PT2314629E
(pt)
|
2002-07-18 |
2014-01-22 |
Merus B V |
Produção recombinante de misturas de anticorpos
|
|
AU2003278790A1
(en)
*
|
2002-09-09 |
2004-03-29 |
California Institute Of Technology |
Methods and compositions for the generation of humanized mice
|
|
US20100069614A1
(en)
|
2008-06-27 |
2010-03-18 |
Merus B.V. |
Antibody producing non-human mammals
|
|
EP2395016A3
(en)
*
|
2003-05-30 |
2012-12-19 |
Merus B.V. |
Design and use of paired variable regions of specific binding molecules
|
|
GB2408980B
(en)
*
|
2003-12-09 |
2006-06-07 |
Nat Biolog Standards Board |
Genetic reference materials
|
|
EP4353819A3
(en)
|
2004-07-22 |
2024-07-17 |
Erasmus University Medical Center Rotterdam |
Binding molecules
|
|
AU2007235496B2
(en)
|
2006-03-31 |
2013-11-21 |
E. R. Squibb & Sons, L.L.C. |
Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
|
|
RS52176B
(sr)
*
|
2006-06-02 |
2012-08-31 |
Regeneron Pharmaceuticals Inc. |
Antitela visokog afiniteta prema humanom il-6 receptoru
|
|
WO2007147167A2
(en)
*
|
2006-06-16 |
2007-12-21 |
Porous Power Technologies, Llc |
Optimized microporous structure of electrochemical cells
|
|
WO2008054606A2
(en)
|
2006-10-02 |
2008-05-08 |
Regeneron Pharmaceuticals, Inc. |
High affinity human antibodies to human il-4 receptor
|
|
US7608693B2
(en)
|
2006-10-02 |
2009-10-27 |
Regeneron Pharmaceuticals, Inc. |
High affinity human antibodies to human IL-4 receptor
|
|
NO347649B1
(no)
|
2006-12-14 |
2024-02-12 |
Regeneron Pharma |
Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
|
|
EP2125894B1
(en)
|
2007-03-22 |
2018-12-19 |
Biogen MA Inc. |
Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind cd154 and uses thereof
|
|
KR102096731B1
(ko)
|
2007-06-01 |
2020-04-02 |
오픈 모노클로날 테크놀로지, 인코포레이티드 |
내생적 면역글로불린 유전자를 억제하고 트랜스제닉 인간 이디오타입 항체를 생산하기 위한 방법 및 조성물
|
|
JP5588866B2
(ja)
*
|
2007-08-10 |
2014-09-10 |
メダレックス エル．エル．シー． |
Ｈｃｏ３２およびｈｃｏ２７、ならびに関連実施例
|
|
KR101709488B1
(ko)
|
2007-08-10 |
2017-02-24 |
리제너론 파아마슈티컬스, 인크. |
인간 신경성장인자에 대한 고친화성 인간 항체
|
|
GB0718029D0
(en)
*
|
2007-09-14 |
2007-10-24 |
Iti Scotland Ltd |
Two step cluster deletion and humanisation
|
|
DK3059246T3
(en)
|
2007-09-26 |
2018-10-01 |
Chugai Pharmaceutical Co Ltd |
Modified constant region of an antibody
|
|
KR20100103810A
(ko)
|
2007-12-10 |
2010-09-28 |
알리바 바이오파마수티컬스, 아이엔씨. |
동종 재조합에 의한 표적화된 영역의 순차적인 치환 방법
|
|
US20090208832A1
(en)
*
|
2008-02-17 |
2009-08-20 |
Porous Power Technologies, Llc |
Lamination Configurations for Battery Applications Using PVDF Highly Porous Film
|
|
US20090222995A1
(en)
*
|
2008-03-05 |
2009-09-10 |
Bernard Perry |
Bedding Applications for Porous Material
|
|
US20090227163A1
(en)
*
|
2008-03-05 |
2009-09-10 |
Bernard Perry |
Protective Apparel with Porous Material Layer
|
|
US20090223155A1
(en)
*
|
2008-03-05 |
2009-09-10 |
Bernard Perry |
Building Construction Applications for Porous Material
|
|
EP2098536A1
(en)
|
2008-03-05 |
2009-09-09 |
4-Antibody AG |
Isolation and identification of antigen- or ligand-specific binding proteins
|
|
US20090226683A1
(en)
*
|
2008-03-05 |
2009-09-10 |
Bernard Perry |
Porous Material Uses in Furniture
|
|
RU2607569C2
(ru)
*
|
2008-03-31 |
2017-01-10 |
Дженентек, Инк. |
Композиции и способы для лечения и диагностики астмы
|
|
EP2669298A3
(en)
*
|
2008-05-23 |
2014-02-26 |
Ablexis, LLC |
Single variable immunoglobulin domain comprising VL-DH-JL
|
|
US20100122358A1
(en)
*
|
2008-06-06 |
2010-05-13 |
Crescendo Biologics Limited |
H-Chain-only antibodies
|
|
US20090328240A1
(en)
*
|
2008-06-24 |
2009-12-31 |
Sing George L |
Genetically modified mice as predictors of immune response
|
|
AU2014203150C1
(en)
*
|
2008-06-27 |
2018-10-18 |
Merus N.V. |
Antibody producing non-human mammals
|
|
PT3456190T
(pt)
*
|
2008-06-27 |
2022-02-15 |
Merus Nv |
Animal murino transgénico produtor de anticorpo
|
|
KR101987351B1
(ko)
|
2008-09-30 |
2019-06-10 |
아블렉시스, 엘엘씨 |
키메라 항체의 제조를 위한 인간 이외의 포유동물
|
|
JO3672B1
(ar)
|
2008-12-15 |
2020-08-27 |
Regeneron Pharma |
أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
|
|
US20130064834A1
(en)
|
2008-12-15 |
2013-03-14 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating hypercholesterolemia using antibodies to pcsk9
|
|
RU2011129459A
(ru)
|
2008-12-18 |
2013-01-27 |
Эрасмус Юниверсити Медикал Сентр Роттердам |
Трансгенные животные (не человек), экспрессирующие гуманизированные антитела, и их применение
|
|
US20100178567A1
(en)
*
|
2008-12-24 |
2010-07-15 |
Porous Power Technologies, Llc |
Mat Forming Spacers in Microporous Membrane Matrix
|
|
GB0905023D0
(en)
|
2009-03-24 |
2009-05-06 |
Univ Erasmus Medical Ct |
Binding molecules
|
|
AU2010229479B2
(en)
|
2009-03-25 |
2013-03-28 |
Genentech, Inc. |
Novel anti-alpha5beta1 antibodies and uses thereof
|
|
WO2010135573A2
(en)
|
2009-05-20 |
2010-11-25 |
Porous Power Technologies, Llc |
Treatment and adhesive for microporous membranes
|
|
TWI513465B
(zh)
|
2009-06-25 |
2015-12-21 |
Regeneron Pharma |
以ｄｌｌ４拮抗劑與化學治療劑治療癌症之方法
|
|
SG176947A1
(en)
|
2009-07-03 |
2012-01-30 |
Avipep Pty Ltd |
Immuno-conjugates and methods for producing them
|
|
US9445581B2
(en)
|
2012-03-28 |
2016-09-20 |
Kymab Limited |
Animal models and therapeutic molecules
|
|
CN102638971B
(zh)
*
|
2009-07-08 |
2015-10-07 |
科马布有限公司 |
动物模型及治疗分子
|
|
CA3040377C
(en)
*
|
2009-10-06 |
2025-12-30 |
Yale University |
Genetically modified mice and engraftment comprising the knock-in of a human thrombopoietin (tpo) gene
|
|
WO2011072204A1
(en)
*
|
2009-12-10 |
2011-06-16 |
Regeneron Pharmaceuticals, Inc. |
Mice that make heavy chain antibodies
|
|
US20110150885A1
(en)
|
2009-12-11 |
2011-06-23 |
Atyr Pharma, Inc. |
Aminoacyl trna synthetases for modulating hematopoiesis
|
|
MY156743A
(en)
|
2009-12-21 |
2016-03-31 |
Regeneron Pharma |
Humanized fc?r mice
|
|
EP2516462B1
(en)
|
2009-12-23 |
2015-05-06 |
Avipep Pty Ltd |
Immuno-conjugates and methods for producing them
|
|
US20130045492A1
(en)
*
|
2010-02-08 |
2013-02-21 |
Regeneron Pharmaceuticals, Inc. |
Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
|
|
US9796788B2
(en)
|
2010-02-08 |
2017-10-24 |
Regeneron Pharmaceuticals, Inc. |
Mice expressing a limited immunoglobulin light chain repertoire
|
|
US20120021409A1
(en)
*
|
2010-02-08 |
2012-01-26 |
Regeneron Pharmaceuticals, Inc. |
Common Light Chain Mouse
|
|
US20130185821A1
(en)
*
|
2010-02-08 |
2013-07-18 |
Regeneron Pharmaceuticals, Inc. |
Common Light Chain Mouse
|
|
US10143186B2
(en)
|
2010-02-08 |
2018-12-04 |
Regeneron Pharmaceuticals, Inc. |
Common light chain mouse
|
|
MX2012008958A
(es)
|
2010-02-18 |
2012-08-23 |
Genentech Inc |
Antagonista de neurogulina y usos de los mismos para el tratamiento contra el cancer.
|
|
US20110200595A1
(en)
|
2010-02-18 |
2011-08-18 |
Roche Glycart |
TREATMENT WITH A HUMANIZED IgG CLASS ANTI EGFR ANTIBODY AND AN ANTIBODY AGAINST INSULIN LIKE GROWTH FACTOR 1 RECEPTOR
|
|
MX2012010853A
(es)
|
2010-03-24 |
2013-01-29 |
Genentech Inc |
Anticuerpos anti-lrp6.
|
|
KR101830020B1
(ko)
|
2010-03-31 |
2018-02-19 |
아블렉시스, 엘엘씨 |
키메라 항체의 제조를 위한 비-인간 동물의 유전적 조작
|
|
CN103118692A
(zh)
|
2010-04-26 |
2013-05-22 |
Atyr医药公司 |
与半胱氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
|
|
CA2797362C
(en)
|
2010-04-27 |
2020-12-08 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of isoleucyl trna synthetases
|
|
CN103097524B
(zh)
|
2010-04-28 |
2016-08-03 |
Atyr医药公司 |
与丙氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
|
|
AU2011248457B2
(en)
|
2010-04-29 |
2017-02-16 |
Pangu Biopharma Limited |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of valyl tRNA synthetases
|
|
US8986680B2
(en)
|
2010-04-29 |
2015-03-24 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Asparaginyl tRNA synthetases
|
|
ES2623805T3
(es)
|
2010-05-03 |
2017-07-12 |
Atyr Pharma, Inc. |
Descubrimiento innovador de composiciones terapéuticas, de diagnóstico y de anticuerpos relacionadas con fragmentos de proteínas de fenilalanil-alfa-ARNt sintetasas
|
|
CN103096925A
(zh)
|
2010-05-03 |
2013-05-08 |
Atyr医药公司 |
与精氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
|
|
EP2566496B1
(en)
|
2010-05-03 |
2018-02-28 |
aTyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of methionyl-trna synthetases
|
|
CN102985103A
(zh)
|
2010-05-04 |
2013-03-20 |
Atyr医药公司 |
与p38多-tRNA合成酶复合物相关的治疗、诊断和抗体组合物的创新发现
|
|
CA2799197C
(en)
|
2010-05-14 |
2019-10-29 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-beta-trna synthetases
|
|
CA2800375C
(en)
|
2010-05-27 |
2021-03-09 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutaminyl-trna synthetases
|
|
CA2800534C
(en)
|
2010-06-11 |
2019-01-22 |
Regeneron Pharmaceuticals, Inc. |
Production of fertile xy female animals from xy es cells
|
|
WO2011159847A2
(en)
|
2010-06-15 |
2011-12-22 |
The Regents Of The University Of California |
Receptor tyrosine kinase-like orphan receptor 1 (ror1) single chain fv antibody fragment conjugates and methods of use thereof
|
|
AU2011266843C9
(en)
*
|
2010-06-17 |
2018-03-01 |
Kymab Limited |
Animal models and therapeutic molecules
|
|
WO2011159980A1
(en)
|
2010-06-18 |
2011-12-22 |
Genentech, Inc. |
Anti-axl antibodies and methods of use
|
|
SG10201504568YA
(en)
*
|
2010-06-22 |
2015-07-30 |
Regeneron Pharma |
Hybrid light chain mice
|
|
JP2013539962A
(ja)
|
2010-07-09 |
2013-10-31 |
ジェネンテック， インコーポレイテッド |
抗ニューロピリン抗体及び使用方法
|
|
AU2011289831C1
(en)
|
2010-07-12 |
2017-06-15 |
Pangu Biopharma Limited |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-tRNA synthetases
|
|
US20120100166A1
(en)
|
2010-07-15 |
2012-04-26 |
Zyngenia, Inc. |
Ang-2 Binding Complexes and Uses Thereof
|
|
WO2012010582A1
(en)
|
2010-07-21 |
2012-01-26 |
Roche Glycart Ag |
Anti-cxcr5 antibodies and methods of use
|
|
DK2597945T3
(da)
*
|
2010-07-26 |
2020-09-21 |
Trianni Inc |
Transgene dyr og fremgangsmåder til anvendelse deraf
|
|
US10793829B2
(en)
|
2010-07-26 |
2020-10-06 |
Trianni, Inc. |
Transgenic mammals and methods of use thereof
|
|
US10662256B2
(en)
|
2010-07-26 |
2020-05-26 |
Trianni, Inc. |
Transgenic mammals and methods of use thereof
|
|
EP3960865A1
(en)
|
2010-08-02 |
2022-03-02 |
Regeneron Pharmaceuticals, Inc. |
Mice that make binding proteins comprising vl domains
|
|
JP2013541501A
(ja)
|
2010-08-03 |
2013-11-14 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
慢性リンパ性白血病（ｃｌｌ）のバイオマーカー
|
|
BR112013002532A2
(pt)
|
2010-08-05 |
2016-05-31 |
Hoffmann La Roche |
proteína de fusão de citocina anti-viral do anticorpo anti-mhc
|
|
KR101653030B1
(ko)
|
2010-08-13 |
2016-08-31 |
로슈 글리카트 아게 |
항-테나신-c a２ 항체 및 이의 사용 방법
|
|
CN104474546A
(zh)
|
2010-08-13 |
2015-04-01 |
弗·哈夫曼-拉罗切有限公司 |
用于疾病治疗的针对IL-1β和IL-18的抗体
|
|
SG187746A1
(en)
|
2010-08-13 |
2013-03-28 |
Roche Glycart Ag |
Anti-fap antibodies and methods of use
|
|
AU2011293294B2
(en)
|
2010-08-25 |
2016-03-24 |
Pangu Biopharma Limited |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Tyrosyl-tRNA synthetases
|
|
CA2808236A1
(en)
|
2010-08-31 |
2012-03-08 |
Genentech, Inc. |
Biomarkers and methods of treatment
|
|
EP2635674A4
(en)
|
2010-11-05 |
2014-11-05 |
Transbio Ltd |
MARKERS FOR ENDOTHELIAL STORAGE CELLS AND USES THEREOF
|
|
AR083819A1
(es)
|
2010-11-10 |
2013-03-27 |
Genentech Inc |
UN ANTICUERPO QUE SE UNE A BACE1 (ENZIMA 1 DE DISOCIACION DE PROTEINA PRECURSORA DEL AMILOIDE DE SITIO b), METODOS Y COMPOSICIONES PARA INMUNOTERAPIA PARA ENFERMEDAD NEURAL
|
|
US8771696B2
(en)
|
2010-11-23 |
2014-07-08 |
Regeneron Pharmaceuticals, Inc. |
Method of reducing the severity of stress hyperglycemia with human antibodies to the glucagon receptor
|
|
JO3756B1
(ar)
*
|
2010-11-23 |
2021-01-31 |
Regeneron Pharma |
اجسام مضادة بشرية لمستقبلات الجلوكاجون
|
|
JP6005657B2
(ja)
|
2010-12-16 |
2016-10-12 |
ジェネンテック， インコーポレイテッド |
Ｔｈ２阻害に関連する診断及び治療
|
|
WO2012087962A2
(en)
|
2010-12-20 |
2012-06-28 |
Genentech, Inc. |
Anti-mesothelin antibodies and immunoconjugates
|
|
CA2820953A1
(en)
|
2010-12-22 |
2012-06-28 |
Genentech, Inc. |
Anti-pcsk9 antibodies and methods of use
|
|
CN103282054A
(zh)
|
2011-01-03 |
2013-09-04 |
弗·哈夫曼-拉罗切有限公司 |
抗dig抗体和与肽缀合的地高辛配基的复合物的药物组合物
|
|
EP3252076B1
(en)
|
2011-01-14 |
2019-09-04 |
The Regents Of The University Of California |
Diagnostic use of antibodies against ror-1 protein
|
|
EP2650016A1
(en)
|
2011-01-28 |
2013-10-16 |
Sanofi |
Human antibodies to PSCK9 for use in methods of treatment based on particular dosage regimens (11565)
|
|
BR112013018740A2
(pt)
|
2011-01-28 |
2019-01-08 |
Sanofi Sa |
anticorpos humanos para pcsk9 para uso em métodos de tratamento de grupos específicos de indivíduos
|
|
SG10201913690SA
(en)
|
2011-02-08 |
2020-03-30 |
Medimmune Llc |
Antibodies that specifically bind staphylococcus aureus alpha toxin and methods of use
|
|
ES3040596T3
(en)
|
2011-02-15 |
2025-11-03 |
Regeneron Pharma |
Humanized m-csf mice and uses thereof
|
|
ME03732B
(me)
|
2011-02-25 |
2021-01-20 |
Regeneron Pharma |
Miševi s ADAM6
|
|
WO2012122590A1
(en)
|
2011-03-14 |
2012-09-20 |
Cellmid Limited |
Antibody recognizing n-domain of midkine
|
|
BR112013024574B1
(pt)
|
2011-03-29 |
2022-08-09 |
Roche Glycart Ag |
Anticorpo e uso do anticorpo
|
|
TW201249867A
(en)
|
2011-04-01 |
2012-12-16 |
Astellas Pharma Inc |
Novel anti-human il-23 receptor antibody
|
|
MX342240B
(es)
|
2011-04-07 |
2016-09-21 |
Genentech Inc |
Anticuerpos anti-fgfr4 y metodos de uso.
|
|
CA2833404A1
(en)
|
2011-04-21 |
2012-10-26 |
Garvan Institute Of Medical Research |
Modified variable domain molecules and methods for producing and using them b
|
|
AR088782A1
(es)
|
2011-04-29 |
2014-07-10 |
Sanofi Sa |
Sistemas de ensayo y metodos para identificar y caracterizar farmacos hipolipemiantes
|
|
MX2013013054A
(es)
|
2011-05-12 |
2014-02-20 |
Genentech Inc |
Metodo de monitoreo de lc-ms/ms de reaccion multiple para detectar anticuerpos terapeuticos en muestras de animales utilizando peptidos de firma de estructura.
|
|
ES2541535T3
(es)
|
2011-05-12 |
2015-07-21 |
Regeneron Pharmaceuticals, Inc. |
Ensayo de liberación de neuropéptido para canales de sodio
|
|
PE20140995A1
(es)
|
2011-05-16 |
2014-08-23 |
Genentech Inc |
Agonistas de fgfr1 y sus metodos de uso
|
|
EP2714738B1
(en)
|
2011-05-24 |
2018-10-10 |
Zyngenia, Inc. |
Multivalent and monovalent multispecific complexes and their uses
|
|
BR112013031943B1
(pt)
|
2011-06-13 |
2021-10-13 |
Csl Limited |
Composição que compreende proteínas e anticorpos contra g-csfr
|
|
KR101629073B1
(ko)
|
2011-06-15 |
2016-06-09 |
에프. 호프만-라 로슈 아게 |
항-인간 에리스로포이에틴 수용체 항체 및 이의 사용 방법
|
|
BR112013030472A2
(pt)
|
2011-06-30 |
2019-09-24 |
Genentech Inc |
formulação farmacêutica, artigo de fabricação e método
|
|
AU2012278944B2
(en)
|
2011-07-05 |
2015-09-17 |
Bioasis Technologies Inc. |
p97-antibody conjugates and methods of use
|
|
US10040826B2
(en)
|
2011-07-05 |
2018-08-07 |
Duke University |
Human immunodeficiency virus type 1 (HIV-1) N-terminal deleted GP120 immunogens
|
|
US9120858B2
(en)
|
2011-07-22 |
2015-09-01 |
The Research Foundation Of State University Of New York |
Antibodies to the B12-transcobalamin receptor
|
|
WO2013015821A1
(en)
|
2011-07-22 |
2013-01-31 |
The Research Foundation Of State University Of New York |
Antibodies to the b12-transcobalamin receptor
|
|
AR087305A1
(es)
|
2011-07-28 |
2014-03-12 |
Regeneron Pharma |
Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
|
|
HRP20192255T1
(hr)
|
2011-08-05 |
2020-03-06 |
Regeneron Pharmaceuticals, Inc. |
Humanizirani miševi s univerzalnim lakim lancem
|
|
EP2739649B1
(en)
|
2011-08-05 |
2017-09-27 |
Bioasis Technologies Inc. |
P97 fragments with transfer activity
|
|
PT2743348T
(pt)
|
2011-08-11 |
2018-02-23 |
Astellas Pharma Inc |
Novo anticorpo anti-ngf humano
|
|
WO2013025944A1
(en)
|
2011-08-17 |
2013-02-21 |
Genentech, Inc. |
Inhibition of angiogenesis in refractory tumors
|
|
KR20140057326A
(ko)
|
2011-08-17 |
2014-05-12 |
제넨테크, 인크. |
뉴레귤린 항체 및 그의 용도
|
|
AU2012299195B9
(en)
|
2011-08-19 |
2018-05-10 |
Regeneron Pharmaceuticals, Inc |
Anti-Tie2 antibodies uses thereof
|
|
WO2013026832A1
(en)
|
2011-08-23 |
2013-02-28 |
Roche Glycart Ag |
Anti-mcsp antibodies
|
|
AR087601A1
(es)
|
2011-08-23 |
2014-04-03 |
Roche Glycart Ag |
Anticuerpos sin fc que comprenden dos fragmentos fab y metodos de utilizacion
|
|
CN107586340B
(zh)
|
2011-08-23 |
2022-01-21 |
罗切格利卡特公司 |
对t细胞活化性抗原和肿瘤抗原特异性的双特异性抗体及使用方法
|
|
BR112014005720A2
(pt)
|
2011-09-15 |
2017-12-12 |
Genentech Inc |
método de seleção e/ou identificação de um antagonista de usp1, antagonista de uaf1 e/ou um antagonista de id que promove uma alteração no destino celular do dito método
|
|
CN103930444B
(zh)
|
2011-09-16 |
2020-08-04 |
瑞泽恩制药公司 |
用前蛋白转化酶枯草溶菌素-9(PCSK9)抑制剂降低脂蛋白(a)水平的方法
|
|
US20130078252A1
(en)
|
2011-09-19 |
2013-03-28 |
Genentech, Inc. |
Combination treatments comprising c-met antagonists and b-raf antagonists
|
|
BR112014006390A2
(pt)
|
2011-09-19 |
2017-03-28 |
Kymab Ltd |
anticorpos, domínios variáveis e cadeias feitos especialmente para uso humano
|
|
JP2014531452A
(ja)
*
|
2011-09-19 |
2014-11-27 |
カイマブ・リミテッド |
動物、レパートリーおよび方法
|
|
CA2791109C
(en)
|
2011-09-26 |
2021-02-16 |
Merus B.V. |
Generation of binding molecules
|
|
WO2013045916A1
(en)
|
2011-09-26 |
2013-04-04 |
Kymab Limited |
Chimaeric surrogate light chains (slc) comprising human vpreb
|
|
CA2850745C
(en)
|
2011-10-03 |
2022-12-13 |
Duke University |
Vaccine
|
|
US9663573B2
(en)
|
2011-10-05 |
2017-05-30 |
Genentech, Inc. |
Methods of treating liver conditions using Notch2 antagonists
|
|
JP6532678B2
(ja)
|
2011-10-14 |
2019-06-19 |
ジェネンテック， インコーポレイテッド |
抗ＨｔｒＡ１抗体及び使用方法
|
|
MX2014004426A
(es)
|
2011-10-15 |
2014-07-09 |
Genentech Inc |
Metodos de uso de antagonistas de scd1.
|
|
HRP20220253T1
(hr)
|
2011-10-17 |
2022-04-29 |
Regeneron Pharmaceuticals, Inc. |
Miševi s ograničenim teškim lancem imunoglobulina
|
|
WO2013059531A1
(en)
|
2011-10-20 |
2013-04-25 |
Genentech, Inc. |
Anti-gcgr antibodies and uses thereof
|
|
WO2013059740A1
(en)
|
2011-10-21 |
2013-04-25 |
Foundation Medicine, Inc. |
Novel alk and ntrk1 fusion molecules and uses thereof
|
|
US9043996B2
(en)
|
2011-10-28 |
2015-06-02 |
Regeneron Pharmaceuticals, Inc. |
Genetically modified major histocompatibility complex animals
|
|
US20140283153A1
(en)
|
2011-10-28 |
2014-09-18 |
Trianni, Inc. |
Transgenic animals and methods of use
|
|
US9591835B2
(en)
|
2011-10-28 |
2017-03-14 |
Regeneron Pharmaceuticals, Inc. |
Genetically modified major histocompatibility complex animals
|
|
RS56330B1
(sr)
|
2011-10-28 |
2017-12-29 |
Regeneron Pharma |
Genetski modifikovani miševi sa ekspresijom himernih molekula klase ii glavnog kompleksa histokompatibilnosti (mhc)
|
|
CN114891797A
(zh)
*
|
2011-10-28 |
2022-08-12 |
瑞泽恩制药公司 |
T细胞受体基因修饰小鼠
|
|
RS56656B1
(sr)
|
2011-10-28 |
2018-03-30 |
Regeneron Pharma |
Miševi sa genetski modifikovanim glavnim kompleksom gena tkivne podudarnosti
|
|
AU2012327878A1
(en)
|
2011-10-28 |
2014-05-29 |
Patrys Limited |
PAT-LM1 epitopes and methods for using same
|
|
CA2850034A1
(en)
|
2011-10-28 |
2013-05-02 |
Genentech, Inc. |
Therapeutic combinations and methods of treating melanoma
|
|
GB2496375A
(en)
*
|
2011-10-28 |
2013-05-15 |
Kymab Ltd |
A non-human assay vertebrate comprising human antibody loci and human epitope knock-in, and uses thereof
|
|
TW201326193A
(zh)
|
2011-11-21 |
2013-07-01 |
Genentech Inc |
抗－ｃ－ｍｅｔ抗體之純化
|
|
GB201122047D0
(en)
|
2011-12-21 |
2012-02-01 |
Kymab Ltd |
Transgenic animals
|
|
US9253965B2
(en)
|
2012-03-28 |
2016-02-09 |
Kymab Limited |
Animal models and therapeutic molecules
|
|
US20140335084A1
(en)
|
2011-12-06 |
2014-11-13 |
Hoffmann-La Roche Inc. |
Antibody formulation
|
|
ME03477B
(me)
|
2011-12-20 |
2020-01-20 |
Regeneron Pharma |
Miševi sa humanizovanim lakim lancem
|
|
HK1200849A1
(en)
|
2011-12-22 |
2015-08-14 |
F. Hoffmann-La Roche Ag |
Full length antibody display system for eukaryotic cells and its use
|
|
CN104114701A
(zh)
|
2011-12-22 |
2014-10-22 |
弗·哈夫曼-拉罗切有限公司 |
表达载体组织、新的生产用细胞产生方法及其在重组产生多肽中的用途
|
|
CN113896787A
(zh)
|
2011-12-22 |
2022-01-07 |
弗·哈夫曼-拉罗切有限公司 |
表达载体元件组合、新的生产用细胞产生方法及其在重组产生多肽中的用途
|
|
MX345019B
(es)
*
|
2011-12-22 |
2017-01-11 |
Astellas Pharma Inc |
Nuevo anticuerpo ctgf antihumano.
|
|
WO2013096791A1
(en)
|
2011-12-23 |
2013-06-27 |
Genentech, Inc. |
Process for making high concentration protein formulations
|
|
JP2015506944A
(ja)
|
2012-01-18 |
2015-03-05 |
ジェネンテック， インコーポレイテッド |
Ｆｇｆ１９修飾薬を使用する方法
|
|
CA2862422A1
(en)
|
2012-01-18 |
2013-07-25 |
Genentech, Inc. |
Anti-lrp5 antibodies and methods of use
|
|
SG10201913428QA
(en)
*
|
2012-02-01 |
2020-03-30 |
Regeneron Pharma |
Humanized rodents that express heavy chains containing vl domains
|
|
MX366804B
(es)
|
2012-02-11 |
2019-07-25 |
Genentech Inc |
Translocaciones de la r-espondina y sus metodos de uso.
|
|
SI2814587T1
(en)
|
2012-02-15 |
2018-08-31 |
F. Hoffmann-La Roche Ag |
Affinity chromatography based on the Fc receptor
|
|
AU2013221317B2
(en)
|
2012-02-16 |
2017-07-06 |
Pangu Biopharma Limited |
Histidyl-tRNA synthetases for treating autoimmune and inflammatory diseases
|
|
WO2013129454A1
(ja)
|
2012-02-28 |
2013-09-06 |
アステラス製薬株式会社 |
新規抗ヒトｉｌ－２３受容体抗体
|
|
SG10201610123UA
(en)
|
2012-03-02 |
2017-01-27 |
Regeneron Pharma |
Human antibodies to clostridium difficile toxins
|
|
CA2865029A1
(en)
|
2012-03-06 |
2013-09-12 |
Regeneron Pharmaceuticals, Inc. |
Common light chain mouse
|
|
BR112014018964A2
(pt)
|
2012-03-13 |
2020-05-12 |
F. Hoffmann-La Roche Ag |
Anticorpo anti-vegf e uso de um anticorpo anti-vegf
|
|
RU2014141536A
(ru)
|
2012-03-16 |
2016-05-10 |
Регенерон Фармасьютикалз, Инк. |
Мыши, которые продуцируют антигенсвязывающие белки с зависимыми от величины ph характеристиками связывания
|
|
SMT201800395T1
(it)
|
2012-03-16 |
2018-09-13 |
Regeneron Pharma |
Anticorpi a catena leggera ingegnerizzati con istidina e roditori modificati geneticamente per la generazione degli stessi
|
|
PT2825037T
(pt)
|
2012-03-16 |
2019-08-07 |
Regeneron Pharma |
Animais não humanos que expressam sequências de imunoglobulinas sensíveis ao ph
|
|
US20140013456A1
(en)
|
2012-03-16 |
2014-01-09 |
Regeneron Pharmaceuticals, Inc. |
Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
|
|
WO2013148315A1
(en)
|
2012-03-27 |
2013-10-03 |
Genentech, Inc. |
Diagnosis and treatments relating to her3 inhibitors
|
|
US10251377B2
(en)
|
2012-03-28 |
2019-04-09 |
Kymab Limited |
Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
|
|
GB2502127A
(en)
*
|
2012-05-17 |
2013-11-20 |
Kymab Ltd |
Multivalent antibodies and in vivo methods for their production
|
|
EP2831245A1
(en)
*
|
2012-03-28 |
2015-02-04 |
Kymab Limited |
Transgenic non-human vertebrate for the expression of class - switched, fully human, antibodies
|
|
AR090549A1
(es)
|
2012-03-30 |
2014-11-19 |
Genentech Inc |
Anticuerpos anti-lgr5 e inmunoconjugados
|
|
TWI619729B
(zh)
|
2012-04-02 |
2018-04-01 |
再生元醫藥公司 |
抗－ｈｌａ－ｂ*２７抗體及其用途
|
|
DK2838917T3
(da)
|
2012-04-20 |
2019-08-26 |
Merus Nv |
Fremgangsmåder og midler til frembringelse af heterodimere ig-lignende molekyler
|
|
CN104364380B
(zh)
|
2012-04-25 |
2018-10-09 |
瑞泽恩制药公司 |
核酸酶介导的使用大靶向载体的靶向
|
|
JP6242865B2
(ja)
|
2012-05-01 |
2017-12-06 |
ジェネンテック， インコーポレイテッド |
抗ｐｍｅｌ１７抗体および免疫複合体
|
|
JO3820B1
(ar)
|
2012-05-03 |
2021-01-31 |
Regeneron Pharma |
أجسام مضادة بشرية لـ fel d1وطرق لاستخدامها
|
|
WO2013170191A1
(en)
|
2012-05-11 |
2013-11-14 |
Genentech, Inc. |
Methods of using antagonists of nad biosynthesis from nicotinamide
|
|
WO2013177470A1
(en)
|
2012-05-23 |
2013-11-28 |
Genentech, Inc. |
Selection method for therapeutic agents
|
|
AR092325A1
(es)
|
2012-05-31 |
2015-04-15 |
Regeneron Pharma |
Formulaciones estabilizadas que contienen anticuerpos anti-dll4 y kit
|
|
CN104582476B
(zh)
*
|
2012-06-05 |
2017-03-08 |
瑞泽恩制药公司 |
使用共同轻链制备完全人双特异性抗体的方法
|
|
KR102484480B1
(ko)
*
|
2012-06-12 |
2023-01-04 |
리제너론 파마슈티칼스 인코포레이티드 |
제한된 면역글로불린 중쇄 유전자좌를 가지는 인간화된 비-인간 동물
|
|
JP2015530867A
(ja)
|
2012-06-15 |
2015-10-29 |
ジェネンテック， インコーポレイテッド |
抗ｐｃｓｋ９抗体、製剤、投薬、及び使用方法
|
|
SI2869848T1
(sl)
|
2012-07-04 |
2017-01-31 |
F. Hoffmann-La Roche Ag |
Kovalentno vezani konjugati antigen-protitelo
|
|
RU2630296C2
(ru)
|
2012-07-04 |
2017-09-06 |
Ф. Хоффманн-Ля Рош Аг |
Антитела к биотину и способы их применения
|
|
CA2872184A1
(en)
|
2012-07-04 |
2014-01-09 |
F. Hoffmann-La Roche Ag |
Anti-theophylline antibodies and methods of use
|
|
SI2870247T1
(sl)
|
2012-07-05 |
2019-10-30 |
Hoffmann La Roche |
Ekspresijski in sekrecijski sistem
|
|
TW201406785A
(zh)
|
2012-07-09 |
2014-02-16 |
Genentech Inc |
抗ｃｄ２２抗體及免疫結合物
|
|
SG11201500142RA
(en)
|
2012-07-09 |
2015-02-27 |
Genentech Inc |
Immunoconjugates comprising anti-cd22 antibodies
|
|
IN2014DN10652A
(enExample)
|
2012-07-09 |
2015-09-11 |
Genentech Inc |
|
|
WO2014011521A1
(en)
|
2012-07-09 |
2014-01-16 |
Genentech, Inc. |
Immunoconjugates comprising anti - cd79b antibodies
|
|
HUE048574T2
(hu)
|
2012-07-12 |
2020-08-28 |
Hangzhou Dac Biotech Co Ltd |
Sejthez kötõdõ molekulák citotoxikus szerekkel képzett konjugátumai
|
|
EP2872534B1
(en)
|
2012-07-13 |
2018-08-08 |
Roche Glycart AG |
Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
|
|
WO2014018375A1
(en)
|
2012-07-23 |
2014-01-30 |
Xenon Pharmaceuticals Inc. |
Cyp8b1 and uses thereof in therapeutic and diagnostic methods
|
|
CN104662150B
(zh)
|
2012-07-31 |
2018-07-10 |
比奥阿赛斯技术有限公司 |
脱磷酸化的溶酶体贮积症蛋白及其使用方法
|
|
SG11201500903XA
(en)
|
2012-08-07 |
2015-03-30 |
Genentech Inc |
Combination therapy for the treatment of glioblastoma
|
|
WO2014031610A1
(en)
|
2012-08-21 |
2014-02-27 |
Sanofi |
Methods for treating or preventing asthma by administering an il-4r antagonist
|
|
TR201900694T4
(tr)
|
2012-08-23 |
2019-02-21 |
Agensys Inc |
158p1d7 proteinlerine bağlanan antikor ilaç konjugatları (adc).
|
|
US9758591B2
(en)
|
2012-08-24 |
2017-09-12 |
The Regents Of The University Of California |
Antibodies and vaccines for use in treating ROR1 cancers and inhibiting metastasis
|
|
EP2703008A1
(en)
|
2012-08-31 |
2014-03-05 |
Sanofi |
Human antibodies to PCSK9 for use in methods of treating particular groups of subjects
|
|
EP2703009A1
(en)
|
2012-08-31 |
2014-03-05 |
Sanofi |
Combination treatments involving antibodies to human PCSK9
|
|
EP2706070A1
(en)
|
2012-09-06 |
2014-03-12 |
Sanofi |
Combination treatments involving antibodies to human PCSK9
|
|
HRP20181227T1
(hr)
|
2012-09-07 |
2018-10-05 |
Regeneron Pharmaceuticals, Inc. |
Metode za liječenje atopijskog dermatitisa primjenom antagonista il-4r
|
|
KR102287541B1
(ko)
|
2012-09-07 |
2021-08-10 |
예일 유니버시티 |
유전적으로 변형된 비-인간 동물 및 이것들의 사용 방법
|
|
BR112015007120A2
(pt)
|
2012-10-08 |
2017-12-12 |
Roche Glycart Ag |
anticorpo biespecífico, composição farmacêutica, uso, célula hospedeira e método de produção de um anticorpo
|
|
ES2720040T3
(es)
*
|
2012-10-12 |
2019-07-17 |
Glaxosmithkline Biologicals Sa |
Procedimientos de modificación de células hospedadoras
|
|
HK1214831A1
(zh)
|
2012-11-05 |
2016-08-05 |
Foundation Medicine, Inc. |
新型融合分子及其应用
|
|
EP4389764B1
(en)
|
2012-11-05 |
2026-03-18 |
Regeneron Pharmaceuticals, Inc. |
Genetically modified rodents and methods of use thereof
|
|
AU2013337277B2
(en)
|
2012-11-05 |
2018-03-08 |
Foundation Medicine, Inc. |
Novel NTRK1 fusion molecules and uses thereof
|
|
CN104968797B
(zh)
|
2012-11-06 |
2018-11-30 |
米迪缪尼有限公司 |
金黄色葡萄球菌表面决定簇的抗体
|
|
EP2917243B1
(en)
|
2012-11-08 |
2018-03-14 |
F.Hoffmann-La Roche Ag |
Her3 antigen binding proteins binding to the beta-hairpin of her3
|
|
AU2013345072B2
(en)
|
2012-11-13 |
2017-12-07 |
Genentech, Inc. |
Anti-hemagglutinin antibodies and methods of use
|
|
AR093445A1
(es)
|
2012-11-14 |
2015-06-10 |
Regeneron Pharma |
Metodos para tratar el cancer de ovario con antagonistas de dll4
|
|
CA2891280C
(en)
|
2012-11-24 |
2018-03-20 |
Hangzhou Dac Biotech Co., Ltd. |
Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules
|
|
EP4269602A3
(en)
|
2012-12-14 |
2023-12-27 |
OmniAB, Inc. |
Polynucleotides encoding rodent antibodies with human idiotypes and animals comprising same
|
|
WO2014107739A1
(en)
|
2013-01-07 |
2014-07-10 |
Eleven Biotherapeutics, Inc. |
Antibodies against pcsk9
|
|
US10980804B2
(en)
|
2013-01-18 |
2021-04-20 |
Foundation Medicine, Inc. |
Methods of treating cholangiocarcinoma
|
|
WO2014116749A1
(en)
|
2013-01-23 |
2014-07-31 |
Genentech, Inc. |
Anti-hcv antibodies and methods of using thereof
|
|
HK1218866A1
(zh)
|
2013-02-06 |
2017-03-17 |
瑞泽恩制药公司 |
基於b细胞谱系的人源化动物的免疫原设计
|
|
FI2953971T3
(fi)
|
2013-02-07 |
2023-04-27 |
Csl Ltd |
Il-11r-sitojaproteiineja ja niiden käyttöjä
|
|
LT2840892T
(lt)
*
|
2013-02-20 |
2018-07-25 |
Regeneron Pharmaceuticals, Inc. |
Nežmogaus tipo gyvūnai su modifikuotomis imunoglobulino sunkiųjų grandinių sekomis
|
|
KR20240147707A
(ko)
*
|
2013-02-20 |
2024-10-08 |
리제너론 파아마슈티컬스, 인크. |
사람화된 ｔ-세포 보조-수용체를 발현하는 마우스
|
|
AU2014218931C1
(en)
|
2013-02-20 |
2020-05-14 |
Regeneron Pharmaceuticals, Inc. |
Genetic modification of rats
|
|
EP2958592A1
(en)
|
2013-02-22 |
2015-12-30 |
F. Hoffmann-La Roche AG |
Methods of treating cancer and preventing drug resistance
|
|
CN110192541B
(zh)
|
2013-02-22 |
2022-02-18 |
瑞泽恩制药公司 |
表达人源化主要组织相容性复合物的小鼠
|
|
US20150342163A1
(en)
|
2013-02-22 |
2015-12-03 |
Regeneron Pharmaceuticals, Inc. |
Genetically modified major histocompatibility complex mice
|
|
KR20150123811A
(ko)
|
2013-02-26 |
2015-11-04 |
로슈 글리카트 아게 |
항-mcsp 항체
|
|
RU2015137610A
(ru)
|
2013-03-06 |
2017-04-10 |
Дженентек, Инк. |
Способы лечения и профилактики лекарственной резистентности злокачественных опухолей
|
|
EP4249507A3
(en)
*
|
2013-03-11 |
2023-12-27 |
Regeneron Pharmaceuticals, Inc. |
Transgenic mice expressing chimeric major histocompatibility complex (mhc) class ii molecules
|
|
JP6586412B2
(ja)
|
2013-03-13 |
2019-10-02 |
バイオアシス テクノロジーズ インコーポレイテッド |
ｐ９７のフラグメントおよびその使用
|
|
SG11201506294TA
(en)
|
2013-03-13 |
2015-09-29 |
Regeneron Pharma |
Common light chain mouse
|
|
LT3501272T
(lt)
|
2013-03-13 |
2023-03-27 |
Regeneron Pharmaceuticals, Inc. |
Pelės, vykdančios imunoglobulino lengvosios grandinės riboto rinkinio raišką
|
|
CN105189548A
(zh)
|
2013-03-14 |
2015-12-23 |
瑞泽恩制药公司 |
Grem1的人抗体
|
|
HK1220916A1
(zh)
|
2013-03-14 |
2017-05-19 |
基因泰克公司 |
治疗癌症和预防癌症药物抗性的方法
|
|
EA201591750A1
(ru)
|
2013-03-14 |
2016-05-31 |
Дженентек, Инк. |
Антитела против b7-h4 и иммуноконъюгаты
|
|
US9562099B2
(en)
|
2013-03-14 |
2017-02-07 |
Genentech, Inc. |
Anti-B7-H4 antibodies and immunoconjugates
|
|
BR112015022576A2
(pt)
|
2013-03-14 |
2017-10-24 |
Genentech Inc |
produto farmacêutico e seu uso, kit e método para tratar uma disfunção hiperproliferativa
|
|
PL2967012T3
(pl)
|
2013-03-14 |
2021-04-19 |
Erasmus University Medical Center Rotterdam |
Transgeniczne ssaki inne niż człowiek do wytwarzania przeciwciał
|
|
WO2014144292A2
(en)
*
|
2013-03-15 |
2014-09-18 |
Sanofi Pasteur Biologics , Llc |
Antibodies against clostridium difficile toxins and methods of using the same
|
|
US9598485B2
(en)
|
2013-03-15 |
2017-03-21 |
Ac Immune S.A. |
Anti-tau antibodies and methods of use
|
|
WO2014141192A1
(en)
|
2013-03-15 |
2014-09-18 |
Erasmus University Medical Center |
Generation of heavy chain-only antibodies
|
|
EP3424530A1
(en)
|
2013-03-15 |
2019-01-09 |
Zyngenia, Inc. |
Multivalent and monovalent multispecific complexes and their uses
|
|
KR20250091304A
(ko)
|
2013-03-15 |
2025-06-20 |
제넨테크, 인크. |
Pd-1 및 pd-l1 관련 상태를 치료하기 위한 바이오마커 및 방법
|
|
US9550829B2
(en)
|
2013-03-15 |
2017-01-24 |
Genentech, Inc. |
Compositions and methods for diagnosis and treatment of hepatic cancers
|
|
US20140328849A1
(en)
|
2013-03-15 |
2014-11-06 |
Genentech, Inc. |
Anti-crth2 antibodies and methods of use
|
|
AU2014233385C1
(en)
|
2013-03-15 |
2019-09-19 |
Regeneron Pharmaceuticals, Inc. |
Biologically active molecules, conjugates thereof, and therapeutic uses
|
|
CN105339001A
(zh)
|
2013-03-15 |
2016-02-17 |
基因泰克公司 |
治疗癌症和预防癌症耐药性的方法
|
|
US9788534B2
(en)
|
2013-03-18 |
2017-10-17 |
Kymab Limited |
Animal models and therapeutic molecules
|
|
CA2908697C
(en)
|
2013-04-16 |
2023-12-12 |
Regeneron Pharmaceuticals, Inc. |
Targeted modification of rat genome
|
|
EP3628685A1
(en)
|
2013-04-29 |
2020-04-01 |
F. Hoffmann-La Roche AG |
Human fcrn-binding modified antibodies and methods of use
|
|
SG10201810481UA
(en)
|
2013-04-29 |
2018-12-28 |
Hoffmann La Roche |
Fcrn-binding abolished anti-igf-1r antibodies and their use in the treatment of vascular eye diseases
|
|
US20160068613A1
(en)
|
2013-04-29 |
2016-03-10 |
Hoffmann-La Roche Inc. |
Fc-receptor binding modified asymmetric antibodies and methods of use
|
|
US9783618B2
(en)
|
2013-05-01 |
2017-10-10 |
Kymab Limited |
Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
|
|
US11707056B2
(en)
*
|
2013-05-02 |
2023-07-25 |
Kymab Limited |
Animals, repertoires and methods
|
|
US9783593B2
(en)
|
2013-05-02 |
2017-10-10 |
Kymab Limited |
Antibodies, variable domains and chains tailored for human use
|
|
US20140331339A1
(en)
*
|
2013-05-03 |
2014-11-06 |
Kymab Limited |
Transgenic Non-Human Assay Vertebrates, Assays and Kits
|
|
SG11201509566RA
(en)
|
2013-05-20 |
2015-12-30 |
Genentech Inc |
Anti-transferrin receptor antibodies and methods of use
|
|
US10111953B2
(en)
|
2013-05-30 |
2018-10-30 |
Regeneron Pharmaceuticals, Inc. |
Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
|
|
TWI682780B
(zh)
|
2013-05-30 |
2020-01-21 |
美商再生元醫藥公司 |
醫藥組成物用於製造治療與ｐｃｓｋ９功能獲得性突變有關之體染色體顯性高膽固醇血症的藥物之用途
|
|
EP2810955A1
(en)
|
2013-06-07 |
2014-12-10 |
Sanofi |
Methods for inhibiting atherosclerosis by administering an inhibitor of PCSK9
|
|
TW202021614A
(zh)
|
2013-06-07 |
2020-06-16 |
法商賽諾菲生物技術公司 |
藉由投與ｐｃｓｋ９抑制劑抑制動脈粥狀硬化的方法
|
|
EP2862877A1
(en)
|
2013-10-18 |
2015-04-22 |
Sanofi |
Methods for inhibiting atherosclerosis by administering an inhibitor of PCSK9
|
|
US9925273B2
(en)
|
2013-08-01 |
2018-03-27 |
Agensys, Inc. |
Antibody drug conjugates (ADC) that bind to CD37 proteins
|
|
CN105518132B
(zh)
|
2013-08-07 |
2021-02-05 |
瑞泽恩制药公司 |
缺乏lincRNA的非人类动物
|
|
ES2730978T3
(es)
|
2013-08-09 |
2019-11-13 |
Astellas Pharma Inc |
Anticuerpo anti-receptor de TSLP humana nuevo
|
|
CA2922113C
(en)
|
2013-08-23 |
2023-05-23 |
Regeneron Pharmaceuticals, Inc. |
Diagnostic tests and methods for assessing safety, efficacy or outcome of allergen-specific immunotherapy (sit)
|
|
KR102252925B1
(ko)
|
2013-08-26 |
2021-05-18 |
리제너론 파마슈티칼스 인코포레이티드 |
마크롤라이드 디아스테레오머를 포함하는 약제학적 조성물, 이의 합성 방법 및 치료학적 용도
|
|
US20150093399A1
(en)
|
2013-08-28 |
2015-04-02 |
Bioasis Technologies, Inc. |
Cns-targeted conjugates having modified fc regions and methods of use thereof
|
|
US10617755B2
(en)
|
2013-08-30 |
2020-04-14 |
Genentech, Inc. |
Combination therapy for the treatment of glioblastoma
|
|
US10456470B2
(en)
|
2013-08-30 |
2019-10-29 |
Genentech, Inc. |
Diagnostic methods and compositions for treatment of glioblastoma
|
|
CA2921982C
(en)
|
2013-09-02 |
2020-08-25 |
Hangzhou Dac Biotech Co., Ltd |
Novel cytotoxic agents for conjugation of drugs to cell binding molecule
|
|
AR097685A1
(es)
|
2013-09-17 |
2016-04-06 |
Genentech Inc |
Métodos de uso de anticuerpos anti-lgr5
|
|
EP3418379B1
(en)
|
2013-09-18 |
2020-12-09 |
Kymab Limited |
Methods, cells & organisms
|
|
KR20200103882A
(ko)
|
2013-09-18 |
2020-09-02 |
리제너론 파마슈티칼스 인코포레이티드 |
히스티딘 엔지니어링된 경쇄 항체 및 그것을 생성하기 위한 유전자 변형된 비-인간 동물
|
|
ES2993142T3
(en)
*
|
2013-10-01 |
2024-12-23 |
Kymab Ltd |
Animal models and therapeutic molecules
|
|
EP3689913B1
(en)
|
2013-10-11 |
2022-03-23 |
Sanofi Biotechnology |
Use of a pcsk9 inhibitor to treat hyperlipidemia
|
|
JP2016537965A
(ja)
|
2013-10-11 |
2016-12-08 |
ジェネンテック， インコーポレイテッド |
Ｎｓｐ４阻害剤及び使用方法
|
|
CN105744954B
(zh)
|
2013-10-18 |
2021-03-05 |
豪夫迈·罗氏有限公司 |
抗rspo2和/或抗rspo3抗体及其用途
|
|
BR112016008694A2
(pt)
|
2013-10-23 |
2017-10-03 |
Genentech Inc |
Métodos de previsão da reação de pacientes com asma, de previsão da capacidade de reação de pacientes com asma, de identificação de pacientes com asma, de tratamento de pacientes portadores de asma e de tratamento de asma, uso de um kit e kit
|
|
MY192757A
(en)
|
2013-11-06 |
2022-09-07 |
Janssen Biotech Inc |
Anti-ccl17 antibodies
|
|
US10428157B2
(en)
|
2013-11-12 |
2019-10-01 |
Sanofi Biotechnology |
Dosing regimens for use with PCSK9 inhibitors
|
|
WO2015075011A1
(en)
|
2013-11-21 |
2015-05-28 |
F. Hoffmann-La Roche Ag |
ANTI-alpha-SYNUCLEIN ANTIBODIES AND METHODS OF USE
|
|
SG10201700961TA
(en)
|
2013-12-11 |
2017-04-27 |
Regeneron Pharma |
Methods and compositions for the targeted modification of a genome
|
|
HUE041331T2
(hu)
|
2013-12-11 |
2019-05-28 |
Regeneron Pharma |
Módszerek és készítmények a genom célzott módosításához
|
|
MX2016007576A
(es)
|
2013-12-13 |
2016-10-03 |
Genentech Inc |
Anticuerpos e inmunoconjugados anti-cd33.
|
|
MX2016007885A
(es)
|
2013-12-17 |
2017-01-11 |
Genentech Inc |
Metodos de tratamiento de cancer usando antagonistas de union del eje de pd-1 y un anticuerpo anti-cd20.
|
|
KR102225489B1
(ko)
|
2013-12-17 |
2021-03-10 |
제넨테크, 인크. |
항-cd3 항체 및 이의 사용 방법
|
|
CA2934028A1
(en)
|
2013-12-17 |
2015-06-25 |
Genentech, Inc. |
Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
|
|
NZ760065A
(en)
|
2013-12-17 |
2022-12-23 |
Genentech Inc |
Methods of treating cancers using pd-1 axis binding antagonists and taxanes
|
|
TWI728373B
(zh)
|
2013-12-23 |
2021-05-21 |
美商建南德克公司 |
抗體及使用方法
|
|
CN114292331A
(zh)
|
2013-12-24 |
2022-04-08 |
安斯泰来制药株式会社 |
抗人bdca-2抗体、其生产方法、多核苷酸、表达载体、宿主细胞及医药组合物
|
|
MX373856B
(es)
|
2014-01-03 |
2020-03-25 |
Hoffmann La Roche |
Conjugados helicoidales-anticuerpo anti-helicoidal unidos covalentemente y usos de los mismos.
|
|
MX373017B
(es)
|
2014-01-03 |
2020-04-28 |
Hoffmann La Roche |
Conjugados de toxina polipeptidica-anticuerpo unidos covalentemente.
|
|
ES2895752T3
(es)
|
2014-01-03 |
2022-02-22 |
Hoffmann La Roche |
Anticuerpos biespecíficos anti-hapteno/anti-receptor de la barrera hematoencefálica, complejos de los mismos y su uso como lanzaderas a través de la barrera hematoencefálica
|
|
WO2015103549A1
(en)
|
2014-01-03 |
2015-07-09 |
The United States Of America, As Represented By The Secretary Department Of Health And Human Services |
Neutralizing antibodies to hiv-1 env and their use
|
|
WO2015107026A1
(en)
|
2014-01-15 |
2015-07-23 |
F. Hoffmann-La Roche Ag |
Fc-region variants with modified fcrn- and maintained protein a-binding properties
|
|
TWI680138B
(zh)
|
2014-01-23 |
2019-12-21 |
美商再生元醫藥公司 |
抗ｐｄ-ｌ１之人類抗體
|
|
TWI681969B
(zh)
|
2014-01-23 |
2020-01-11 |
美商再生元醫藥公司 |
針對ｐｄ-１的人類抗體
|
|
KR20160111469A
(ko)
|
2014-01-24 |
2016-09-26 |
제넨테크, 인크. |
항-steap1 항체 및 면역접합체를 사용하는 방법
|
|
WO2015116852A1
(en)
|
2014-01-29 |
2015-08-06 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating rheumatoid arthritis by administering an il-6r antibody
|
|
ES2764973T3
(es)
|
2014-02-03 |
2020-06-05 |
Bioasis Technologies Inc |
Proteínas de fusión de P97
|
|
TWI769970B
(zh)
|
2014-02-08 |
2022-07-11 |
美商建南德克公司 |
治療阿茲海默症之方法
|
|
AU2015214058B2
(en)
|
2014-02-08 |
2020-07-09 |
Genentech, Inc. |
Methods of treating Alzheimer's Disease
|
|
WO2015123325A1
(en)
|
2014-02-12 |
2015-08-20 |
Genentech, Inc. |
Anti-jagged1 antibodies and methods of use
|
|
WO2015123423A2
(en)
|
2014-02-14 |
2015-08-20 |
Regeneron Pharmaceuticals, Inc |
Methods for treating patients with hypercholesterolemia that is not adequately controlled by moderate-dose statin therapy
|
|
ES2762672T3
(es)
|
2014-02-19 |
2020-05-25 |
Bioasis Technologies Inc |
Proteínas de fusión de P97-IDS
|
|
IL315136A
(en)
|
2014-02-21 |
2024-10-01 |
Sanofi Biotechnology |
Methods for treating or preventing asthma by administering an il-4rantagonist
|
|
CN106029693A
(zh)
|
2014-02-21 |
2016-10-12 |
豪夫迈·罗氏有限公司 |
抗il-13/il-17双特异性抗体及其用途
|
|
CN106414465B
(zh)
|
2014-02-28 |
2021-11-16 |
杭州多禧生物科技有限公司 |
带电荷链接体及其在共轭反应上的应用
|
|
BR112016020822A2
(pt)
|
2014-03-14 |
2017-10-03 |
Genentech Inc |
Métodos e composições para secreção de polipeptídeos heterólogos
|
|
CN114642661A
(zh)
|
2014-03-17 |
2022-06-21 |
赛诺菲生物技术公司 |
用于降低心血管风险的方法
|
|
WO2015140591A1
(en)
|
2014-03-21 |
2015-09-24 |
Nordlandssykehuset Hf |
Anti-cd14 antibodies and uses thereof
|
|
SG10201808225TA
(en)
|
2014-03-21 |
2018-10-30 |
Regeneron Pharma |
Non-human animals that make single domain binding proteins
|
|
BR112016023417A2
(pt)
|
2014-03-21 |
2019-04-16 |
F. Hoffmann-La Roche Ag |
predição in vitro de meia-vida in vivo
|
|
BR112016021679A2
(pt)
|
2014-03-21 |
2018-12-04 |
Regeneron Pharmaceuticals, Inc. |
proteína de ligação ao antígeno, métodos de produção de uma proteína de ligação ao antígeno e de identificação de uma ou mais proteínas de ligação ao antígeno, hibridoma, ácido nucleico, célula, e, animal não humano geneticamente modificado.
|
|
BR112016021383A2
(pt)
|
2014-03-24 |
2017-10-03 |
Genentech Inc |
Método para identificar um paciente com câncer que é susceptível ou menos susceptível a responder ao tratamento com um antagonista de cmet, método para identificar um paciente apresentando câncer previamente tratado, método para determinar a expressão do biomarcador hgf, antagonista anti-c-met e seu uso, kit de diagnóstico e seu método de preparo
|
|
HRP20192285T1
(hr)
|
2014-03-31 |
2020-03-06 |
F. Hoffmann - La Roche Ag |
Anti-ox40 protutijela i postupci uporabe
|
|
RU2016142476A
(ru)
|
2014-03-31 |
2018-05-07 |
Дженентек, Инк. |
Комбинированная терапия, включающая антиангиогенезные агенты и агонисты, связывающие ох40
|
|
KR102376287B1
(ko)
|
2014-04-02 |
2022-03-17 |
에프. 호프만-라 로슈 아게 |
다중특이적 항체 경쇄 잘못짝짓기의 검출 방법
|
|
KR102380402B1
(ko)
|
2014-04-03 |
2022-03-31 |
아이쥐엠 바이오사이언스 인코포레이티드 |
변형된 j-사슬
|
|
MX388380B
(es)
|
2014-04-18 |
2025-03-19 |
Acceleron Pharma Inc |
Composiciones para usarse en el incremento de los niveles de glóbulos rojos y el tratamiento de enfermedad de células falciformes.
|
|
WO2015164615A1
(en)
|
2014-04-24 |
2015-10-29 |
University Of Oslo |
Anti-gluten antibodies and uses thereof
|
|
WO2015168521A2
(en)
|
2014-05-01 |
2015-11-05 |
Bioasis Technologies, Inc. |
P97-polynucleotide conjugates
|
|
PT3613432T
(pt)
|
2014-05-07 |
2025-10-29 |
Regeneron Pharma |
Métodos para tratar a polipose nasal através da administração de um antagonista de il-4r
|
|
NO2785538T3
(enExample)
*
|
2014-05-07 |
2018-08-04 |
|
|
|
KR20250096864A
(ko)
|
2014-05-19 |
2025-06-27 |
리제너론 파마슈티칼스 인코포레이티드 |
인간 epo를 발현하는 유전자 변형된 비-인간 동물
|
|
RU2016150370A
(ru)
|
2014-05-22 |
2018-06-26 |
Дженентек, Инк. |
Антитела и иммуноконъюгаты против GPC3
|
|
MX2016015163A
(es)
|
2014-05-23 |
2017-03-03 |
Genentech Inc |
Biomarcadores mit y metodos para su uso.
|
|
ES2877275T3
(es)
*
|
2014-05-30 |
2021-11-16 |
Regeneron Pharma |
Animales con dipeptidil peptidasa IV (DPP4) humanizada
|
|
HUE049776T2
(hu)
|
2014-06-06 |
2020-10-28 |
Regeneron Pharma |
Módszerek és készítmények egy célzott lókusz módosítására
|
|
KR20170010785A
(ko)
|
2014-06-11 |
2017-02-01 |
제넨테크, 인크. |
항-lgr5 항체 및 이의 용도
|
|
TN2016000553A1
(en)
|
2014-06-13 |
2018-04-04 |
Acceleron Pharma Inc |
Methods and compositions for treating ulcers
|
|
CN107073121A
(zh)
|
2014-06-13 |
2017-08-18 |
基因泰克公司 |
治疗及预防癌症药物抗性的方法
|
|
MX384887B
(es)
|
2014-06-23 |
2025-03-14 |
Regeneron Pharma |
Ensamblaje de adn mediado por nucleasa.
|
|
TWI713453B
(zh)
|
2014-06-23 |
2020-12-21 |
美商健生生物科技公司 |
干擾素α及ω抗體拮抗劑
|
|
EP3161128B1
(en)
|
2014-06-26 |
2018-09-26 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for targeted genetic modifications and methods of use
|
|
TW201623329A
(zh)
|
2014-06-30 |
2016-07-01 |
亞佛瑞司股份有限公司 |
針對骨調素截斷變異體的疫苗及單株抗體暨其用途
|
|
CA2954687A1
(en)
|
2014-07-10 |
2016-01-14 |
Affiris Ag |
Substances and methods for the use in prevention and/or treatment in huntington's disease
|
|
BR112017000130A2
(pt)
|
2014-07-11 |
2018-01-09 |
Genentech Inc |
método para atenuar a toxicidade associada à inibição da via de notch e método de tratamento do câncer
|
|
WO2016011052A1
(en)
|
2014-07-14 |
2016-01-21 |
Genentech, Inc. |
Diagnostic methods and compositions for treatment of glioblastoma
|
|
EP3169362B1
(en)
|
2014-07-16 |
2020-06-10 |
Sanofi Biotechnology |
Methods for treating high cardiovascular risk patients with hypercholesterolemia
|
|
KR20230074283A
(ko)
|
2014-07-16 |
2023-05-26 |
사노피 바이오테크놀로지 |
이형접합성 가족성 고콜레스테롤혈증(heFH) 환자의 치료방법
|
|
WO2016025829A1
(en)
|
2014-08-15 |
2016-02-18 |
Adynxx, Inc. |
Oligonucleotide decoys for the treatment of pain
|
|
AU2015314954B2
(en)
|
2014-09-12 |
2021-05-13 |
Genentech, Inc. |
Anti-HER2 antibodies and immunoconjugates
|
|
SG11201701627PA
(en)
|
2014-09-12 |
2017-03-30 |
Genentech Inc |
Anti-cll-1 antibodies and immunoconjugates
|
|
US10059768B2
(en)
|
2014-09-12 |
2018-08-28 |
Genentech, Inc. |
Anti-B7-H4 antibodies and immunoconjugates
|
|
MX2017003535A
(es)
|
2014-09-16 |
2017-10-27 |
Regeneron Pharma |
Anticuerpos anti-glucagon y sus usos.
|
|
WO2016044396A1
(en)
|
2014-09-17 |
2016-03-24 |
Genentech, Inc. |
Immunoconjugates comprising anti-her2 antibodies and pyrrolobenzodiazepines
|
|
WO2016044745A1
(en)
|
2014-09-19 |
2016-03-24 |
Regeneron Pharmaceuticals, Inc. |
Chimeric antigen receptors
|
|
DK3262071T3
(da)
|
2014-09-23 |
2020-06-15 |
Hoffmann La Roche |
Fremgangsmåde til anvendelse af anti-CD79b-immunkonjugater
|
|
EP3197914B1
(en)
|
2014-09-23 |
2024-02-07 |
Regeneron Pharmaceuticals, Inc. |
Anti-il-25 antibodies and uses thereof
|
|
DK3207124T3
(da)
|
2014-10-15 |
2019-08-12 |
Regeneron Pharma |
Fremgangsmåder og sammensætninger til generering eller bevaring af pluripotente celler
|
|
JP2017536102A
(ja)
|
2014-10-16 |
2017-12-07 |
ジェネンテック， インコーポレイテッド |
抗アルファ−シヌクレイン抗体及び使用方法
|
|
EP3209697A4
(en)
|
2014-10-23 |
2018-05-30 |
La Trobe University |
Fn14-binding proteins and uses thereof
|
|
US10626176B2
(en)
|
2014-10-31 |
2020-04-21 |
Jounce Therapeutics, Inc. |
Methods of treating conditions with antibodies that bind B7-H4
|
|
AU2015343337A1
(en)
|
2014-11-03 |
2017-06-15 |
Genentech, Inc. |
Assays for detecting T cell immune subsets and methods of use thereof
|
|
CN107109484B
(zh)
|
2014-11-03 |
2021-12-14 |
豪夫迈·罗氏有限公司 |
用于ox40激动剂治疗的功效预测和评估的方法和生物标志物
|
|
EP3215524B1
(en)
|
2014-11-06 |
2021-01-13 |
F.Hoffmann-La Roche Ag |
Fc-region variants with modified fcrn- and protein a-binding properties
|
|
KR20170072343A
(ko)
|
2014-11-06 |
2017-06-26 |
제넨테크, 인크. |
Ox40 결합 효능제 및 tigit 억제제를 포함하는 병용 요법
|
|
SI3215528T1
(sl)
|
2014-11-06 |
2019-11-29 |
Hoffmann La Roche |
Variante regije Fc s spremenjeno vezavo FcRn in postopki uporabe
|
|
CA2960297A1
(en)
|
2014-11-10 |
2016-05-19 |
Genentech, Inc. |
Anti-interleukin-33 antibodies and uses thereof
|
|
EP3217787B1
(en)
|
2014-11-10 |
2019-04-17 |
F.Hoffmann-La Roche Ag |
Animal model for nephropathy and agents for treating the same
|
|
EP3218396B1
(en)
|
2014-11-14 |
2022-12-28 |
Regeneron Pharmaceuticals, Inc. |
Method for generating high affinity antibodies
|
|
US10066017B2
(en)
|
2014-11-14 |
2018-09-04 |
Sanofi Biotechnology |
Methods for treating chronic sinusitis with nasal polyps by administering an IL-4R antagonist
|
|
EP3875481B1
(en)
|
2014-11-14 |
2025-01-22 |
The U.S.A. as represented by the Secretary, Department of Health and Human Services |
Neutralizing antibodies to ebola virus glycoprotein and their use
|
|
MX2017006320A
(es)
|
2014-11-17 |
2017-08-10 |
Genentech Inc |
Terapia combinada que comprende agonistas de unión de ox40 y antagonistas de unión del eje de pd-1.
|
|
EP3221364B1
(en)
|
2014-11-19 |
2020-12-16 |
Genentech, Inc. |
Antibodies against bace1 and use thereof for neural disease immunotherapy
|
|
JP6993228B2
(ja)
|
2014-11-19 |
2022-03-03 |
ジェネンテック， インコーポレイテッド |
抗トランスフェリン受容体／抗ｂａｃｅ１多重特異性抗体および使用方法
|
|
WO2016081643A1
(en)
|
2014-11-19 |
2016-05-26 |
Genentech, Inc. |
Anti-transferrin receptor antibodies and methods of use
|
|
RU2753902C2
(ru)
|
2014-11-20 |
2021-08-24 |
Ф.Хоффманн-Ля Рош Аг |
Комбинированная терапия на основе активирующих т-клетки биспецифических антигенсвязывающих молекул против cd3 и фолатного рецептора 1 (folr1) и антагонистов, связывающихся с осью pd-1
|
|
EP3221457B1
(en)
|
2014-11-21 |
2019-03-20 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for targeted genetic modification using paired guide rnas
|
|
KR20240055876A
(ko)
|
2014-11-24 |
2024-04-29 |
리제너론 파마슈티칼스 인코포레이티드 |
인간화 cd3 복합체를 발현하는 비인간 동물
|
|
JP6554280B2
(ja)
*
|
2014-11-28 |
2019-07-31 |
株式会社デンソーテン |
データ処理装置、画像処理方法、及び、プログラム
|
|
MA41119A
(fr)
|
2014-12-03 |
2017-10-10 |
Acceleron Pharma Inc |
Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique
|
|
AU2015358325A1
(en)
|
2014-12-05 |
2017-05-25 |
Genentech, Inc. |
Anti-CD79b antibodies and methods of use
|
|
WO2016094566A2
(en)
|
2014-12-10 |
2016-06-16 |
Genentech, Inc. |
Blood brain barrier receptor antibodies and methods of use
|
|
JP6840077B2
(ja)
|
2014-12-19 |
2021-03-10 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
単一ステップの複数標的化を通じた標的化された遺伝子修飾のための方法及び組成物
|
|
TWI656133B
(zh)
|
2014-12-19 |
2019-04-11 |
日商中外製藥股份有限公司 |
抗肌抑素之抗體、含變異Ｆｃ區域之多胜肽及使用方法
|
|
WO2016094962A1
(en)
|
2014-12-19 |
2016-06-23 |
Monash University |
Il-21 antibodies
|
|
KR101838645B1
(ko)
|
2014-12-19 |
2018-03-14 |
추가이 세이야쿠 가부시키가이샤 |
항-c5 항체 및 그의 사용 방법
|
|
TWI702229B
(zh)
|
2014-12-19 |
2020-08-21 |
美商再生元醫藥公司 |
流行性感冒病毒血球凝集素之人類抗體
|
|
US20160200815A1
(en)
|
2015-01-05 |
2016-07-14 |
Jounce Therapeutics, Inc. |
Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof
|
|
JP2018511557A
(ja)
|
2015-01-22 |
2018-04-26 |
中外製薬株式会社 |
２種以上の抗ｃ５抗体の組み合わせおよび使用方法
|
|
TWI710573B
(zh)
|
2015-01-26 |
2020-11-21 |
美商再生元醫藥公司 |
抗伊波拉病毒醣蛋白之人類抗體
|
|
WO2016125495A1
(en)
|
2015-02-05 |
2016-08-11 |
Chugai Seiyaku Kabushiki Kaisha |
Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof
|
|
WO2016130539A2
(en)
|
2015-02-09 |
2016-08-18 |
Memorial Sloan Kettering Cancer Center |
Multi-specific antibodies with affinity for human a33 antigen and dota metal complex and uses thereof
|
|
CA2975899A1
(en)
|
2015-02-13 |
2016-08-18 |
Biommune Technologies Inc. |
Antibodies to l-type voltage gated channels and related methods
|
|
ES2884844T3
(es)
|
2015-03-09 |
2021-12-13 |
Agensys Inc |
Conjugados de anticuerpo fármaco (ADC) que se unen a proteínas FLT3
|
|
RU2744831C2
(ru)
|
2015-03-16 |
2021-03-16 |
Регенерон Фармасьютикалз, Инк. |
Не относящееся к человеку животное, у которого проявляется снижение функции верхних и нижних моторных нейронов и чувственного восприятия
|
|
CA2977285A1
(en)
|
2015-03-16 |
2016-09-22 |
F. Hoffmann-La Roche Ag |
Methods of detecting and quantifying il-13 and uses in diagnosing and treating th2-associated diseases
|
|
HK1250038A1
(zh)
|
2015-03-19 |
2018-11-23 |
瑞泽恩制药公司 |
选择结合抗原的轻链可变区的非人动物
|
|
WO2016146833A1
(en)
|
2015-03-19 |
2016-09-22 |
F. Hoffmann-La Roche Ag |
Biomarkers for nad(+)-diphthamide adp ribosyltransferase resistance
|
|
SMT202000255T1
(it)
|
2015-03-20 |
2020-07-08 |
The United States Of America As Represented By The Secretary Department Of Health And Human Services |
Anticorpi neutralizzanti diretti contro gp120 e loro utilizzo
|
|
KR20170129902A
(ko)
|
2015-03-23 |
2017-11-27 |
조운스 테라퓨틱스, 인크. |
Icos에 대한 항체
|
|
KR20240142591A
(ko)
|
2015-03-27 |
2024-09-30 |
리제너론 파아마슈티컬스, 인크. |
메이탄시노이드 유도체, 이의 컨주게이트, 및 사용 방법
|
|
MA41919A
(fr)
|
2015-04-06 |
2018-02-13 |
Acceleron Pharma Inc |
Hétéromultimères alk4:actriib et leurs utilisations
|
|
HK1250373A1
(zh)
|
2015-04-06 |
2018-12-14 |
Acceleron Pharma Inc. |
Alk7:actriib异多聚体和其用途
|
|
KR20240132525A
(ko)
|
2015-04-06 |
2024-09-03 |
리제너론 파아마슈티컬스, 인크. |
비인간 동물에서의 인간화 t 세포 매개 면역반응
|
|
MX2017012805A
(es)
|
2015-04-07 |
2018-04-11 |
Genentech Inc |
Complejo de unión a antígenos con actividad agonista y métodos de uso.
|
|
HUE057432T2
(hu)
|
2015-04-07 |
2022-05-28 |
Alector Llc |
Anti-sortilin antitestek és ezek alkalmazási módjai
|
|
JP6752221B2
(ja)
|
2015-04-13 |
2020-09-09 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
ヒト化ｓｉｒｐａ−ｉｌ１５ノックインマウス及びその使用方法
|
|
CN107810197B
(zh)
|
2015-04-24 |
2022-10-25 |
豪夫迈·罗氏有限公司 |
鉴定包含结合多肽的细菌的方法
|
|
HK1250997A1
(zh)
|
2015-05-01 |
2019-01-18 |
基因泰克公司 |
掩蔽抗cd3抗体和使用方法
|
|
WO2016179194A1
(en)
|
2015-05-04 |
2016-11-10 |
Jounce Therapeutics, Inc. |
Lilra3 and method of using the same
|
|
HK1248577A1
(zh)
|
2015-05-11 |
2018-10-19 |
F. Hoffmann-La Roche Ag |
治疗狼疮性肾炎的组合物和方法
|
|
EP3294770B2
(en)
|
2015-05-12 |
2024-03-20 |
F. Hoffmann-La Roche AG |
Therapeutic and diagnostic methods for cancer
|
|
JP6913030B2
(ja)
|
2015-05-18 |
2021-08-04 |
アジェンシス，インコーポレイテッド |
Ａｘｌタンパク質に結合する抗体
|
|
WO2016187354A1
(en)
|
2015-05-18 |
2016-11-24 |
Agensys, Inc. |
Antibodies that bind to axl proteins
|
|
US10395759B2
(en)
|
2015-05-18 |
2019-08-27 |
Regeneron Pharmaceuticals, Inc. |
Methods and systems for copy number variant detection
|
|
EP3302563A1
(en)
|
2015-05-29 |
2018-04-11 |
H. Hoffnabb-La Roche Ag |
Humanized anti-ebola virus glycoprotein antibodies and methods of use
|
|
KR20250151554A
(ko)
|
2015-05-29 |
2025-10-21 |
제넨테크, 인크. |
암에 대한 치료 및 진단 방법
|
|
RU2725737C2
(ru)
|
2015-05-29 |
2020-07-03 |
Регенерон Фармасьютикалс, Инк. |
Животные, отличные от человека, с нарушением в локусе c9orf72
|
|
EP3302552A1
(en)
|
2015-06-02 |
2018-04-11 |
H. Hoffnabb-La Roche Ag |
Compositions and methods for using anti-il-34 antibodies to treat neurological diseases
|
|
WO2016196975A1
(en)
|
2015-06-03 |
2016-12-08 |
The United States Of America, As Represented By The Secretary Department Of Health & Human Services |
Neutralizing antibodies to hiv-1 env and their use
|
|
UA126272C2
(uk)
|
2015-06-05 |
2022-09-14 |
Дженентек, Інк. |
Антитіло проти тау-білка та спосіб його застосування
|
|
EP3303399A1
(en)
|
2015-06-08 |
2018-04-11 |
H. Hoffnabb-La Roche Ag |
Methods of treating cancer using anti-ox40 antibodies
|
|
US20170000885A1
(en)
|
2015-06-08 |
2017-01-05 |
Genentech, Inc. |
Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists
|
|
EP3307779A2
(en)
|
2015-06-12 |
2018-04-18 |
Alector LLC |
Anti-cd33 antibodies and methods of use thereof
|
|
CA2988982A1
(en)
|
2015-06-12 |
2016-12-15 |
Alector Llc |
Anti-cd33 antibodies and methods of use thereof
|
|
EP3307780A1
(en)
|
2015-06-15 |
2018-04-18 |
Genentech, Inc. |
Antibodies and immunoconjugates
|
|
ES2957567T3
(es)
|
2015-06-16 |
2024-01-22 |
Hoffmann La Roche |
Anticuerpos humanizados y de afinidad madurada contra FcRH5 y procedimientos de uso
|
|
TW201718647A
(zh)
|
2015-06-16 |
2017-06-01 |
建南德克公司 |
抗-cll-1抗體及使用方法
|
|
EP3916018A1
(en)
|
2015-06-16 |
2021-12-01 |
Genentech, Inc. |
Anti-cd3 antibodies and methods of use
|
|
ES3043088T3
(en)
|
2015-06-17 |
2025-11-24 |
Hoffmann La Roche |
Anti-her2 antibodies and methods of use
|
|
IL256080B2
(en)
|
2015-06-17 |
2025-06-01 |
Genentech Inc |
Methods of treating locally advanced or metastatic breast cancers using pd-1 axis binding antagonists and taxanes
|
|
PE20221007A1
(es)
|
2015-06-24 |
2022-06-15 |
Hoffmann La Roche |
Anticuerpos anti-receptor de transferrina con afinidad disenada
|
|
WO2017004091A1
(en)
|
2015-06-29 |
2017-01-05 |
Genentech, Inc. |
Type ii anti-cd20 antibody for use in organ transplantation
|
|
NZ739830A
(en)
|
2015-07-12 |
2021-12-24 |
Hangzhou Dac Biotech Co Ltd |
Bridge linkers for conjugation of cell-binding molecules
|
|
US9839687B2
(en)
|
2015-07-15 |
2017-12-12 |
Suzhou M-Conj Biotech Co., Ltd. |
Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
|
|
WO2017024171A1
(en)
|
2015-08-04 |
2017-02-09 |
Acceleron Pharma Inc. |
Methods for treating myeloproliferative disorders
|
|
KR20180030917A
(ko)
|
2015-08-05 |
2018-03-26 |
얀센 바이오테크 인코포레이티드 |
항-cd154 항체 및 그의 사용 방법
|
|
TW201713690A
(zh)
|
2015-08-07 |
2017-04-16 |
再生元醫藥公司 |
抗ａｎｇｐｔｌ８抗體及其用途
|
|
CN105384825B
(zh)
|
2015-08-11 |
2018-06-01 |
南京传奇生物科技有限公司 |
一种基于单域抗体的双特异性嵌合抗原受体及其应用
|
|
JP2018523684A
(ja)
|
2015-08-18 |
2018-08-23 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
リポタンパク質アフェレーシスを受けている高脂血症の患者を治療するための抗ｐｃｓｋ９阻害抗体
|
|
US20180230238A1
(en)
|
2015-08-24 |
2018-08-16 |
Trianni, Inc |
Enhanced production of immunoglobulins
|
|
US9862760B2
(en)
|
2015-09-16 |
2018-01-09 |
Novartis Ag |
Polyomavirus neutralizing antibodies
|
|
IL258088B2
(en)
|
2015-09-18 |
2024-02-01 |
Chugai Pharmaceutical Co Ltd |
Antibodies that bind to IL-8 and their uses
|
|
CN108137681B
(zh)
|
2015-09-23 |
2024-06-18 |
豪夫迈·罗氏有限公司 |
抗-vegf抗体的优化的变体
|
|
RU2757135C2
(ru)
|
2015-09-24 |
2021-10-11 |
АБВИТРО ЭлЭлСи |
Композиции антител к вич и способы их применения
|
|
KR20250021613A
(ko)
|
2015-09-25 |
2025-02-13 |
제넨테크, 인크. |
항-tigit 항체 및 이의 이용 방법
|
|
US20190048089A1
(en)
|
2015-09-30 |
2019-02-14 |
Janssen Biotech, Inc. |
Antagonistic Antibodies Specifically Binding Human CD40 and Methods of Use
|
|
DK3355913T3
(da)
|
2015-09-30 |
2024-12-02 |
Igm Biosciences Inc |
Bindingsmolekyler med modificeret j-kæde
|
|
US11639389B2
(en)
|
2015-09-30 |
2023-05-02 |
Igm Biosciences, Inc. |
Binding molecules with modified J-chain
|
|
NZ741261A
(en)
|
2015-10-02 |
2019-11-29 |
Genentech Inc |
Pyrrolobenzodiazepine antibody drug conjugates and methods of use
|
|
WO2017055542A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Bispecific anti-human cd20/human transferrin receptor antibodies and methods of use
|
|
AR106189A1
(es)
|
2015-10-02 |
2017-12-20 |
Hoffmann La Roche |
ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
|
|
IL257858B
(en)
|
2015-10-02 |
2022-09-01 |
Hoffmann La Roche |
Anti-pd1 antibodies and methods of use
|
|
TWI756187B
(zh)
|
2015-10-09 |
2022-03-01 |
美商再生元醫藥公司 |
抗ｌａｇ３抗體及其用途
|
|
TW202417497A
(zh)
|
2015-10-12 |
2024-05-01 |
美商再生元醫藥公司 |
活化瘦素受體的抗原結合蛋白
|
|
MA43354A
(fr)
|
2015-10-16 |
2018-08-22 |
Genentech Inc |
Conjugués médicamenteux à pont disulfure encombré
|
|
EP3365025B1
(en)
|
2015-10-20 |
2020-07-15 |
Genentech, Inc. |
Calicheamicin-antibody-drug conjugates and methods of use
|
|
KR20180066236A
(ko)
|
2015-10-22 |
2018-06-18 |
조운스 테라퓨틱스, 인크. |
Icos 발현을 계측하기 위한 유전자 특질
|
|
EP3184547A1
(en)
|
2015-10-29 |
2017-06-28 |
F. Hoffmann-La Roche AG |
Anti-tpbg antibodies and methods of use
|
|
NZ741780A
(en)
|
2015-10-30 |
2019-11-29 |
Genentech Inc |
Anti-htra1 antibodies and methods of use thereof
|
|
US10407510B2
(en)
|
2015-10-30 |
2019-09-10 |
Genentech, Inc. |
Anti-factor D antibodies and conjugates
|
|
SMT202200118T1
(it)
|
2015-11-03 |
2022-05-12 |
Janssen Biotech Inc |
Anticorpi che legano specificamente pd-1 e loro usi
|
|
EP3370754A4
(en)
|
2015-11-04 |
2019-10-23 |
Acceleron Pharma Inc. |
METHOD FOR INCREASING ERYTHROCYTE CONCENTRATION AND TREATMENT OF INEFFICIENT ERYTHROPOIESE
|
|
CN108602884B
(zh)
|
2015-11-08 |
2024-06-25 |
豪夫迈·罗氏有限公司 |
筛选多特异性抗体的方法
|
|
CA3005975A1
(en)
|
2015-11-23 |
2017-06-01 |
Acceleron Pharma Inc. |
Methods for treating eye disorders
|
|
KR102802396B1
(ko)
|
2015-11-27 |
2025-05-07 |
씨에스엘 리미티드 |
Cd131 결합 단백질 및 이의 용도
|
|
EP3384030A4
(en)
|
2015-12-03 |
2019-07-03 |
Trianni, Inc. |
IMPROVED IMMUNOGLULINIVITY
|
|
ES2901794T3
(es)
|
2015-12-09 |
2022-03-23 |
Hoffmann La Roche |
Anticuerpo anti-CD20 de tipo II para reducir la formación de anticuerpos antifármaco
|
|
EP3178848A1
(en)
|
2015-12-09 |
2017-06-14 |
F. Hoffmann-La Roche AG |
Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies
|
|
KR20180087430A
(ko)
|
2015-12-17 |
2018-08-01 |
얀센 바이오테크 인코포레이티드 |
Hla-dr에 특이적으로 결합하는 항체 및 이의 용도
|
|
AR107078A1
(es)
|
2015-12-18 |
2018-03-21 |
Chugai Pharmaceutical Co Ltd |
Anticuerpo antimiostatina, polipéptidos que contienen regiones fc variantes así como métodos de uso
|
|
KR102467124B1
(ko)
|
2015-12-18 |
2022-11-15 |
추가이 세이야쿠 가부시키가이샤 |
항-c5 항체 및 사용 방법
|
|
MA44146B1
(fr)
|
2015-12-22 |
2023-10-31 |
Regeneron Pharma |
Combinaison d'anticorps anti-pd-1 et d'anticorps bispécifiques anti-cd20/anti-cd3 pour traiter le cancer
|
|
AR107303A1
(es)
|
2016-01-08 |
2018-04-18 |
Hoffmann La Roche |
Métodos de tratamiento de cánceres positivos para ace utilizando antagonistas de unión a eje pd-1 y anticuerpos biespecíficos anti-ace / anti-cd3, uso, composición, kit
|
|
EP3402326A1
(en)
|
2016-01-13 |
2018-11-21 |
Regeneron Pharmaceuticals, Inc. |
Rodents having an engineered heavy chain diversity region
|
|
CA3011739A1
(en)
|
2016-01-20 |
2017-07-27 |
Genentech, Inc. |
High dose treatments for alzheimer's disease
|
|
KR102885186B1
(ko)
|
2016-01-25 |
2025-11-17 |
리제너론 파아마슈티컬스, 인크. |
메이탄시노이드 유도체, 그의 접합체, 및 사용 방법
|
|
WO2017136734A1
(en)
|
2016-02-04 |
2017-08-10 |
Trianni, Inc. |
Enhanced production of immunoglobulins
|
|
US12071669B2
(en)
|
2016-02-12 |
2024-08-27 |
Regeneron Pharmaceuticals, Inc. |
Methods and systems for detection of abnormal karyotypes
|
|
RU2018130010A
(ru)
*
|
2016-02-16 |
2020-03-17 |
Регенерон Фармасьютикалз, Инк. |
Животные, отличные от человека, имеющие мутантный ген кинурениназы
|
|
ES2951262T3
(es)
|
2016-02-17 |
2023-10-19 |
Regeneron Pharma |
Métodos para tratar o prevenir la aterosclerosis mediante la administración de un inhibidor de ANGPTL3
|
|
KR102500659B1
(ko)
|
2016-02-29 |
2023-02-16 |
제넨테크, 인크. |
암에 대한 치료 및 진단 방법
|
|
KR102456731B1
(ko)
|
2016-03-03 |
2022-10-24 |
리제너론 파아마슈티컬스, 인크. |
Pcsk9 억제제를 angptl3 억제제와 병용하여 투여함으로써 고지혈증을 갖는 환자를 치료하기 위한 방법
|
|
MX2018010546A
(es)
|
2016-03-15 |
2019-02-20 |
Chugai Pharmaceutical Co Ltd |
Metodos de tratamiento de cancer que usan antagonistas de union al eje de muerte programada 1 (pd-1) y anticuerpos anti glipicano 3 (gpc3).
|
|
EP3433621A1
(en)
|
2016-03-25 |
2019-01-30 |
H. Hoffnabb-La Roche Ag |
Multiplexed total antibody and antibody-conjugated drug quantification assay
|
|
SG11201808261RA
(en)
|
2016-03-29 |
2018-10-30 |
Regeneron Pharma |
Genetic variant-phenotype analysis system and methods of use
|
|
US11802281B2
(en)
*
|
2016-04-04 |
2023-10-31 |
Eth Zurich |
Mammalian cell line for protein production and library generation
|
|
US20170306027A1
(en)
|
2016-04-06 |
2017-10-26 |
Acceleron Pharma Inc. |
Alk7 antagonists and uses thereof
|
|
EP3228630A1
(en)
|
2016-04-07 |
2017-10-11 |
IMBA-Institut für Molekulare Biotechnologie GmbH |
Combination of an apelin antagonist and an angiogenesis inhibitor for the treatment of cancer
|
|
LT3439689T
(lt)
|
2016-04-08 |
2021-11-10 |
Regeneron Pharmaceuticals, Inc. |
Hiperlipidemijos gydymo būdai angptl8 inhibitoriumi ir angptl3 inhibitoriumi
|
|
EP3443004A1
(en)
|
2016-04-14 |
2019-02-20 |
H. Hoffnabb-La Roche Ag |
Anti-rspo3 antibodies and methods of use
|
|
EP3443120A2
(en)
|
2016-04-15 |
2019-02-20 |
H. Hoffnabb-La Roche Ag |
Methods for monitoring and treating cancer
|
|
CA3019921A1
(en)
|
2016-04-15 |
2017-10-19 |
Genentech, Inc. |
Methods for monitoring and treating cancer
|
|
CA3021884A1
(en)
|
2016-04-28 |
2017-11-02 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating patients with familial hypercholesterolemia
|
|
CA3019524A1
(en)
|
2016-05-02 |
2017-11-09 |
F. Hoffmann-La Roche Ag |
The contorsbody - a single chain target binder
|
|
WO2017194441A1
(en)
|
2016-05-11 |
2017-11-16 |
F. Hoffmann-La Roche Ag |
Modified anti-tenascin antibodies and methods of use
|
|
TWI786044B
(zh)
|
2016-05-13 |
2022-12-11 |
美商再生元醫藥公司 |
藉由投予ｐｄ-１抑制劑治療皮膚癌之方法
|
|
CN118436801A
(zh)
|
2016-05-20 |
2024-08-06 |
豪夫迈·罗氏有限公司 |
Protac抗体缀合物及其使用方法
|
|
CN109475109B
(zh)
|
2016-05-20 |
2021-10-29 |
瑞泽恩制药公司 |
用于使用多个引导rna来破坏免疫耐受性的方法
|
|
US20170370906A1
(en)
|
2016-05-27 |
2017-12-28 |
Genentech, Inc. |
Bioanalytical analysis of site-specific antibody drug conjugates
|
|
EP3252078A1
(en)
|
2016-06-02 |
2017-12-06 |
F. Hoffmann-La Roche AG |
Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
|
|
CA3059010A1
(en)
|
2016-06-02 |
2018-12-06 |
F. Hoffmann-La Roche Ag |
Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
|
|
SI3462853T1
(sl)
|
2016-06-03 |
2023-05-31 |
Regeneron Pharmaceuticals, Inc. |
Glodavci, ki izražajo eksogeno terminalno deoksinukleotidiltransferazo
|
|
EP3464280B1
(en)
|
2016-06-06 |
2021-10-06 |
F. Hoffmann-La Roche AG |
Silvestrol antibody-drug conjugates and methods of use
|
|
WO2017214089A1
(en)
|
2016-06-06 |
2017-12-14 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals expressing antibodies with human lambda light chains
|
|
IL262996B2
(en)
|
2016-06-06 |
2024-03-01 |
Hoffmann La Roche |
Fusion proteins for ophthalmology with increased eye retention
|
|
GB201610162D0
(en)
|
2016-06-10 |
2016-07-27 |
Imp Innovations Ltd And Inst Pasteur |
Methods
|
|
KR102667023B1
(ko)
|
2016-06-14 |
2024-05-21 |
리제너론 파아마슈티컬스, 인크. |
항-c5 항체 및 이의 용도
|
|
KR102306744B1
(ko)
|
2016-06-17 |
2021-09-28 |
추가이 세이야쿠 가부시키가이샤 |
항-마이오스타틴 항체 및 사용 방법
|
|
CN109563160B
(zh)
|
2016-06-24 |
2023-02-28 |
豪夫迈·罗氏有限公司 |
抗聚泛素多特异性抗体
|
|
MX2018016330A
(es)
|
2016-06-27 |
2020-02-17 |
Univ California |
Combinaciones para tratamiento del cáncer.
|
|
EP3478717B1
(en)
|
2016-07-04 |
2022-01-05 |
F. Hoffmann-La Roche AG |
Novel antibody format
|
|
RU2748278C2
(ru)
|
2016-07-15 |
2021-05-21 |
Акселерон Фарма Инк. |
Композиции и способы лечения легочной гипертензии
|
|
TW201815821A
(zh)
|
2016-07-18 |
2018-05-01 |
美商再生元醫藥公司 |
抗茲卡病毒抗體及使用方法
|
|
WO2018014260A1
(en)
|
2016-07-20 |
2018-01-25 |
Nanjing Legend Biotech Co., Ltd. |
Multispecific antigen binding proteins and methods of use thereof
|
|
EA201990226A1
(ru)
|
2016-07-27 |
2019-08-30 |
Акселерон Фарма Инк. |
Способы и композиции для лечения миелофиброза
|
|
RU2721125C1
(ru)
|
2016-07-29 |
2020-05-18 |
Регенерон Фармасьютикалз, Инк. |
Мыши, содержащие мутации, вследствие которых экспрессируется укороченный на с-конце фибриллин-1
|
|
AU2017303205B2
(en)
|
2016-07-29 |
2024-08-01 |
Chugai Seiyaku Kabushiki Kaisha |
Bispecific antibody exhibiting increased alternative FVIII-cofactor-function activity
|
|
CN109689099B
(zh)
|
2016-08-05 |
2023-02-28 |
中外制药株式会社 |
用于预防或治疗il-8相关疾病的组合物
|
|
EP3494139B1
(en)
|
2016-08-05 |
2022-01-12 |
F. Hoffmann-La Roche AG |
Multivalent and multiepitopic anitibodies having agonistic activity and methods of use
|
|
CN109476748B
(zh)
|
2016-08-08 |
2023-05-23 |
豪夫迈·罗氏有限公司 |
用于癌症的治疗和诊断方法
|
|
EP3282019A1
(en)
|
2016-08-09 |
2018-02-14 |
Medizinische Universität Wien |
Genotyping and treatment of cancer, in particular chronic lymphocytic leukemia
|
|
WO2018031662A1
(en)
|
2016-08-11 |
2018-02-15 |
Genentech, Inc. |
Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof
|
|
CN109843916B
(zh)
|
2016-08-12 |
2023-10-31 |
詹森生物科技公司 |
具有增强的激动活性的Fc工程化抗TNFR超家族成员抗体及其使用方法
|
|
CN109863170B
(zh)
|
2016-08-12 |
2024-08-16 |
詹森生物科技公司 |
具有增强的激动作用和效应子功能的工程化抗体及其他含Fc结构域分子
|
|
MA45999A
(fr)
|
2016-08-22 |
2019-06-26 |
Arbutus Biopharma Corp |
Anticorps anti-pd-1, ou leurs fragments, pour le traitement de l'hépatite b
|
|
KR20190040320A
(ko)
|
2016-08-29 |
2019-04-17 |
리제너론 파아마슈티컬스, 인크. |
항-그렘린-1 (grem1) 항체 및 폐동맥 고혈압을 치료하기 위한 그의 사용 방법
|
|
SG10201607778XA
(en)
|
2016-09-16 |
2018-04-27 |
Chugai Pharmaceutical Co Ltd |
Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
|
|
WO2018050878A1
(en)
|
2016-09-19 |
2018-03-22 |
F. Hoffmann-La Roche Ag |
Complement factor based affinity chromatography
|
|
CA3031589C
(en)
|
2016-09-23 |
2025-05-06 |
Genentech, Inc. |
USES OF IL-13 ANTAGONISTS FOR THE TREATMENT OF ATOPIC DERMATITIS
|
|
AU2017331739A1
(en)
|
2016-09-23 |
2019-03-07 |
Csl Limited |
Coagulation factor binding proteins and uses thereof
|
|
CA3038548A1
(en)
|
2016-09-30 |
2018-04-05 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals having a hexanucleotide repeat expansion in a c9orf72 locus
|
|
JP7050770B2
(ja)
|
2016-10-05 |
2022-04-08 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
抗体薬物コンジュゲートの調製方法
|
|
US11976111B2
(en)
|
2016-10-05 |
2024-05-07 |
Acceleron Pharma Inc. |
ActRIIa and ALK4 polypeptides for treating kidney fibrosis, inflammation and injury
|
|
IL265759B2
(en)
|
2016-10-06 |
2025-10-01 |
Genentech Inc |
Therapeutic and diagnostic methods for cancer
|
|
WO2018068201A1
(en)
|
2016-10-11 |
2018-04-19 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies and variants thereof against ctla-4
|
|
CA3040893A1
(en)
|
2016-10-21 |
2018-04-26 |
Adimab, Llc |
Anti-respiratory syncytial virus antibodies, and methods of their generation and use
|
|
US11479600B2
(en)
|
2016-10-21 |
2022-10-25 |
Adimab, Llc |
Anti-respiratory syncytial virus antibodies, and methods of their generation and use
|
|
SG11201903287PA
(en)
|
2016-10-21 |
2019-05-30 |
Adimab Llc |
Anti-respiratory syncytial virus antibodies, and methods of their generation and use
|
|
JP2019535250A
(ja)
|
2016-10-29 |
2019-12-12 |
ジェネンテック， インコーポレイテッド |
抗ｍｉｃ抗体及び使用方法
|
|
CN109906272A
(zh)
|
2016-10-31 |
2019-06-18 |
国立大学法人鸟取大学 |
产生人抗体的非人动物和使用该非人动物的人抗体制作方法
|
|
HRP20211703T1
(hr)
|
2016-11-02 |
2022-02-04 |
Jounce Therapeutics, Inc. |
Protutijela protiv pd-1 i njihova upotreba
|
|
EP3766343B1
(en)
|
2016-11-04 |
2022-05-11 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals having an engineered immunoglobulin lambda light chain locus
|
|
KR20190074310A
(ko)
|
2016-11-08 |
2019-06-27 |
리제너론 파마슈티칼스 인코포레이티드 |
스테로이드 및 이의 단백질-접합체
|
|
CN116143678A
(zh)
|
2016-11-14 |
2023-05-23 |
杭州多禧生物科技有限公司 |
偶联连接体，含有此连接体的细胞结合分子-药物偶联物及其制备和应用
|
|
EA201991203A1
(ru)
|
2016-11-17 |
2019-10-31 |
|
Способы лечения ожирения антителами к angptl8
|
|
TW201829463A
(zh)
|
2016-11-18 |
2018-08-16 |
瑞士商赫孚孟拉羅股份公司 |
抗hla-g抗體及其用途
|
|
WO2018091720A1
(en)
|
2016-11-21 |
2018-05-24 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the prophylactic treatment of metastases
|
|
AU2017366870B2
(en)
|
2016-11-29 |
2024-09-19 |
Regeneron Pharmaceuticals, Inc. |
A pharmaceutical composition for averting opioid addiction
|
|
JP6951444B2
(ja)
|
2016-11-30 |
2021-10-20 |
クローダ インターナショナル パブリック リミティド カンパニー |
水性バインダ系、コーティング組成物及びコーティング
|
|
CA3045294A1
(en)
|
2016-12-07 |
2018-06-14 |
Genentech, Inc. |
Anti-tau antibodies and methods of use
|
|
MX2019006334A
(es)
|
2016-12-07 |
2019-08-01 |
Genentech Inc |
Anticuerpos antitau y métodos de uso.
|
|
CA3046432A1
(en)
|
2016-12-13 |
2018-06-21 |
Astellas Pharma Inc. |
Anti-human cd73 antibody
|
|
CA3044920C
(en)
|
2016-12-21 |
2022-06-28 |
Roberto Falkenstein |
In vitro glycoengineering of antibodies
|
|
CN110100007B
(zh)
|
2016-12-21 |
2024-05-28 |
豪夫迈·罗氏有限公司 |
用于体外糖工程化抗体的酶的再使用
|
|
WO2018114879A1
(en)
|
2016-12-21 |
2018-06-28 |
F. Hoffmann-La Roche Ag |
Method for in vitro glycoengineering of antibodies
|
|
EP3558347B1
(en)
|
2016-12-22 |
2026-01-21 |
Regeneron Pharmaceuticals, Inc. |
Method of treating an allergy with allergen-specific monoclonal antibodies
|
|
WO2018124155A1
(ja)
*
|
2016-12-27 |
2018-07-05 |
国立大学法人群馬大学 |
条件付きノックアウト動物の製造方法
|
|
TWI781130B
(zh)
|
2017-01-03 |
2022-10-21 |
美商再生元醫藥公司 |
抗金黃色葡萄球菌溶血素ａ毒素之人類抗體
|
|
SG10202109874VA
(en)
|
2017-01-19 |
2021-10-28 |
Open Monoclonal Tech Inc |
Human antibodies from transgenic rodents with multiple heavy chain immunoglobulin loci
|
|
WO2018136758A1
(en)
|
2017-01-23 |
2018-07-26 |
Regeneron Pharmaceuticals, Inc. |
Hsd17b13 variants and uses thereof
|
|
US10713373B2
(en)
*
|
2017-02-09 |
2020-07-14 |
Lifesite, Inc. |
Computing system with information storage mechanism and method of operation thereof
|
|
AU2018219909B2
(en)
|
2017-02-10 |
2025-02-27 |
Regeneron Pharmaceuticals, Inc. |
Radiolabeled anti-LAG3 antibodies for immuno-PET imaging
|
|
CN110494453B
(zh)
|
2017-02-10 |
2023-05-26 |
豪夫迈·罗氏有限公司 |
抗类胰蛋白酶抗体、其组合物及其用途
|
|
EP3580235B1
(en)
|
2017-02-10 |
2024-05-01 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use
|
|
PL3589754T3
(pl)
|
2017-03-01 |
2023-10-09 |
F. Hoffmann-La Roche Ag |
Sposoby diagnostyczne i terapeutyczne w chorobach nowotworowych
|
|
AR111249A1
(es)
|
2017-03-22 |
2019-06-19 |
Genentech Inc |
Composiciones de anticuerpo optimizadas para el tratamiento de trastornos oculares
|
|
AU2018247767B2
(en)
|
2017-04-03 |
2025-01-30 |
F. Hoffmann-La Roche Ag |
Antibodies binding to STEAP-1
|
|
EP3606947B1
(en)
|
2017-04-03 |
2022-12-21 |
F. Hoffmann-La Roche AG |
Immunoconjugates of il-2 with an anti-pd-1 and tim-3 bispecific antibody
|
|
KR20190121816A
(ko)
|
2017-04-03 |
2019-10-28 |
에프. 호프만-라 로슈 아게 |
항-pd-1 항체와 돌연변이 il-2 또는 il-15의 면역접합체
|
|
HUE060019T2
(hu)
|
2017-04-05 |
2023-01-28 |
Hoffmann La Roche |
Anti-LAG3 antitestek
|
|
US11603407B2
(en)
|
2017-04-06 |
2023-03-14 |
Regeneron Pharmaceuticals, Inc. |
Stable antibody formulation
|
|
ES2994451T3
(en)
|
2017-04-20 |
2025-01-24 |
Atyr Pharma Inc |
Compositions for treating lung inflammation
|
|
EP3624820A1
(en)
|
2017-04-21 |
2020-03-25 |
H. Hoffnabb-La Roche Ag |
Use of klk5 antagonists for treatment of a disease
|
|
SG10201913677SA
(en)
|
2017-04-27 |
2020-03-30 |
Tesaro Inc |
Antibody agents directed against lymphocyte activation gene-3 (lag-3) and uses thereof
|
|
US11168129B2
(en)
|
2017-05-15 |
2021-11-09 |
University Of Rochester |
Broadly neutralizing anti-influenza human monoclonal antibody and uses thereof
|
|
CA3063871A1
(en)
|
2017-05-18 |
2018-11-22 |
Regeneron Pharmaceuticals, Inc. |
Cyclodextrin protein drug conjugates
|
|
CN110997713B
(zh)
|
2017-06-01 |
2024-01-02 |
瑞泽恩制药公司 |
抗bet v 1人抗体及其使用方法
|
|
AU2018282094B2
(en)
|
2017-06-05 |
2024-06-27 |
Janssen Biotech, Inc. |
Antibodies that specifically bind PD-1 and methods of use
|
|
CN110785185B
(zh)
|
2017-06-05 |
2024-05-24 |
詹森生物科技公司 |
具有非对称ch2-ch3区突变的工程化多特异性抗体和其他多聚体蛋白
|
|
US20190031774A1
(en)
|
2017-06-09 |
2019-01-31 |
Sanofi Biotechnology |
Methods for treating hyperlipidemia in diabetic patients by administering a pcsk9 inhibitor
|
|
MA49512A
(fr)
|
2017-06-28 |
2020-05-06 |
Regeneron Pharma |
Protéines de liaison à l'antigène anti-papillomavirus humain et leurs méthodés d'utilisation
|
|
CN111492245A
(zh)
|
2017-07-21 |
2020-08-04 |
基因泰克公司 |
癌症的治疗和诊断方法
|
|
WO2019018770A1
(en)
|
2017-07-21 |
2019-01-24 |
Trianni, Inc. |
SINGLE CHAIN VH-L1-CK1-L2-CH1 ANTIBODY
|
|
IL316355A
(en)
|
2017-07-24 |
2024-12-01 |
Regeneron Pharma |
Anti-CD8 antibodies and their uses
|
|
US11174322B2
(en)
|
2017-07-24 |
2021-11-16 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antibodies and peptides to treat HCMV related diseases
|
|
TWI799432B
(zh)
|
2017-07-27 |
2023-04-21 |
美商再生元醫藥公司 |
抗ctla-4抗體及其用途
|
|
AU2018310985A1
(en)
|
2017-08-03 |
2019-11-07 |
Alector Llc |
Anti-CD33 antibodies and methods of use thereof
|
|
US11021540B2
(en)
|
2017-09-07 |
2021-06-01 |
Augusta University Research Institute, Inc. |
Antibodies to programmed cell death protein 1
|
|
EP4512469A3
(en)
|
2017-09-11 |
2025-05-21 |
Monash University |
Binding proteins to the human thrombin receptor, par4
|
|
SG11202001160XA
(en)
|
2017-09-29 |
2020-03-30 |
Regeneron Pharma |
Bispecific antigen-binding molecules that bind a staphylococcus target antigen and a complement component and uses thereof
|
|
TW202423960A
(zh)
|
2017-09-29 |
2024-06-16 |
日商中外製藥股份有限公司 |
具有第viii凝血因子(fviii)輔因子機能替代活性的多重特異性抗原結合分子及含有此分子作為有效成分之藥學製劑
|
|
EP3476942B1
(en)
|
2017-10-27 |
2022-01-26 |
Trianni, Inc. |
Long germline dh genes and long hcdr3 antibodies
|
|
PL3703818T3
(pl)
|
2017-10-30 |
2024-03-25 |
Sanofi Biotechnology |
Antagonista IL-4R do zastosowania w sposobie leczenia lub zapobiegania astmie
|
|
JP2021500930A
(ja)
|
2017-11-01 |
2021-01-14 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
Ｃｏｍｐボディ−多価標的結合物質
|
|
MX2020004196A
(es)
|
2017-11-01 |
2020-11-09 |
Hoffmann La Roche |
Trifab-contorsbody.
|
|
WO2019090263A1
(en)
|
2017-11-06 |
2019-05-09 |
Genentech, Inc. |
Diagnostic and therapeutic methods for cancer
|
|
JP7426931B2
(ja)
|
2017-11-07 |
2024-02-02 |
レゲネロン ファーマシューティカルス，インコーポレーテッド |
抗体薬物コンジュゲートのための親水性リンカー
|
|
EP3710589A4
(en)
|
2017-11-14 |
2021-11-10 |
Chugai Seiyaku Kabushiki Kaisha |
ANTI-C1S ANTIBODIES AND METHOD OF USING
|
|
EP3717514A1
(en)
|
2017-11-30 |
2020-10-07 |
Regeneron Pharmaceuticals, Inc. |
Anti-trkb monoclonal antibodies and methods of use
|
|
LT3720279T
(lt)
*
|
2017-12-05 |
2022-10-25 |
Regeneron Pharmaceuticals, Inc. |
Pelės, turinčios sukonstruotą imunoglobulino lambda lengvąją grandinę, ir jų panaudojimas
|
|
CN120571008A
(zh)
|
2017-12-13 |
2025-09-02 |
瑞泽恩制药公司 |
抗c5抗体组合及其用途
|
|
WO2019126194A1
(en)
|
2017-12-18 |
2019-06-27 |
Regeneron Pharmaceuticals, Inc. |
Angptl8 assay and uses thereof
|
|
EP3728317A2
(en)
|
2017-12-21 |
2020-10-28 |
F. Hoffmann-La Roche AG |
Antibodies binding to hla-a2/wt1
|
|
TW201929907A
(zh)
|
2017-12-22 |
2019-08-01 |
美商建南德克公司 |
Pilra結合劑用於治療疾病之用途
|
|
JP7391868B2
(ja)
|
2017-12-22 |
2023-12-05 |
ジョウンセ セラピューティクス， インク． |
Ｌｉｌｒｂ２に対する抗体
|
|
CN111542543B
(zh)
|
2017-12-28 |
2023-12-22 |
南京传奇生物科技有限公司 |
针对pd-l1的抗体及其变体
|
|
AU2018396970B2
(en)
|
2017-12-28 |
2025-09-25 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies and variants thereof against TIGIT
|
|
US11440957B2
(en)
|
2017-12-29 |
2022-09-13 |
Alector Llc |
Anti-TMEM106B antibodies and methods of use thereof
|
|
BR112020013492A2
(pt)
|
2018-01-08 |
2020-12-08 |
Regeneron Pharmaceuticals, Inc. |
Esteroides e conjugados de anticorpo dos mesmos
|
|
US12247060B2
(en)
|
2018-01-09 |
2025-03-11 |
Marengo Therapeutics, Inc. |
Calreticulin binding constructs and engineered T cells for the treatment of diseases
|
|
CN111699200B
(zh)
|
2018-01-15 |
2023-05-26 |
南京传奇生物科技有限公司 |
针对pd-1的单域抗体和其变体
|
|
EP3740505A1
(en)
|
2018-01-16 |
2020-11-25 |
Lakepharma Inc. |
Bispecific antibody that binds cd3 and another target
|
|
US12398209B2
(en)
|
2018-01-22 |
2025-08-26 |
Janssen Biotech, Inc. |
Methods of treating cancers with antagonistic anti-PD-1 antibodies
|
|
SG11202006379UA
(en)
|
2018-01-26 |
2020-07-29 |
Regeneron Pharma |
Human antibodies to influenza hemagglutinin
|
|
SMT202100307T1
(it)
|
2018-01-26 |
2021-07-12 |
Regeneron Pharma |
Anticorpi e frammenti di legame di anti-tmprss2
|
|
JP7268038B2
(ja)
|
2018-01-31 |
2023-05-02 |
アレクトル エルエルシー |
抗ｍｓ４ａ４ａ抗体及びその使用方法
|
|
US12180285B2
(en)
|
2018-02-01 |
2024-12-31 |
Memorial Sloan Kettering Cancer Center |
Antibodies to galectin-3 and methods of use thereof
|
|
CN118772287A
(zh)
|
2018-02-08 |
2024-10-15 |
豪夫迈·罗氏有限公司 |
双特异性抗原结合分子和使用方法
|
|
EP3749362A1
(en)
|
2018-02-09 |
2020-12-16 |
F. Hoffmann-La Roche AG |
Therapeutic and diagnostic methods for mast cell-mediated inflammatory diseases
|
|
TWI829667B
(zh)
|
2018-02-09 |
2024-01-21 |
瑞士商赫孚孟拉羅股份公司 |
結合gprc5d之抗體
|
|
WO2019157342A1
(en)
|
2018-02-09 |
2019-08-15 |
Acceleron Pharma Inc. |
Methods for treating heterotopic ossification
|
|
MX2020008882A
(es)
|
2018-02-26 |
2021-01-08 |
Genentech Inc |
Dosificación para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1.
|
|
AU2019231703A1
(en)
|
2018-03-06 |
2020-10-22 |
Regeneron Pharmaceuticals, Inc. |
Use of PCSK9 inhibitor for reducing cardiovascular risk
|
|
US20200040103A1
(en)
|
2018-03-14 |
2020-02-06 |
Genentech, Inc. |
Anti-klk5 antibodies and methods of use
|
|
WO2019178362A1
(en)
|
2018-03-14 |
2019-09-19 |
Elstar Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
|
IL277375B2
(en)
|
2018-03-15 |
2025-08-01 |
Chugai Pharmaceutical Co Ltd |
Anti-dengue virus antibodies having cross-reactivity to zika virus and methods of use
|
|
US11747340B2
(en)
|
2018-03-24 |
2023-09-05 |
Regeneron Pharmaceuticals, Inc. |
Systems and methods for identifying HLA-associated tumor peptides
|
|
HUE070158T2
(hu)
|
2018-03-24 |
2025-05-28 |
Regeneron Pharma |
Genetikailag módosított egerek vagy patkányok peptid-mhc komplexek elleni terápiás antitestek létrehozásra, ezek elõállítására szolgáló módszerek, valamint alkalmazásuk
|
|
SG11202008848XA
(en)
|
2018-03-26 |
2020-10-29 |
Regeneron Pharma |
Anti-pfrh5 antibodies and antigen-binding fragments thereof
|
|
JP7328243B2
(ja)
|
2018-03-26 |
2023-08-16 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
治療薬を試験するためのヒト化げっ歯類
|
|
JP2021519073A
(ja)
|
2018-03-29 |
2021-08-10 |
ジェネンテック， インコーポレイテッド |
哺乳動物細胞におけるラクトジェニック活性の制御
|
|
AU2019241350B2
(en)
|
2018-03-30 |
2025-10-02 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies against LAG-3 and uses thereof
|
|
WO2019192432A1
(zh)
|
2018-04-02 |
2019-10-10 |
上海博威生物医药有限公司 |
结合淋巴细胞活化基因-3(lag-3)的抗体及其用途
|
|
TW202011029A
(zh)
|
2018-04-04 |
2020-03-16 |
美商建南德克公司 |
偵測及定量fgf21之方法
|
|
PT3773713T
(pt)
|
2018-04-06 |
2025-07-29 |
Regeneron Pharma |
Anticorpo agonista do recetor de leptina para usar no aumento da massa óssea num sujeito que sofre de disfunção metabólica ou de hipoleptinemia
|
|
AR115052A1
(es)
|
2018-04-18 |
2020-11-25 |
Hoffmann La Roche |
Anticuerpos multiespecíficos y utilización de los mismos
|
|
AR114789A1
(es)
|
2018-04-18 |
2020-10-14 |
Hoffmann La Roche |
Anticuerpos anti-hla-g y uso de los mismos
|
|
WO2019213384A1
(en)
|
2018-05-03 |
2019-11-07 |
University Of Rochester |
Anti-influenza neuraminidase monoclonal antibodies and uses thereof
|
|
KR20210008008A
(ko)
|
2018-05-09 |
2021-01-20 |
리제너론 파마슈티칼스 인코포레이티드 |
항-msr1 항체 및 이의 사용 방법
|
|
PE20211916A1
(es)
|
2018-05-24 |
2021-09-28 |
Janssen Biotech Inc |
Agentes aglutinantes del psma y usos de estos
|
|
MA52772A
(fr)
|
2018-05-24 |
2021-04-14 |
Janssen Biotech Inc |
Anticorps anti-tmeff2 monospécifiques et multispécifiques et leurs utilisations
|
|
MX420253B
(es)
|
2018-05-24 |
2025-02-10 |
Janssen Biotech Inc |
Anticuerpos anti-cd3 y usos de estos.
|
|
TW202448946A
(zh)
|
2018-05-25 |
2024-12-16 |
美商阿列克特有限責任公司 |
抗-sirpa 抗體及其使用方法
|
|
KR102480815B1
(ko)
|
2018-05-31 |
2022-12-26 |
글라이코넥스 인코포레이티드 |
바이안테나리 루이스 b 및 루이스 y 항원에 결합하는 치료 항체
|
|
EP3811364A1
(en)
|
2018-06-01 |
2021-04-28 |
Regeneron Pharmaceuticals, Inc. |
Methods and systems for sparse vector-based matrix transformations
|
|
WO2019227490A1
(en)
|
2018-06-01 |
2019-12-05 |
Tayu Huaxia Biotech Medical Group Co., Ltd. |
Compositions and methods for imaging
|
|
EP3818085A4
(en)
|
2018-06-01 |
2022-03-09 |
Tayu Huaxia Biotech Medical Group Co., Ltd. |
COMPOSITIONS AND THEIR USES FOR THE TREATMENT OF DISEASES OR DISORDERS
|
|
IL318469A
(en)
|
2018-06-14 |
2025-03-01 |
Regeneron Pharma |
Non-human animals capable of reorganizing transgenic DH-DH, and their uses
|
|
MA52966A
(fr)
|
2018-06-19 |
2021-04-28 |
Regeneron Pharma |
Anticorps anti-facteur xii/xiia et leurs utilisations
|
|
AU2019288728A1
(en)
|
2018-06-23 |
2021-01-14 |
Genentech, Inc. |
Methods of treating lung cancer with a pd-1 axis binding antagonist, a platinum agent, and a topoisomerase ii inhibitor
|
|
CN112384532B
(zh)
|
2018-06-29 |
2025-01-10 |
艾利妥 |
抗SIRP-β1抗体及其使用方法
|
|
CA3105448A1
(en)
|
2018-07-03 |
2020-01-09 |
Elstar Therapeutics, Inc. |
Anti-tcr antibody molecules and uses thereof
|
|
IL316308A
(en)
|
2018-07-10 |
2024-12-01 |
Regeneron Pharma |
Modifying binding molecules to minimize pre-existing interactions
|
|
RS64034B1
(sr)
|
2018-07-13 |
2023-04-28 |
Alector Llc |
Anti-sortilin antitela i načini njihove upotrebe
|
|
WO2020018503A2
(en)
|
2018-07-16 |
2020-01-23 |
Regeneron Pharmaceuticals, Inc. |
Anti-il36r antibodies
|
|
JP2021530237A
(ja)
|
2018-07-17 |
2021-11-11 |
ウーマブス ビオメド エセアー |
Ｃａｍｐｙｌｏｂａｃｔｅｒの種に対する抗体
|
|
BR112021000673A2
(pt)
|
2018-07-18 |
2021-04-20 |
Genentech, Inc. |
métodos para tratar um indivíduo com câncer de pulmão, kits, anticorpo anti-pd-l1 e composições
|
|
TWI902669B
(zh)
|
2018-07-24 |
2025-11-01 |
美商麥迪紐有限責任公司 |
抗金黃色葡萄球菌凝集因子a(clfa)之抗體
|
|
EP3833687A1
(en)
|
2018-08-10 |
2021-06-16 |
Regeneron Pharmaceuticals, Inc. |
A pharmaceutical composition for safe and effective treatment of knee and/or hip pain
|
|
KR102697702B1
(ko)
|
2018-08-10 |
2024-08-22 |
추가이 세이야쿠 가부시키가이샤 |
항cd137 항원 결합 분자 및 그의 사용
|
|
TW202021618A
(zh)
|
2018-08-17 |
2020-06-16 |
美商２３與我有限公司 |
抗ｉｌ１ｒａｐ抗體及其使用方法
|
|
CN112955222A
(zh)
|
2018-08-29 |
2021-06-11 |
里珍纳龙药品有限公司 |
用于治疗患有类风湿性关节炎的个体的方法和组合物
|
|
SG11202101552SA
(en)
|
2018-08-31 |
2021-03-30 |
Alector Llc |
Anti-cd33 antibodies and methods of use thereof
|
|
GB201814281D0
(en)
|
2018-09-03 |
2018-10-17 |
Femtogenix Ltd |
Cytotoxic agents
|
|
CN112673022B
(zh)
|
2018-09-10 |
2024-07-09 |
南京传奇生物科技有限公司 |
针对cd33的单结构域抗体及其构建体
|
|
CN112969367B
(zh)
|
2018-09-13 |
2023-04-07 |
瑞泽恩制药公司 |
作为c3肾小球病模型的补体因子h基因敲除大鼠
|
|
CN112955747A
(zh)
|
2018-09-19 |
2021-06-11 |
豪夫迈·罗氏有限公司 |
膀胱癌的治疗和诊断方法
|
|
MX2021003213A
(es)
|
2018-09-21 |
2021-05-12 |
Genentech Inc |
Metodos de diagnostico para cancer de mama triple negativo.
|
|
WO2020076789A2
(en)
|
2018-10-09 |
2020-04-16 |
Medimmune, Llc |
Combinations of anti-staphylococcus aureus antibodies
|
|
TW202028244A
(zh)
|
2018-10-09 |
2020-08-01 |
美商建南德克公司 |
用於確定突觸形成之方法及系統
|
|
EP3867646A1
(en)
|
2018-10-18 |
2021-08-25 |
F. Hoffmann-La Roche AG |
Diagnostic and therapeutic methods for sarcomatoid kidney cancer
|
|
WO2020086406A2
(en)
|
2018-10-23 |
2020-04-30 |
Regeneron Pharmaceuticals, Inc. |
Anti-npr1 antibodies and uses thereof
|
|
WO2020086858A1
(en)
|
2018-10-24 |
2020-04-30 |
Genentech, Inc. |
Conjugated chemical inducers of degradation and methods of use
|
|
KR102467349B1
(ko)
|
2018-10-29 |
2022-11-16 |
에프. 호프만-라 로슈 아게 |
항체 제형
|
|
IL282650B2
(en)
|
2018-10-31 |
2024-09-01 |
Astellas Pharma Inc |
Anti-human fn14 antibody
|
|
WO2020094609A1
(en)
|
2018-11-06 |
2020-05-14 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of acute myeloid leukemia by eradicating leukemic stem cells
|
|
AU2019384790A1
(en)
|
2018-11-21 |
2021-03-18 |
Regeneron Pharmaceuticals, Inc. |
Anti-staphylococcus antibodies and uses thereof
|
|
AU2018451747A1
(en)
|
2018-12-06 |
2021-06-17 |
F. Hoffmann-La Roche Ag |
Combination therapy of diffuse large B-cell lymphoma comprising an anti-CD79b immunoconjugates, an alkylating agent and an anti-CD20 antibody
|
|
EP3894427A1
(en)
|
2018-12-10 |
2021-10-20 |
Genentech, Inc. |
Photocrosslinking peptides for site specific conjugation to fc-containing proteins
|
|
US20220064260A1
(en)
|
2018-12-14 |
2022-03-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Isolated mhc-derived human peptides and uses thereof for stimulating and activating the suppressive function of cd8+cd45rclow tregs
|
|
GB201820547D0
(en)
|
2018-12-17 |
2019-01-30 |
Oxford Univ Innovation |
Modified antibodies
|
|
GB201820554D0
(en)
|
2018-12-17 |
2019-01-30 |
Univ Oxford Innovation Ltd |
BTLA antibodies
|
|
AR117327A1
(es)
|
2018-12-20 |
2021-07-28 |
23Andme Inc |
Anticuerpos anti-cd96 y métodos de uso de estos
|
|
EP3883609A2
(en)
|
2018-12-20 |
2021-09-29 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Ebola virus glycoprotein-specific monoclonal antibodies and uses thereof
|
|
US11690362B2
(en)
|
2018-12-20 |
2023-07-04 |
Regeneran Pharmaceuticals, Inc. |
Nuclease-mediated repeat expansion
|
|
EP3898667A2
(en)
|
2018-12-20 |
2021-10-27 |
F. Hoffmann-La Roche AG |
Modified antibody fcs and methods of use
|
|
EP3898673A1
(en)
|
2018-12-21 |
2021-10-27 |
23Andme, Inc. |
Anti-il-36 antibodies and methods of use thereof
|
|
TWI852977B
(zh)
|
2019-01-10 |
2024-08-21 |
美商健生生物科技公司 |
前列腺新抗原及其用途
|
|
MX2021008434A
(es)
|
2019-01-14 |
2021-09-23 |
Genentech Inc |
Metodos para tratar el cancer con un antagonista de union al eje de pd-1 y una vacuna de arn.
|
|
CA3126359A1
(en)
|
2019-01-22 |
2020-07-30 |
Genentech, Inc. |
Immunoglobulin a antibodies and methods of production and use
|
|
CN113795511B
(zh)
|
2019-01-23 |
2024-07-23 |
大有华夏生物医药集团有限公司 |
抗pd-l1双抗体及其用途
|
|
EP3915581A4
(en)
|
2019-01-24 |
2023-03-22 |
Chugai Seiyaku Kabushiki Kaisha |
NOVEL CANCER ANTIGENS AND ANTIBODIES OF THESE ANTIGENS
|
|
GB201901197D0
(en)
|
2019-01-29 |
2019-03-20 |
Femtogenix Ltd |
G-A Crosslinking cytotoxic agents
|
|
MX2021008958A
(es)
|
2019-02-01 |
2021-11-04 |
Regeneron Pharma |
Proteínas de unión a antígeno del receptor gamma anti-il2.
|
|
US12459991B2
(en)
|
2019-02-12 |
2025-11-04 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for using bispecific antibodies to bind complement and a target antigen
|
|
US11478553B2
(en)
|
2019-02-15 |
2022-10-25 |
Wuxi Biologies Ireland Limited |
Process for preparing antibody-drug conjugates with improved homogeneity
|
|
US12109273B2
(en)
|
2019-02-15 |
2024-10-08 |
Wuxi Xdc Singapore Private Limited |
Process for preparing antibody-drug conjugates with improved homogeneity
|
|
WO2020169472A2
(en)
|
2019-02-18 |
2020-08-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of inducing phenotypic changes in macrophages
|
|
WO2020169022A1
(en)
*
|
2019-02-18 |
2020-08-27 |
Beijing Biocytogen Co., Ltd |
Genetically modified non-human animals with humanized immunoglobulin locus
|
|
GB2597851B
(en)
|
2019-02-21 |
2024-05-29 |
Marengo Therapeutics Inc |
Antibody molecules that bind to NKP30 and uses thereof
|
|
EP3927744A1
(en)
|
2019-02-21 |
2021-12-29 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to t cell related cancer cells and uses thereof
|
|
SG11202107589PA
(en)
|
2019-02-22 |
2021-08-30 |
Regeneron Pharma |
Rodents having genetically modified sodium channels and methods of use thereof
|
|
BR112021016923A2
(pt)
|
2019-02-27 |
2021-11-03 |
Genentech Inc |
Métodos para tratar um paciente com câncer hematológico, métodos para tratar um paciente com mm recidivante ou refratário, métodos para tratar um paciente tendo um lnh recidivante ou refratário e kits
|
|
MX2021010441A
(es)
|
2019-03-01 |
2021-09-21 |
Allogene Therapeutics Inc |
Receptores antigenicos quimericos y agentes de union dirigidos a dll3.
|
|
EP3935385A1
(en)
|
2019-03-08 |
2022-01-12 |
F. Hoffmann-La Roche AG |
Methods for detecting and quantifying membrane-associated proteins on extracellular vesicles
|
|
WO2020206139A1
(en)
|
2019-04-04 |
2020-10-08 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals comprising a humanized coagulation factor 12 locus
|
|
US11111504B2
(en)
|
2019-04-04 |
2021-09-07 |
Regeneron Pharmaceuticals, Inc. |
Methods for scarless introduction of targeted modifications into targeting vectors
|
|
CA3134258A1
(en)
|
2019-04-10 |
2020-10-15 |
Regeneron Pharmaceuticals, Inc. |
Human antibodies that bind ret and methods of use thereof
|
|
EP3955957A1
(en)
|
2019-04-15 |
2022-02-23 |
Qwixel Therapeutics LLC |
Fusion protein composition(s) comprising targeted masked type i interferons (ifna and ifnb) and an antibody against tumor antigen, for use in the treatment of cancer
|
|
CN113747944A
(zh)
|
2019-04-19 |
2021-12-03 |
詹森生物科技公司 |
用抗psma/cd3抗体治疗前列腺癌的方法
|
|
MX2021012692A
(es)
|
2019-04-19 |
2021-11-12 |
Genentech Inc |
Anticuerpos anti-mertk y sus metodos de uso.
|
|
WO2020219812A1
(en)
|
2019-04-26 |
2020-10-29 |
Allogene Therapeutics, Inc. |
Methods of manufacturing allogeneic car t cells
|
|
BR112021021195A2
(pt)
|
2019-05-01 |
2022-03-03 |
Regeneron Pharma |
Métodos para tratamento ou prevenção da asma pela administração de um antagonista de il-33
|
|
WO2020227228A2
(en)
|
2019-05-03 |
2020-11-12 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use
|
|
TWI879768B
(zh)
|
2019-05-03 |
2025-04-11 |
美商建南德克公司 |
用抗pd-l1抗體治療癌症之方法
|
|
KR20220007136A
(ko)
|
2019-05-14 |
2022-01-18 |
제넨테크, 인크. |
소포 림프종을 치료하기 위한 항-CD79b 면역접합체의 사용 방법
|
|
BR112021021689A2
(pt)
|
2019-05-15 |
2022-03-22 |
Chugai Pharmaceutical Co Ltd |
Molécula de ligação a antígeno, composição farmacêutica, e método
|
|
US12559544B2
(en)
|
2019-05-21 |
2026-02-24 |
University Of Georgia Research Foundation, Inc. |
Antibodies that bind human metapneumovirus fusion protein and their use
|
|
EP3801011A1
(en)
|
2019-06-04 |
2021-04-14 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals comprising a humanized ttr locus with a beta-slip mutation and methods of use
|
|
MX2021014893A
(es)
|
2019-06-05 |
2022-03-11 |
Regeneron Pharma |
Animales no humanos que tienen un repertorio de cadena ligera lambda limitado expresado a partir del locus kappa y usos de estos.
|
|
AU2020289581B2
(en)
|
2019-06-07 |
2024-11-21 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals comprising a humanized albumin locus
|
|
KR102919581B1
(ko)
|
2019-06-11 |
2026-01-30 |
알렉터 엘엘씨 |
치료요법에 사용하기 위한 항-소르틸린 항체
|
|
CN113966343A
(zh)
|
2019-06-11 |
2022-01-21 |
瑞泽恩制药公司 |
结合PcrV的抗PcrV抗体、包含抗PcrV抗体的组合物及其使用方法
|
|
AU2020292246A1
(en)
|
2019-06-12 |
2022-01-27 |
Regeneron Pharmaceuticals, Inc. |
Human antibodies to bone morphogenetic protein 6
|
|
WO2020257604A1
(en)
|
2019-06-21 |
2020-12-24 |
Regeneron Pharmaceuticals, Inc. |
Use of bispecific antigen-binding molecules that bind muc16 and cd3 in combination with 4-1bb co-stimulation
|
|
JP7743313B2
(ja)
|
2019-06-21 |
2025-09-24 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
Ｐｓｍａおよびｃｄ３に結合する二重特異性抗原結合分子の４－１ｂｂ共刺激と組み合わせての使用
|
|
CN114040778A
(zh)
|
2019-06-29 |
2022-02-11 |
杭州多禧生物科技有限公司 |
一种细胞结合分子-Tubulysin衍生物偶联物及其制备方法
|
|
AU2020299569A1
(en)
|
2019-07-01 |
2022-01-20 |
Trianni, Inc. |
Transgenic mammals and methods of use
|
|
ES3027509T3
(en)
|
2019-07-01 |
2025-06-16 |
Zoetis Services Llc |
Transgenic rodents and methods of use thereof
|
|
WO2021001289A1
(en)
|
2019-07-02 |
2021-01-07 |
F. Hoffmann-La Roche Ag |
Immunoconjugates comprising a mutant interleukin-2 and an anti-cd8 antibody
|
|
AR119393A1
(es)
|
2019-07-15 |
2021-12-15 |
Hoffmann La Roche |
Anticuerpos que se unen a nkg2d
|
|
JP7592064B2
(ja)
|
2019-07-16 |
2024-11-29 |
サノフィ・バイオテクノロジー |
Ｉｌ－４ｒアンタゴニストを投与することにより喘息を治療するまたは予防するための方法
|
|
CN114375302B
(zh)
|
2019-07-26 |
2024-12-24 |
詹森生物科技公司 |
包含激肽释放酶相关肽酶2抗原结合结构域的蛋白质及其用途
|
|
SG11202112491WA
(en)
|
2019-07-31 |
2021-12-30 |
Hoffmann La Roche |
Antibodies binding to gprc5d
|
|
BR112022001733A2
(pt)
|
2019-07-31 |
2022-06-28 |
Alector Llc |
Anticorpos anti-ms4a4a e métodos de uso dos mesmos
|
|
WO2021018925A1
(en)
|
2019-07-31 |
2021-02-04 |
F. Hoffmann-La Roche Ag |
Antibodies binding to gprc5d
|
|
AU2020326713A1
(en)
|
2019-08-05 |
2022-02-17 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating atopic dermatitis by administering an il-4r antagonist
|
|
CN114173819A
(zh)
|
2019-08-05 |
2022-03-11 |
瑞泽恩制药公司 |
通过施用il-4r拮抗剂治疗过敏和增强过敏原特异性免疫疗法的方法
|
|
US12098212B2
(en)
|
2019-08-12 |
2024-09-24 |
Purinomia Biotech, Inc. |
Methods and compositions for promoting and potentiating T-cell mediated immune responses through ADCC targeting of CD39 expressing cells
|
|
CR20220054A
(es)
|
2019-08-15 |
2022-06-06 |
Janssen Biotech Inc |
Materiales y métodos para fragmentos variables de cadena única mejorado
|
|
DK3785536T4
(da)
|
2019-08-28 |
2025-10-27 |
Trianni Inc |
Adam6-knockin-mus
|
|
CA3146616A1
(en)
|
2019-09-12 |
2021-03-18 |
Matthew Dominic CASCINO |
Compositions and methods of treating lupus nephritis
|
|
CN114423791B
(zh)
|
2019-09-18 |
2026-01-09 |
豪夫迈·罗氏有限公司 |
抗klk7抗体、抗klk5抗体、多特异性抗klk5/klk7抗体及使用方法
|
|
MX2022003266A
(es)
|
2019-09-20 |
2022-04-11 |
Genentech Inc |
Dosis para anticuerpos anti-triptasa.
|
|
CN114746119A
(zh)
|
2019-09-27 |
2022-07-12 |
詹森生物科技公司 |
抗-ceacam抗体及其用途
|
|
TW202126690A
(zh)
|
2019-09-27 |
2021-07-16 |
美商建南德克公司 |
用抗ｔｉｇｉｔ和抗ｐｄ－ｌ１拮抗劑抗體給藥治療
|
|
WO2021058729A1
(en)
|
2019-09-27 |
2021-04-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Anti-müllerian inhibiting substance type i receptor antibodies and uses thereof
|
|
EP4034560A1
(en)
|
2019-09-27 |
2022-08-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Anti-müllerian inhibiting substance antibodies and uses thereof
|
|
CN114829401A
(zh)
|
2019-09-27 |
2022-07-29 |
南京金斯瑞生物科技有限公司 |
抗vhh域抗体及其用途
|
|
US12202893B2
(en)
|
2019-10-04 |
2025-01-21 |
Tae Life Sciences, Llc |
Antibody compositions comprising Fc mutations and site-specific conjugation properties for use in treating cancer, immunological disorders, and methods thereof
|
|
WO2021076196A1
(en)
|
2019-10-18 |
2021-04-22 |
Genentech, Inc. |
Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
|
|
BR112022007923A2
(pt)
|
2019-10-28 |
2022-07-26 |
Regeneron Pharma |
Anticorpo recombinante isolado ou fragmento de ligação ao antígeno deste, composição farmacêutica, molécula de polinucleotídeo, vetor, célula, e, método para prevenir, tratar ou melhorar pelo menos um sintoma da infecção por influenza
|
|
CN115066613A
(zh)
|
2019-11-06 |
2022-09-16 |
基因泰克公司 |
用于治疗血液癌症的诊断和治疗方法
|
|
TWI895295B
(zh)
|
2019-11-12 |
2025-09-01 |
美商方得生醫療公司 |
偵測編碼新生抗原之融合基因之方法
|
|
CN114641270A
(zh)
|
2019-11-15 |
2022-06-17 |
豪夫迈·罗氏有限公司 |
防止水性蛋白质溶液中可见颗粒的形成
|
|
AU2020385683A1
(en)
|
2019-11-18 |
2022-06-30 |
Janssen Biotech, Inc. |
Vaccines based on mutant CALR and JAK2 and their uses
|
|
WO2021099600A1
(en)
|
2019-11-22 |
2021-05-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Inhibitors of adrenomedullin for the treatment of acute myeloid leukemia by eradicating leukemic stem cells
|
|
EP4065601A1
(en)
|
2019-11-25 |
2022-10-05 |
Mabloc, LLC |
Anti-yellow fever virus antibodies, and methods of their generation and use
|
|
WO2021108363A1
(en)
|
2019-11-25 |
2021-06-03 |
Regeneron Pharmaceuticals, Inc. |
Crispr/cas-mediated upregulation of humanized ttr allele
|
|
AU2020395122A1
(en)
|
2019-12-02 |
2022-06-09 |
Regeneron Pharmaceuticals, Inc. |
Peptide-MHC II protein constructs and uses thereof
|
|
MX2022006812A
(es)
|
2019-12-06 |
2022-08-25 |
Sanofi Biotechnology |
Metodos para tratar epoc mediante la administracion de un antagonista de il-33.
|
|
EP3992974A1
(en)
|
2020-11-02 |
2022-05-04 |
Sanofi Biotechnology |
Methods for treating digitally-identified il-4/il-13 related disorders
|
|
EP4073810A1
(en)
|
2019-12-09 |
2022-10-19 |
Sanofi Biotechnology |
Methods for treating digitally-identified il-4/il-13 related disorders
|
|
EP4072672A1
(en)
|
2019-12-10 |
2022-10-19 |
Regeneron Pharmaceuticals, Inc. |
Use of a pcsk9 inhibitor to treat homozygous familial hypercholesterolemia
|
|
AU2020401319A1
(en)
|
2019-12-13 |
2022-06-30 |
Alector Llc |
Anti-MerTK antibodies and methods of use thereof
|
|
PE20221511A1
(es)
|
2019-12-13 |
2022-10-04 |
Genentech Inc |
Anticuerpos anti-ly6g6d y metodos de uso
|
|
KR20220100963A
(ko)
|
2019-12-18 |
2022-07-18 |
에프. 호프만-라 로슈 아게 |
Hla-a2/mage-a4에 결합하는 항체
|
|
JP7807372B2
(ja)
|
2019-12-20 |
2026-01-27 |
ハドソン インスティチュート オブ メディカル リサーチ |
Ｃｘｃｌ１０結合タンパク質及びその使用
|
|
JP2023508360A
(ja)
|
2019-12-23 |
2023-03-02 |
サノフィ・バイオテクノロジー |
Ｉｌ－３３アンタゴニストおよび／またはｉｌ－４ｒアンタゴニストを投与することによりアレルギー性喘息を治療するまたは予防するための方法
|
|
EP4082570B1
(en)
|
2019-12-27 |
2026-02-25 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-ctla-4 antibody and use thereof
|
|
EP4084823A4
(en)
|
2020-01-03 |
2024-05-15 |
Marengo Therapeutics, Inc. |
ANTI-TCR ANTIBODY MOLECULES AND THEIR USES
|
|
AU2021205910A1
(en)
|
2020-01-08 |
2022-09-01 |
Regeneron Pharmaceuticals, Inc. |
Use of amino acids to enhance signal in mass spectral analyses
|
|
CN110818795B
(zh)
|
2020-01-10 |
2020-04-24 |
上海复宏汉霖生物技术股份有限公司 |
抗tigit抗体和使用方法
|
|
IL294989A
(en)
|
2020-01-24 |
2022-09-01 |
Regeneron Pharma |
Conjugated protein-antiviral compounds
|
|
WO2021194481A1
(en)
|
2020-03-24 |
2021-09-30 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
|
EP4097484A1
(en)
|
2020-01-27 |
2022-12-07 |
Regeneron Pharmaceuticals, Inc. |
Tandem mass tag multiplexed quantitation of post-translational modifications of proteins
|
|
WO2022050954A1
(en)
|
2020-09-04 |
2022-03-10 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
|
US12250931B2
(en)
|
2020-01-28 |
2025-03-18 |
Regeneron Pharmaceuticals, Inc. |
Genetically modified mouse with a humanized PNPLA3 gene and methods of use
|
|
KR20220133942A
(ko)
|
2020-01-30 |
2022-10-05 |
리제너론 파아마슈티컬스, 인크. |
네이티브 액체 크로마토그래피-질량 분석용 플랫폼
|
|
EP4096708A1
(en)
|
2020-01-31 |
2022-12-07 |
Genentech, Inc. |
Methods of inducing neoepitope-specific t cells with a pd-1 axis binding antagonist and an rna vaccine
|
|
CN115210574A
(zh)
|
2020-01-31 |
2022-10-18 |
瑞泽恩制药公司 |
通过液相色谱-质谱法进行高置信度化合物鉴定
|
|
BR112022015374A2
(pt)
|
2020-02-03 |
2022-10-11 |
Vir Biotechnology Inc |
Anticorpos contra sars-cov-2 e métodos de uso dos mesmos
|
|
EP3862023A1
(en)
|
2020-02-05 |
2021-08-11 |
Hangzhou DAC Biotech Co, Ltd |
Conjugates of cell-binding molecules with cytotoxic agents
|
|
EP4099821A1
(en)
|
2020-02-07 |
2022-12-14 |
Regeneron Pharmaceuticals, Inc. |
<smallcaps/>? ? ?klkb1? ? ? ? ?non-human animals comprising a humanizedlocus and methods of use
|
|
KR102929927B1
(ko)
|
2020-02-10 |
2026-02-25 |
상하이 에스쿠겐 바이오테크놀로지 컴퍼니 리미티드 |
클라우딘18.2 항체 및 그것의 사용
|
|
CN115427453B
(zh)
|
2020-02-10 |
2024-07-12 |
上海诗健生物科技有限公司 |
Cldn18.2抗体及其用途
|
|
JP7772702B2
(ja)
|
2020-02-10 |
2025-11-18 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
抗ｔｍｐｒｓｓ２抗体および抗原結合断片
|
|
KR20220140802A
(ko)
|
2020-02-11 |
2022-10-18 |
리제너론 파아마슈티컬스, 인크. |
항-acvr1 항체 및 이의 용도
|
|
TWI895351B
(zh)
|
2020-02-12 |
2025-09-01 |
日商中外製藥股份有限公司 |
用於癌症之治療的抗cd137抗原結合分子
|
|
TWI900527B
(zh)
|
2020-02-12 |
2025-10-11 |
比利時商健生藥品公司 |
用於治療尿路上皮癌的ｆｇｆｒ酪胺酸激酶抑制劑和抗ｐｄ１藥劑
|
|
IL295023A
(en)
|
2020-02-14 |
2022-09-01 |
Jounce Therapeutics Inc |
Antibodies and fusion proteins that bind to ccr8 and their uses
|
|
TW202144388A
(zh)
|
2020-02-14 |
2021-12-01 |
美商健生生物科技公司 |
在卵巢癌中表現之新抗原及其用途
|
|
TW202144389A
(zh)
|
2020-02-14 |
2021-12-01 |
美商健生生物科技公司 |
在多發性骨髓瘤中表現之新抗原及其用途
|
|
EP3872091B1
(en)
|
2020-02-26 |
2023-06-14 |
VIR Biotechnology, Inc. |
Antibodies against sars-cov-2
|
|
CN115151573A
(zh)
|
2020-02-28 |
2022-10-04 |
上海复宏汉霖生物技术股份有限公司 |
抗cd137构建体、多特异性抗体及其用途
|
|
BR112022016491A2
(pt)
|
2020-02-28 |
2022-10-11 |
Shanghai Henlius Biotech Inc |
Construto anti-cd137 e usos do mesmo
|
|
CA3174680A1
(en)
|
2020-03-13 |
2021-09-16 |
Genentech, Inc. |
Anti-interleukin-33 antibodies and uses thereof
|
|
US20240293453A1
(en)
|
2020-03-13 |
2024-09-05 |
Janssen Biotech, Inc. |
Materials and methods for binding siglec-3/cd33
|
|
PE20230259A1
(es)
|
2020-03-19 |
2023-02-07 |
Genentech Inc |
Anticuerpos anti-tgf-beta con selectividad de isoforma y metodos de uso
|
|
WO2021195079A1
(en)
|
2020-03-23 |
2021-09-30 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals comprising a humanized ttr locus comprising a v30m mutation and methods of use
|
|
US11999787B2
(en)
|
2020-03-24 |
2024-06-04 |
Genentech, Inc. |
Tie2-binding agents and methods of use
|
|
JP2023518841A
(ja)
|
2020-03-26 |
2023-05-08 |
ジェネンテック， インコーポレイテッド |
宿主細胞タンパク質が減少した修飾哺乳動物細胞
|
|
WO2021195530A1
(en)
|
2020-03-27 |
2021-09-30 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating atopic dermatitis by administering an il-4r antagonist
|
|
US20240294650A1
(en)
|
2020-03-31 |
2024-09-05 |
Alector Llc |
Anti-mertk antibodies and methods of use thereof
|
|
EP4126934A1
(en)
|
2020-04-01 |
2023-02-08 |
University of Rochester |
Monoclonal antibodies against the hemagglutinin (ha) and neuraminidase (na) of influenza h3n2 viruses
|
|
CR20220552A
(es)
|
2020-04-02 |
2023-01-17 |
Regeneron Pharma |
Anticuerpos contra glicoproteína de espícula anti-sars-cov-2 y fragmentos de unión al antígeno
|
|
EP4127724A1
(en)
|
2020-04-03 |
2023-02-08 |
Genentech, Inc. |
Therapeutic and diagnostic methods for cancer
|
|
WO2021203053A1
(en)
|
2020-04-03 |
2021-10-07 |
Vir Biotechnology, Inc. |
Immunotherapy targeting a conserved region in sars coronaviruses
|
|
US20240059757A1
(en)
|
2020-04-14 |
2024-02-22 |
Vir Biotechnology, Inc. |
Antibodies against sars-cov-2 and methods of using the same
|
|
IL297024A
(en)
|
2020-04-14 |
2022-12-01 |
Regeneron Pharma |
Ultraviolet monitoring of chromatography performance using orthogonal partial least squares
|
|
CN115485028A
(zh)
|
2020-04-15 |
2022-12-16 |
豪夫迈·罗氏有限公司 |
免疫缀合物
|
|
US11701427B2
(en)
|
2020-04-16 |
2023-07-18 |
Regeneron Pharmaceuticals, Inc. |
Diels-alder conjugation methods
|
|
EP4139359A1
(en)
|
2020-04-24 |
2023-03-01 |
Genentech, Inc. |
Methods of using anti-cd79b immunoconjugates
|
|
CN115427443A
(zh)
|
2020-04-24 |
2022-12-02 |
豪夫迈·罗氏有限公司 |
巯基化合物及其衍生物的酶和途径调节
|
|
JP2023523450A
(ja)
|
2020-04-28 |
2023-06-05 |
ジェネンテック， インコーポレイテッド |
非小細胞肺がん免疫療法のための方法及び組成物
|
|
KR20230002261A
(ko)
|
2020-04-28 |
2023-01-05 |
더 락커펠러 유니버시티 |
항-sars-cov-2 중화 항체 및 이의 사용 방법
|
|
JP2023527962A
(ja)
|
2020-05-03 |
2023-07-03 |
レヴィーナ （スジョウ） バイオファーマ カンパニー， リミテッド |
抗ｔｒｏｐ２抗体を含む抗体薬物複合体（ａｄｃ）、かかるａｄｃを含む組成物、ならびにそれらを作製および使用する方法
|
|
PH12022500020A1
(en)
|
2020-05-08 |
2024-05-06 |
Vir Biotechnology Inc |
Antibodies against sars-cov-2
|
|
IL298099A
(en)
|
2020-05-12 |
2023-01-01 |
Regeneron Pharma |
Anti-glp1r antagonist antibodies and methods of use thereof
|
|
CN115551553A
(zh)
|
2020-05-12 |
2022-12-30 |
Inserm(法国国家健康医学研究院) |
治疗皮肤t细胞淋巴瘤和tfh起源淋巴瘤的新方法
|
|
WO2021228917A1
(en)
|
2020-05-15 |
2021-11-18 |
F. Hoffmann-La Roche Ag |
Prevention of visible particle formation in parenteral protein solutions
|
|
JP2023525898A
(ja)
|
2020-05-19 |
2023-06-19 |
エフ． ホフマン－ラ ロシュ アーゲー |
非経口タンパク質溶液における可視粒子の形成を防止するためのキレート剤の使用
|
|
KR20230015965A
(ko)
|
2020-05-22 |
2023-01-31 |
리제너론 파아마슈티컬스, 인크. |
Il-4r 억제제를 투여함에 의해 호산구성 식도염을 치료하기 위한 방법
|
|
WO2021242815A1
(en)
|
2020-05-26 |
2021-12-02 |
Regeneron Pharmaceuticals, Inc. |
Anti-sars-cov-2-spike glycoprotein antibodies and antigen-binding fragments
|
|
IL298444A
(en)
|
2020-05-27 |
2023-01-01 |
Janssen Biotech Inc |
Proteins containing cd3 antigen binding sites and uses thereof
|
|
JP2023528375A
(ja)
|
2020-05-29 |
2023-07-04 |
２３アンドミー・インコーポレイテッド |
抗ｃｄ２００ｒ１抗体及びその使用方法
|
|
CN116529260A
(zh)
|
2020-06-02 |
2023-08-01 |
当康生物技术有限责任公司 |
抗cd93构建体及其用途
|
|
IL298632A
(en)
*
|
2020-06-02 |
2023-01-01 |
Biocytogen Pharmaceuticals Beijing Co Ltd |
Non-human animals genetically modified with a common light chain immunoglobulin locus
|
|
BR112022024629A2
(pt)
|
2020-06-02 |
2023-02-23 |
Dynamicure Biotechnology Llc |
Construtos anti-cd93 e seus usos
|
|
WO2021247925A1
(en)
|
2020-06-03 |
2021-12-09 |
Vir Biotechnology, Inc. |
Structure-guided immunotherapy against sars-cov-2
|
|
EP4161644A2
(en)
|
2020-06-08 |
2023-04-12 |
F. Hoffmann-La Roche AG |
Anti-hbv antibodies and methods of use
|
|
RU2751237C1
(ru)
*
|
2020-06-10 |
2021-07-12 |
Регенерон Фармасьютикалс, Инк. |
Способы и композиции для направленной модификации генома
|
|
GB202008860D0
(en)
|
2020-06-11 |
2020-07-29 |
Univ Oxford Innovation Ltd |
BTLA antibodies
|
|
EP4165415A1
(en)
|
2020-06-12 |
2023-04-19 |
Genentech, Inc. |
Methods and compositions for cancer immunotherapy
|
|
CA3180477A1
(en)
|
2020-06-12 |
2021-12-16 |
Elizabeth Alexander |
Antibody therapies for sars-cov-2 infection
|
|
CA3181820A1
(en)
|
2020-06-16 |
2021-12-23 |
Genentech, Inc. |
Methods and compositions for treating triple-negative breast cancer
|
|
BR112022025700A2
(pt)
|
2020-06-18 |
2023-02-28 |
Regeneron Pharma |
Formulações de anticorpo de activina a e métodos de uso das mesmas
|
|
IL298946A
(en)
|
2020-06-18 |
2023-02-01 |
Genentech Inc |
Treatment with anti-tigit antibodies and pd-1 axis binding antagonists
|
|
CN116234824A
(zh)
|
2020-06-22 |
2023-06-06 |
阿尔米雷尔有限公司 |
抗il-36抗体及其使用方法
|
|
US20220041672A1
(en)
|
2020-06-24 |
2022-02-10 |
Genentech, Inc. |
Apoptosis resistant cell lines
|
|
KR20230024822A
(ko)
|
2020-06-25 |
2023-02-21 |
주식회사 휴맵 |
이형접합성 형질전환 동물
|
|
CN115698059A
(zh)
|
2020-07-01 |
2023-02-03 |
瑞泽恩制药公司 |
使用抗bet v 1抗体治疗过敏的方法
|
|
WO2022009052A2
(en)
|
2020-07-06 |
2022-01-13 |
Janssen Biotech, Inc. |
Prostate neoantigens and their uses
|
|
JP2023532764A
(ja)
|
2020-07-07 |
2023-07-31 |
エフ． ホフマン－ラ ロシュ アーゲー |
治療用タンパク質製剤の安定剤としての代替界面活性剤
|
|
KR20240038138A
(ko)
|
2020-07-13 |
2024-03-22 |
리제너론 파마슈티칼스 인코포레이티드 |
단백질에서 글루타민 잔기에 접합된 캄토테신 유사체 및 그의 용도
|
|
MX2023000617A
(es)
|
2020-07-17 |
2023-02-13 |
Genentech Inc |
Anticuerpos anti-notch2 y metodos de uso.
|
|
CR20230017A
(es)
|
2020-07-21 |
2023-02-17 |
Genentech Inc |
Inductores químicos de degradación conjugados con anticuerpo de brm y métodos de estos
|
|
GB2597532A
(en)
|
2020-07-28 |
2022-02-02 |
Femtogenix Ltd |
Cytotoxic compounds
|
|
EP4188439A2
(en)
|
2020-07-29 |
2023-06-07 |
Janssen Biotech, Inc. |
Proteins comprising hla-g antigen binding domains and their uses
|
|
EP4188550A1
(en)
|
2020-07-29 |
2023-06-07 |
Dynamicure Biotechnology LLC |
Anti-cd93 constructs and uses thereof
|
|
JP2023538522A
(ja)
|
2020-08-07 |
2023-09-08 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
Ａｎｇｐｔｌ３阻害剤を伴う難治性高コレステロール血症を処置するための方法
|
|
CA3128035A1
(en)
|
2020-08-13 |
2022-02-13 |
Bioasis Technologies, Inc. |
Combination therapies for delivery across the blood brain barrier
|
|
US20220064270A1
(en)
|
2020-08-26 |
2022-03-03 |
Regeneron Pharmaceuticals, Inc. |
Method of treating an allergy with allergen-specific monoclonal antibodies
|
|
CN116648507A
(zh)
|
2020-08-28 |
2023-08-25 |
基因泰克公司 |
宿主细胞蛋白的CRISPR/Cas9多重敲除
|
|
EP4211155A1
(en)
|
2020-09-11 |
2023-07-19 |
Regeneron Pharmaceuticals, Inc. |
Identification and production of antigen-specific antibodies
|
|
JP2023541627A
(ja)
|
2020-09-14 |
2023-10-03 |
イシュノス サイエンシズ ソシエテ アノニム |
Ｉｌ１ｒａｐに結合する抗体及びその使用
|
|
WO2022056494A1
(en)
|
2020-09-14 |
2022-03-17 |
Regeneron Pharmaceuticals, Inc. |
Antibody-drug conjugates comprising glp1 peptidomimetics and uses thereof
|
|
CA3193569A1
(en)
|
2020-09-28 |
2022-03-31 |
Xiaofeng Liu |
Anti-sclerostin constructs and uses thereof
|
|
WO2022067269A2
(en)
|
2020-09-28 |
2022-03-31 |
Humabs Biomed Sa |
Antibodies against sars-cov-2
|
|
IL301547A
(en)
|
2020-10-05 |
2023-05-01 |
Genentech Inc |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
|
US20220169739A1
(en)
|
2020-10-05 |
2022-06-02 |
Sanofi Biotechnology |
Methods for treating asthma in pediatric subjects by administering an il-4r antagonist
|
|
EP4248743A1
(en)
|
2020-10-08 |
2023-09-27 |
Humab Co. Ltd. |
Method for preparing transgenic non-human animal having genome including humanized immunoglobulin gene locus
|
|
AR123767A1
(es)
|
2020-10-13 |
2023-01-11 |
Janssen Biotech Inc |
Inmunidad mediada por células t mediante bioingeniería, materiales y otros métodos para modular el cúmulo de diferenciación iv y/o viii
|
|
CA3198456A1
(en)
|
2020-10-14 |
2022-04-21 |
Five Prime Therapeutics, Inc. |
Anti-c-c chemokine receptor 8 (ccr8) antibodies and methods of use thereof
|
|
WO2022084210A1
(en)
|
2020-10-20 |
2022-04-28 |
F. Hoffmann-La Roche Ag |
Combination therapy of pd-1 axis binding antagonists and lrrk2 inhitibors
|
|
NZ797493A
(en)
|
2020-10-22 |
2024-05-31 |
Regeneron Pharma |
Anti-fgfr2 antibodies and methods of use thereof
|
|
JP2023548034A
(ja)
|
2020-10-22 |
2023-11-15 |
ヤンセン バイオテツク，インコーポレーテツド |
デルタ様リガンド３（ｄｌｌ３）抗原結合ドメインを含むタンパク質及びその使用
|
|
WO2022093981A1
(en)
|
2020-10-28 |
2022-05-05 |
Genentech, Inc. |
Combination therapy comprising ptpn22 inhibitors and pd-l1 binding antagonists
|
|
CA3196539A1
(en)
|
2020-11-04 |
2022-05-12 |
Chi-Chung Li |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
|
|
IL302400A
(en)
|
2020-11-04 |
2023-06-01 |
Genentech Inc |
Subcutaneous dosing of bispecific anti-CD20/anti-CD3 antibodies
|
|
WO2022098870A1
(en)
|
2020-11-04 |
2022-05-12 |
The Rockefeller University |
Neutralizing anti-sars-cov-2 antibodies
|
|
CA3196191A1
(en)
|
2020-11-04 |
2022-05-12 |
Chi-Chung Li |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies and anti-cd79b antibody drug conjugates
|
|
AR124063A1
(es)
|
2020-11-16 |
2023-02-08 |
Astellas Pharma Inc |
Anticuerpo biespecífico anti-tspan8 / anti-cd3 y anticuerpo anti-tspan8
|
|
AU2021376837A1
(en)
|
2020-11-16 |
2023-06-15 |
F. Hoffmann-La Roche Ag |
Fab high mannose glycoforms
|
|
TW202229329A
(zh)
|
2020-11-23 |
2022-08-01 |
美商維爾生物科技股份有限公司 |
針對流感神經胺酸酶的廣泛中和抗體
|
|
WO2022109317A1
(en)
|
2020-11-23 |
2022-05-27 |
Vir Biotechnology, Inc. |
Anti-influenza antibodies and combinations thereof
|
|
KR20230135569A
(ko)
|
2020-11-23 |
2023-09-25 |
비르 바이오테크놀로지, 인코포레이티드 |
인플루엔자 a 바이러스에 대한 항체
|
|
TW202235107A
(zh)
|
2020-11-25 |
2022-09-16 |
美商維爾生物科技股份有限公司 |
結合至多種乙型冠狀病毒的抗體
|
|
JP2023553861A
(ja)
|
2020-12-02 |
2023-12-26 |
上海復宏漢霖生物技術股▲フン▼有限公司 |
抗ＧＡＲＰ／ＴＧＦβ抗体及び使用方法
|
|
WO2022120352A1
(en)
|
2020-12-02 |
2022-06-09 |
Alector Llc |
Methods of use of anti-sortilin antibodies
|
|
WO2022126113A1
(en)
|
2020-12-09 |
2022-06-16 |
Trianni, Inc. |
Heavy chain-only antibodies
|
|
CA3199879A1
(en)
|
2020-12-16 |
2022-06-23 |
Regeneron Pharmaceuticals, Inc. |
Mice expressing humanized fc alpha receptors
|
|
EP4263609A1
(en)
|
2020-12-17 |
2023-10-25 |
F. Hoffmann-La Roche AG |
Anti-hla-g antibodies and use thereof
|
|
WO2022132904A1
(en)
|
2020-12-17 |
2022-06-23 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Human monoclonal antibodies targeting sars-cov-2
|
|
CA3202629A1
(en)
|
2020-12-18 |
2022-06-23 |
Regeneron Pharmaceuticals, Inc. |
Immunoglobulin proteins that bind to npr1 agonists
|
|
CN116745609A
(zh)
|
2020-12-20 |
2023-09-12 |
瑞泽恩制药公司 |
鉴定生物分子中乱序二硫键的方法
|
|
JP2024501796A
(ja)
|
2020-12-23 |
2024-01-16 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
膜貫通タンパク質に結合する抗体、および抗体を産生する細胞を取得する方法
|
|
US20240317849A1
(en)
|
2020-12-23 |
2024-09-26 |
Regeneron Pharmaceuticals, Inc. |
Nucleic acids encoding anchor modified antibodies and uses thereof
|
|
WO2022150605A1
(en)
|
2021-01-08 |
2022-07-14 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating peanut allergy and enhancing peanut allergen-specific immunotherapy by administering an il-4r antagonist
|
|
WO2022148853A1
(en)
|
2021-01-11 |
2022-07-14 |
F. Hoffmann-La Roche Ag |
Immunoconjugates
|
|
KR20230131207A
(ko)
|
2021-01-13 |
2023-09-12 |
아스텔라스세이야쿠 가부시키가이샤 |
ActRIIA, ActRIIB 및 Fn14에 결합하는 다중 특이성항체
|
|
EP4277926A1
(en)
|
2021-01-15 |
2023-11-22 |
The Rockefeller University |
Neutralizing anti-sars-cov-2 antibodies
|
|
JP2024505195A
(ja)
|
2021-01-25 |
2024-02-05 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
抗ｐｄｇｆ－ｂ抗体及び肺動脈高血圧症（ｐａｈ）を治療するための使用方法
|
|
WO2022159842A1
(en)
|
2021-01-25 |
2022-07-28 |
Vir Biotechnology, Inc. |
Antibody combination therapies for sars-cov-2 infection
|
|
JP2024504758A
(ja)
|
2021-01-28 |
2024-02-01 |
ヤンセン バイオテツク，インコーポレーテツド |
Ｐｓｍａ結合タンパク質及びその使用
|
|
CN117642178A
(zh)
|
2021-02-09 |
2024-03-01 |
美国政府(由卫生和人类服务部的部长所代表) |
靶向冠状病毒刺突蛋白的抗体
|
|
CN117136197A
(zh)
|
2021-02-09 |
2023-11-28 |
胡默波斯生物医学公司 |
抗呼吸道合胞病毒、人偏肺病毒和小鼠肺炎病毒的抗体和其使用方法
|
|
CN117396502A
(zh)
|
2021-02-09 |
2024-01-12 |
佐治亚大学研究基金会有限公司 |
针对肺炎球菌抗原的人类单克隆抗体
|
|
CN117440832A
(zh)
|
2021-03-03 |
2024-01-23 |
索伦托药业有限公司 |
包括抗bcma抗体的抗体-药物缀合物
|
|
WO2022187626A1
(en)
|
2021-03-05 |
2022-09-09 |
Regeneron Pharmaceuticals, Inc. |
Anti-sars-cov-2-variant-spike glycoprotein antibodies and antigen-binding fragments
|
|
WO2022187863A1
(en)
|
2021-03-05 |
2022-09-09 |
Dynamicure Biotechnology Llc |
Anti-vista constructs and uses thereof
|
|
JP2024512377A
(ja)
|
2021-03-12 |
2024-03-19 |
ジェネンテック， インコーポレイテッド |
抗ｋｌｋ７抗体、抗ｋｌｋ５抗体、多重特異性抗ｋｌｋ５／ｋｌｋ７抗体、及び使用方法
|
|
IL305283A
(en)
|
2021-03-15 |
2023-10-01 |
Genentech Inc |
Compositions and methods for the treatment of lupus nephritis
|
|
JP2024512002A
(ja)
|
2021-03-18 |
2024-03-18 |
アレクトル エルエルシー |
抗ｔｍｅｍ１０６ｂ抗体、及び、その使用方法
|
|
WO2022197877A1
(en)
|
2021-03-19 |
2022-09-22 |
Genentech, Inc. |
Methods and compositions for time delayed bio-orthogonal release of cytotoxic agents
|
|
JP2024511610A
(ja)
|
2021-03-23 |
2024-03-14 |
アレクトル エルエルシー |
コロナウイルス感染の治療及び予防のための抗ｔｍｅｍ１０６ｂ抗体
|
|
WO2022204202A1
(en)
|
2021-03-23 |
2022-09-29 |
Vir Biotechnology, Inc. |
Antibodies that bind to multiple sarbecoviruses
|
|
KR20230160314A
(ko)
|
2021-03-24 |
2023-11-23 |
얀센 바이오테크 인코포레이티드 |
Cd22 및 cd79b를 표적화하는 항체
|
|
EP4314056A1
(en)
|
2021-03-24 |
2024-02-07 |
Janssen Biotech, Inc. |
Proteins comprising cd3 antigen binding domains and uses thereof
|
|
TW202300648A
(zh)
|
2021-03-25 |
2023-01-01 |
美商當康生物科技有限公司 |
抗-igfbp7構築體及其用途
|
|
AU2022249328A1
(en)
|
2021-03-31 |
2023-09-21 |
Regeneron Pharmaceuticals, Inc. |
Genetically modified mice comprising humanized cellular immune system components with improved diversity of tcrβ repertoire
|
|
AR125255A1
(es)
|
2021-04-02 |
2023-06-28 |
Regeneron Pharma |
Métodos de predicción y modulación de la glicación de una proteína
|
|
AR125344A1
(es)
|
2021-04-15 |
2023-07-05 |
Chugai Pharmaceutical Co Ltd |
Anticuerpo anti-c1s
|
|
WO2022220603A1
(ko)
|
2021-04-16 |
2022-10-20 |
고려대학교 산학협력단 |
코로나-19 바이러스 표적 인간 항체
|
|
WO2022225880A1
(en)
|
2021-04-19 |
2022-10-27 |
Genentech, Inc. |
Modified mammalian cells
|
|
MX2023012300A
(es)
|
2021-04-20 |
2023-10-26 |
Regeneron Pharma |
Anticuerpos humanos contra artemina y metodos de uso de estos.
|
|
JP7365654B2
(ja)
|
2021-04-22 |
2023-10-20 |
アステラス製薬株式会社 |
抗ｃｌｄｎ４－抗ｃｄ１３７二重特異性抗体
|
|
AU2021443318A1
(en)
|
2021-04-30 |
2023-09-07 |
F. Hoffmann-La Roche Ag |
Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
|
|
EP4329800A1
(en)
|
2021-04-30 |
2024-03-06 |
F. Hoffmann-La Roche AG |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibody
|
|
MX2023012974A
(es)
|
2021-05-04 |
2023-11-15 |
Regeneron Pharma |
Agonistas multiespecificos de receptores del fgf21 y sus usos.
|
|
US20240215556A1
(en)
|
2021-05-05 |
2024-07-04 |
Trianni, Inc. |
Transgenic rodents expressing chimeric equine-rodent antibodies and methods of use thereof
|
|
EP4334343A2
(en)
|
2021-05-06 |
2024-03-13 |
The Rockefeller University |
Neutralizing anti-sars- cov-2 antibodies and methods of use thereof
|
|
CA3218455A1
(en)
|
2021-05-11 |
2022-11-17 |
Harvey CHIN |
Anti-tmprss6 antibodies and uses thereof
|
|
CA3218170A1
(en)
|
2021-05-12 |
2022-11-17 |
Jamie Harue HIRATA |
Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
|
|
KR20240010469A
(ko)
|
2021-05-21 |
2024-01-23 |
제넨테크, 인크. |
관심 재조합 생성물의 생성을 위한 변형된 세포
|
|
IL308509A
(en)
|
2021-05-24 |
2024-01-01 |
Vir Biotechnology Inc |
Transgenic polypeptides
|
|
CN113278071B
(zh)
|
2021-05-27 |
2021-12-21 |
江苏荃信生物医药股份有限公司 |
抗人干扰素α受体1单克隆抗体及其应用
|
|
WO2022255440A1
(en)
|
2021-06-04 |
2022-12-08 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-ddr2 antibodies and uses thereof
|
|
CA3216220A1
(en)
|
2021-06-09 |
2022-12-15 |
F. Hoffmann-La Roche Ag |
Combination of a particular braf inhibitor (paradox breaker) and a pd-1 axis binding antagonist for use in the treatment of cancer
|
|
WO2022266223A1
(en)
|
2021-06-16 |
2022-12-22 |
Alector Llc |
Bispecific anti-mertk and anti-pdl1 antibodies and methods of use thereof
|
|
WO2022266221A1
(en)
|
2021-06-16 |
2022-12-22 |
Alector Llc |
Monovalent anti-mertk antibodies and methods of use thereof
|
|
US12227574B2
(en)
|
2021-06-17 |
2025-02-18 |
Amberstone Biosciences, Inc. |
Anti-CD3 constructs and uses thereof
|
|
CA3221878A1
(en)
|
2021-06-18 |
2022-12-22 |
David Stover |
Fusion protein composition(s) comprising masked type i interferons (ifna and ifnb) for use in the treatment of cancer and methods thereof
|
|
CN117616123B
(zh)
|
2021-06-25 |
2024-11-08 |
中外制药株式会社 |
抗ctla-4抗体
|
|
CN117545779B
(zh)
|
2021-06-25 |
2025-04-04 |
中外制药株式会社 |
抗ctla-4抗体的用途
|
|
US20240316169A1
(en)
|
2021-07-05 |
2024-09-26 |
Regeneron Pharmaceuticals, Inc. |
Utilization of antibodies to shape antibody responses to an antigen
|
|
CA3224853A1
(en)
|
2021-07-14 |
2023-01-19 |
Gautham GAMPA |
Anti-c-c motif chemokine receptor 8 (ccr8) antibodies and methods of use
|
|
CA3225575A1
(en)
|
2021-07-14 |
2023-01-19 |
Regeneron Pharmaceuticals, Inc. |
Anti-sars-cov-2-spike glycoprotein antibodies and antigen-binding fragments
|
|
WO2023004386A1
(en)
|
2021-07-22 |
2023-01-26 |
Genentech, Inc. |
Brain targeting compositions and methods of use thereof
|
|
AU2022315528A1
(en)
|
2021-07-22 |
2023-10-19 |
F. Hoffmann-La Roche Ag |
Heterodimeric fc domain antibodies
|
|
JP2024529434A
(ja)
|
2021-07-26 |
2024-08-06 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
Ｉｌ－４ｒアンタゴニストを投与することによる慢性自発性蕁麻疹を治療するための方法
|
|
CA3220081A1
(en)
|
2021-07-28 |
2023-02-02 |
Thomas Nittoli |
Protein-antiviral compound conjugates
|
|
WO2023012147A1
(en)
|
2021-08-03 |
2023-02-09 |
F. Hoffmann-La Roche Ag |
Bispecific antibodies and methods of use
|
|
EP4384553A1
(en)
|
2021-08-13 |
2024-06-19 |
Genentech, Inc. |
Dosing for anti-tryptase antibodies
|
|
JP2024532263A
(ja)
|
2021-08-23 |
2024-09-05 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
Ｉｌ－４ｒアンタゴニストを投与することによってアトピー性皮膚炎を治療する方法
|
|
EP4392454A4
(en)
|
2021-08-27 |
2025-10-15 |
Janssen Biotech Inc |
ANTI-PSMA ANTIBODIES AND THEIR USES
|
|
JP2024534853A
(ja)
|
2021-08-30 |
2024-09-26 |
ジェネンテック， インコーポレイテッド |
抗ポリビキチン多重特異性抗体
|
|
EP4396236A4
(en)
|
2021-08-30 |
2025-10-01 |
Lassen Therapeutics 1 Inc |
ANTI-IL-11R ALPHA ANTIBODIES
|
|
WO2023034871A1
(en)
|
2021-09-01 |
2023-03-09 |
Vir Biotechnology, Inc. |
High concentration antibody therapies for sars-cov-2 infection
|
|
EP4396221A1
(en)
|
2021-09-01 |
2024-07-10 |
VIR Biotechnology, Inc. |
Antibody therapies for sars-cov-2 infection in pediatric subjects
|
|
CN113603775B
(zh)
|
2021-09-03 |
2022-05-20 |
江苏荃信生物医药股份有限公司 |
抗人白介素-33单克隆抗体及其应用
|
|
CN113683694B
(zh)
|
2021-09-03 |
2022-05-13 |
江苏荃信生物医药股份有限公司 |
一种抗人tslp单克隆抗体及其应用
|
|
WO2023039442A1
(en)
|
2021-09-08 |
2023-03-16 |
Vir Biotechnology, Inc. |
Broadly neutralizing antibody combination therapies for sars-cov-2 infection
|
|
WO2023046322A1
(en)
|
2021-09-24 |
2023-03-30 |
Janssen Pharmaceutica Nv |
Proteins comprising cd20 binding domains, and uses thereof
|
|
CN118541392A
(zh)
|
2021-09-28 |
2024-08-23 |
准星生物医药有限公司 |
多种形式的分子复合物
|
|
WO2023056403A1
(en)
|
2021-09-30 |
2023-04-06 |
Genentech, Inc. |
Methods for treatment of hematologic cancers using anti-tigit antibodies, anti-cd38 antibodies, and pd-1 axis binding antagonists
|
|
CA3232212A1
(en)
|
2021-10-01 |
2023-04-06 |
Ping XIANG |
Transgenic rodents for cell line identification and enrichment
|
|
WO2023058723A1
(ja)
|
2021-10-08 |
2023-04-13 |
中外製薬株式会社 |
プレフィルドシリンジ製剤の調製方法
|
|
JP2024537335A
(ja)
|
2021-10-14 |
2024-10-10 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
新規インターロイキン－７イムノコンジュゲート
|
|
WO2023062048A1
(en)
|
2021-10-14 |
2023-04-20 |
F. Hoffmann-La Roche Ag |
Alternative pd1-il7v immunoconjugates for the treatment of cancer
|
|
WO2023069919A1
(en)
|
2021-10-19 |
2023-04-27 |
Alector Llc |
Anti-cd300lb antibodies and methods of use thereof
|
|
AU2022369296A1
(en)
|
2021-10-20 |
2024-05-30 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating prurigo nodularis by administering an il-4r antagonist
|
|
IL312308A
(en)
|
2021-10-22 |
2024-06-01 |
Regeneron Pharma |
Antibodies that bind to the A2 domain of factor XI and their uses
|
|
EP4423271A2
(en)
|
2021-10-28 |
2024-09-04 |
Regeneron Pharmaceuticals, Inc. |
Crispr/cas-related methods and compositions for knocking out c5
|
|
WO2022078524A2
(en)
|
2021-11-03 |
2022-04-21 |
Hangzhou Dac Biotech Co., Ltd. |
Specific conjugation of an antibody
|
|
IL312359A
(en)
|
2021-11-10 |
2024-06-01 |
Trianni Inc |
Transgenic mammals and methods of use thereof
|
|
WO2023086807A1
(en)
|
2021-11-10 |
2023-05-19 |
Genentech, Inc. |
Anti-interleukin-33 antibodies and uses thereof
|
|
IL312692A
(en)
|
2021-11-16 |
2024-07-01 |
Genentech Inc |
Methods and compositions for the treatment of systemic lupus erythematosus (SLE) with musontuzumab
|
|
EP4433500A1
(en)
|
2021-11-19 |
2024-09-25 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for reducing centralized pain
|
|
AU2022392829A1
(en)
|
2021-11-22 |
2024-07-11 |
Janssen Biotech, Inc. |
Compositions comprising enhanced multispecific binding agents for an immune response
|
|
JP7367262B1
(ja)
|
2021-12-01 |
2023-10-23 |
中外製薬株式会社 |
抗体含有製剤の調製方法
|
|
IL313265A
(en)
|
2021-12-06 |
2024-08-01 |
Regeneron Pharma |
Antagonistic antibodies against NPR1 and methods of using them
|
|
KR20240117571A
(ko)
|
2021-12-08 |
2024-08-01 |
리제너론 파마슈티칼스 인코포레이티드 |
돌연변이 마이오실린 질환 모델 및 이의 용도
|
|
EP4448579A4
(en)
|
2021-12-17 |
2026-02-18 |
Shanghai Henlius Biotech Inc |
ANTI-OX40 ANTIBODIES AND METHODS OF USE
|
|
CA3240585A1
(en)
|
2021-12-17 |
2023-06-22 |
Wenfeng Xu |
Anti-ox40 antibodies, multispecific antibodies and methods of use
|
|
AU2022425608A1
(en)
|
2021-12-30 |
2024-08-15 |
Regeneron Pharmaceuticals, Inc. |
Methods for attenuating atopic march by administering an il-4/il-13 antagonist
|
|
MX2024008640A
(es)
|
2022-01-12 |
2024-07-24 |
Regeneron Pharma |
Analogos de camptotecina conjugados a un residuo de glutamina en una proteina y su uso.
|
|
AU2023208050A1
(en)
|
2022-01-14 |
2024-07-04 |
Regeneron Pharmaceuticals, Inc. |
Verrucarin a derivatives and antibody drug conjugates thereof
|
|
WO2023141445A1
(en)
|
2022-01-19 |
2023-07-27 |
Genentech, Inc. |
Anti-notch2 antibodies and conjugates and methods of use
|
|
WO2023147399A1
(en)
|
2022-01-27 |
2023-08-03 |
The Rockefeller University |
Broadly neutralizing anti-sars-cov-2 antibodies targeting the n-terminal domain of the spike protein and methods of use thereof
|
|
WO2023147470A2
(en)
|
2022-01-28 |
2023-08-03 |
Georgiamune Inc. |
Antibodies to programmed cell death protein 1 that are pd-1 agonists
|
|
JP2025508677A
(ja)
|
2022-02-02 |
2025-04-10 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
ポンペ病の処置のための抗ＴｆＲ：ＧＡＡ及び抗ＣＤ６３：ＧＡＡの挿入
|
|
US20250194571A1
(en)
|
2022-02-07 |
2025-06-19 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for defining optimal treatment timeframes in lysosomal disease
|
|
WO2023152581A1
(en)
|
2022-02-09 |
2023-08-17 |
Janssen Biotech, Inc. |
Method of treating cancer with psmaxcd3 antibody
|
|
EP4476251A1
(en)
|
2022-02-10 |
2024-12-18 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Human monoclonal antibodies that broadly target coronaviruses
|
|
JP2025506095A
(ja)
|
2022-02-11 |
2025-03-07 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
４ｒタウ標的化剤をスクリーニングするための組成物及び方法
|
|
WO2023155902A1
(en)
|
2022-02-18 |
2023-08-24 |
Chongqing Mingdao Haoyue Biotechnology Co., Ltd. |
Intranasal formulations and anti-sars-cov-2-spike protein antibodies
|
|
US20250205350A1
(en)
|
2022-03-10 |
2025-06-26 |
Vivasor, Inc. |
Antibody-Drug Conjugates and Uses Thereof
|
|
WO2024026472A2
(en)
|
2022-07-29 |
2024-02-01 |
Alector Llc |
Transferrin receptor antigen-binding domains and uses therefor
|
|
MX2024011468A
(es)
|
2022-03-23 |
2024-09-25 |
Hoffmann La Roche |
Tratamiento conjunto de un anticuerpo biespecifico anti-cd20/anti-cd3 y quimioterapia.
|
|
EP4499708A1
(en)
|
2022-03-25 |
2025-02-05 |
Shanghai Henlius Biotech, Inc. |
Anti-msln antibodies and methods of use
|
|
KR20240169042A
(ko)
|
2022-04-01 |
2024-12-02 |
제넨테크, 인크. |
항-fcrh5/항-cd3 이중특이성 항체로 치료하기 위한 투약법
|
|
WO2023201256A1
(en)
|
2022-04-12 |
2023-10-19 |
Vir Biotechnology, Inc. |
High dose antibody therapies for sars-cov-2 infection
|
|
AU2023251832A1
(en)
|
2022-04-13 |
2024-10-17 |
F. Hoffmann-La Roche Ag |
Pharmaceutical compositions of anti-cd20/anti-cd3 bispecific antibodies and methods of use
|
|
WO2023210670A1
(ja)
|
2022-04-26 |
2023-11-02 |
中外製薬株式会社 |
医薬製剤含有フィルター内蔵シリンジ
|
|
US20240002491A1
(en)
|
2022-04-27 |
2024-01-04 |
Regeneron Pharmaceuticals, Inc. |
Methods for selecting patients for treatment with an ngf antagonist
|
|
EP4514389A1
(en)
|
2022-04-29 |
2025-03-05 |
Purinomia Biotech, Inc. |
Methods and compositions for treating eosinophil driven diseases and disorders
|
|
CA3257258A1
(en)
|
2022-05-03 |
2023-11-09 |
Genentech, Inc. |
Anti-Ly6E antibodies, immunoconjugates, and their uses
|
|
AU2022458320A1
(en)
|
2022-05-11 |
2024-11-28 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
|
WO2023230448A1
(en)
|
2022-05-23 |
2023-11-30 |
Vir Biotechnology, Inc. |
Combination immunotherapy for influenza
|
|
CN119907679A
(zh)
|
2022-05-23 |
2025-04-29 |
胡默波斯生物医学公司 |
针对流感神经氨酸苷酶的广谱中和抗体
|
|
WO2023235699A1
(en)
|
2022-05-31 |
2023-12-07 |
Jounce Therapeutics, Inc. |
Antibodies to lilrb4 and uses thereof
|
|
IL317449A
(en)
|
2022-06-07 |
2025-02-01 |
Genentech Inc |
Method for determining the efficacy of a lung cancer treatment comprising an anti-PD-L1 antagonist and an anti-TIGIT antibody-antagonist
|
|
WO2023245078A1
(en)
|
2022-06-15 |
2023-12-21 |
Humabs Biomed Sa |
Anti-parvovirus antibodies and uses thereof
|
|
WO2024006472A1
(en)
|
2022-06-30 |
2024-01-04 |
Vir Biotechnology, Inc. |
Antibodies that bind to multiple sarbecoviruses
|
|
MA71395A
(fr)
|
2022-07-08 |
2025-04-30 |
Regeneron Pharmaceuticals, Inc. |
Méthodes de traitement de l'oesophagite à éosinophiles chez un sujet pédiatrique par administration d'un antagoniste d'il-4 r
|
|
WO2024015816A1
(en)
|
2022-07-12 |
2024-01-18 |
Regeneron Pharmaceuticals, Inc. |
Antibodies to ciliary neurotrophic factor receptor (cntfr) and methods of use thereof
|
|
EP4554978A1
(en)
|
2022-07-13 |
2025-05-21 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
|
WO2024020057A1
(en)
|
2022-07-19 |
2024-01-25 |
Regeneron Pharmaceuticals, Inc. |
Genetically modified animal model and its use to model the human immune system
|
|
IL318252A
(en)
|
2022-07-19 |
2025-03-01 |
Genentech Inc |
Dosage for treatment with bispecific anti-FCRH5/anti-CD3 antibodies
|
|
CR20250056A
(es)
|
2022-07-22 |
2025-03-19 |
Genentech Inc |
Moléculas de unión al antígeno anti-steap1 y sus usos.
|
|
JP2025526405A
(ja)
|
2022-07-27 |
2025-08-13 |
ヒューマブス・バイオメッド・ソシエテ・アノニム |
Ｒｓｖ及びｍｐｖパラミクソウイルスに対する広域中和抗体
|
|
AU2023314808A1
(en)
|
2022-07-29 |
2025-03-20 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for transferrin receptor (tfr)-mediated delivery to the brain and muscle
|
|
AU2023312978A1
(en)
|
2022-07-29 |
2025-03-20 |
Regeneron Pharmaceuticals, Inc. |
Anti-tfr:payload fusions and methods of use thereof
|
|
EP4561703A1
(en)
|
2022-07-29 |
2025-06-04 |
Alector LLC |
Anti-gpnmb antibodies and methods of use thereof
|
|
WO2024026471A1
(en)
|
2022-07-29 |
2024-02-01 |
Alector Llc |
Cd98hc antigen-binding domains and uses therefor
|
|
EP4565329A1
(en)
|
2022-08-01 |
2025-06-11 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Monoclonal antibodies that bind to the underside of influenza viral neuraminidase
|
|
WO2024044770A1
(en)
|
2022-08-26 |
2024-02-29 |
Core Biotherapeutics, Inc. |
Oligonucleotides for the treatment of breast cancer
|
|
WO2024047021A1
(en)
|
2022-08-29 |
2024-03-07 |
Sanofi |
Methods for treating chronic inducible cold urticaria by administering an il-4r antagonist
|
|
WO2024049949A1
(en)
|
2022-09-01 |
2024-03-07 |
Genentech, Inc. |
Therapeutic and diagnostic methods for bladder cancer
|
|
WO2024054822A1
(en)
|
2022-09-07 |
2024-03-14 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Engineered sars-cov-2 antibodies with increased neutralization breadth
|
|
US20260078185A1
(en)
|
2022-09-07 |
2026-03-19 |
Dynamicure Biotechnology Llc |
Anti-vista constructs and uses thereof
|
|
WO2024073606A1
(en)
|
2022-09-28 |
2024-04-04 |
Regeneron Pharmaceuticals, Inc. |
Antibody resistant modified receptors to enhance cell-based therapies
|
|
WO2024073679A1
(en)
|
2022-09-29 |
2024-04-04 |
Regeneron Pharmaceuticals, Inc. |
Correction of hepatosteatosis in humanized liver animals through restoration of il6/il6r/gp130 signaling in human hepatocytes
|
|
WO2024077239A1
(en)
|
2022-10-07 |
2024-04-11 |
Genentech, Inc. |
Methods of treating cancer with anti-c-c motif chemokine receptor 8 (ccr8) antibodies
|
|
CN115724975A
(zh)
|
2022-10-20 |
2023-03-03 |
江苏荃信生物医药股份有限公司 |
抗人白介素36受体单克隆抗体及其应用
|
|
WO2024086796A1
(en)
|
2022-10-20 |
2024-04-25 |
Alector Llc |
Anti-ms4a4a antibodies with amyloid-beta therapies
|
|
TW202426505A
(zh)
|
2022-10-25 |
2024-07-01 |
美商建南德克公司 |
癌症之治療及診斷方法
|
|
EP4608865A1
(en)
|
2022-10-27 |
2025-09-03 |
Regeneron Pharmaceuticals, Inc. |
Anti-acvr1 antibodies and their use in the treatment of trauma-induced heterotopic ossification
|
|
WO2024097714A1
(en)
|
2022-11-01 |
2024-05-10 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating hand and foot dermatitis by administering an il-4r antagonist
|
|
EP4612184A1
(en)
|
2022-11-04 |
2025-09-10 |
Regeneron Pharmaceuticals, Inc. |
Calcium voltage-gated channel auxiliary subunit gamma 1 (cacng1) binding proteins and cacng1-mediated delivery to skeletal muscle
|
|
KR20250099702A
(ko)
|
2022-11-04 |
2025-07-02 |
길리애드 사이언시즈, 인코포레이티드 |
항-ccr8 항체, 화학요법 및 면역요법 조합을 사용하는 항암 요법
|
|
IL320397A
(en)
|
2022-11-07 |
2025-06-01 |
Regeneron Pharma |
Antibodies binding to the catalytic domain of factor XI and methods of using them
|
|
AU2023375342A1
(en)
|
2022-11-08 |
2025-04-24 |
F. Hoffmann-La Roche Ag |
Compositions and methods of treating childhood onset idiopathic nephrotic syndrome
|
|
WO2024100170A1
(en)
|
2022-11-11 |
2024-05-16 |
F. Hoffmann-La Roche Ag |
Antibodies binding to hla-a*02/foxp3
|
|
US20240158515A1
(en)
|
2022-11-14 |
2024-05-16 |
Regeneron Pharmaceuticals, Inc. |
Anti-fgfr3 antibodies and antigen-binding fragments and methods of use thereof
|
|
WO2024107765A2
(en)
|
2022-11-14 |
2024-05-23 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for fibroblast growth factor receptor 3-mediated delivery to astrocytes
|
|
WO2024112818A1
(en)
|
2022-11-22 |
2024-05-30 |
Humabs Biomed Sa |
Engineered anti-sars-cov-2 antibodies and uses thereof
|
|
WO2024112935A1
(en)
|
2022-11-23 |
2024-05-30 |
Regeneron Pharmaceuticals, Inc. |
Methods for improving bone growth by administering an il-4r antagonist
|
|
TW202440623A
(zh)
|
2022-11-28 |
2024-10-16 |
美商艾洛基因醫療公司 |
靶向密連蛋白１８﹒２之嵌合抗原受體及結合劑以及其用途
|
|
WO2024118998A2
(en)
|
2022-12-01 |
2024-06-06 |
Vir Biotechnology, Inc. |
Engineered anti-sars-cov-2 antibodies and methods of using the same
|
|
CN119546630A
(zh)
|
2022-12-08 |
2025-02-28 |
南京诺唯赞生物科技股份有限公司 |
特异性结合rsv的抗体
|
|
CN120693406A
(zh)
|
2022-12-12 |
2025-09-23 |
基因泰克公司 |
优化多肽唾液酸含量
|
|
EP4638491A1
(en)
|
2022-12-19 |
2025-10-29 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Monoclonal antibodies for treating sars-cov-2 infection
|
|
CN120380024A
(zh)
|
2022-12-21 |
2025-07-25 |
建新公司 |
抗pd-1×4-1bb结合蛋白
|
|
WO2024138000A1
(en)
|
2022-12-21 |
2024-06-27 |
Regeneron Pharmaceuticals, Inc. |
Prodrugs of topoisomerase i inhibitor for adc conjugations and methods of use thereof
|
|
WO2024138151A1
(en)
|
2022-12-22 |
2024-06-27 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Ebolavirus (sudan and zaire) antibodies from non-human primates and human vaccinees
|
|
IL321947A
(en)
|
2023-01-06 |
2025-09-01 |
Lassen Therapeutics Inc |
Anti-IL-11R antibodies – for the treatment of thyroid-related eye disease
|
|
WO2024148243A1
(en)
|
2023-01-06 |
2024-07-11 |
Lassen Therapeutics 1, Inc. |
Anti-il-18bp antibodies
|
|
CN120858108A
(zh)
|
2023-01-06 |
2025-10-28 |
拉森医疗公司 |
抗il-18bp抗体
|
|
WO2024148232A2
(en)
|
2023-01-06 |
2024-07-11 |
Alector Llc |
Anti-il18 binding protein antibodies and methods of use thereof
|
|
WO2024152014A1
(en)
|
2023-01-13 |
2024-07-18 |
Regeneron Pharmaceuticals, Inc. |
Fgfr3 binding molecules and methods of use thereof
|
|
IL321951A
(en)
|
2023-01-18 |
2025-09-01 |
Genentech Inc |
Multispecific antibodies and their uses
|
|
TWI897189B
(zh)
|
2023-01-18 |
2025-09-11 |
美商基利科學股份有限公司 |
具有經改變重鏈基因座之嵌合基因轉殖免疫球蛋白小鼠及其製造及使用方法
|
|
AU2024209384A1
(en)
|
2023-01-20 |
2025-06-26 |
F. Hoffmann-La Roche Ag |
Recombinant fc domain - il2 variant polypeptides and combination therapy with membrane-anchored antigen binding polypeptides
|
|
AR131856A1
(es)
|
2023-02-16 |
2025-05-07 |
Sanofi Sa |
Proteínas de unión a cd40
|
|
US20240299601A1
(en)
|
2023-02-17 |
2024-09-12 |
Regeneron Pharmaceuticals, Inc. |
Radiolabeled anti-lag3 antibodies for immuno-pet imaging
|
|
WO2024191785A1
(en)
|
2023-03-10 |
2024-09-19 |
Genentech, Inc. |
Fusions with proteases and uses thereof
|
|
US20240345083A1
(en)
|
2023-03-15 |
2024-10-17 |
Regeneron Pharmaceuticals, Inc. |
Methods for obtaining antibody molecules with high affinity
|
|
TW202502819A
(zh)
|
2023-03-22 |
2025-01-16 |
法商賽諾菲生物技術公司 |
藉由投予il-4r拮抗劑治療慢性阻塞性肺病(copd)之方法
|
|
TW202502820A
(zh)
|
2023-03-27 |
2025-01-16 |
美商再生元醫藥公司 |
藉由投予ｉｌ—４ｒ拮抗劑治療嗜酸性球性胃腸炎之方法
|
|
WO2024206788A1
(en)
|
2023-03-31 |
2024-10-03 |
Genentech, Inc. |
Anti-alpha v beta 8 integrin antibodies and methods of use
|
|
EP4688856A1
(en)
|
2023-04-03 |
2026-02-11 |
Regeneron Pharmaceuticals, Inc. |
Methods of improving transplant survival using il-2 receptor gamma chain antibodies
|
|
EP4687997A2
(en)
|
2023-04-05 |
2026-02-11 |
Sorrento Therapeutics, Inc. |
Antibody-drug conjugates and uses thereof
|
|
WO2024211235A1
(en)
|
2023-04-05 |
2024-10-10 |
Sorrento Therapeutics, Inc. |
Antibody-drug conjugates and uses thereof
|
|
WO2024211234A1
(en)
|
2023-04-05 |
2024-10-10 |
Sorrento Therapeutics, Inc. |
Antibody-drug conjugates and uses thereof
|
|
WO2024215762A1
(en)
|
2023-04-10 |
2024-10-17 |
Vir Biotechnology, Inc. |
Antibodies that bind to multiple sarbecoviruses
|
|
EP4696321A1
(en)
|
2023-04-14 |
2026-02-18 |
Chugai Seiyaku Kabushiki Kaisha |
Method for stabilizing protein-containing pharmaceutical preparation
|
|
CN121263210A
(zh)
|
2023-04-17 |
2026-01-02 |
沛科生物公司 |
抗体和抗体-药物偶联物以及使用方法和合成工艺及中间体
|
|
TW202448949A
(zh)
|
2023-05-05 |
2024-12-16 |
美商建南德克公司 |
用抗ｆｃｒｈ５／抗ｃｄ３雙特異性抗體進行治療之給藥
|
|
AU2024269754A1
(en)
|
2023-05-08 |
2025-10-23 |
F. Hoffmann-La Roche Ag |
Targeted interferon alpha fusion proteins and methods of use
|
|
IL324490A
(en)
|
2023-05-10 |
2026-01-01 |
Genentech Inc |
Methods and preparations for treating cancer
|
|
TW202509065A
(zh)
|
2023-05-16 |
2025-03-01 |
瑞士商赫孚孟拉羅股份公司 |
經ｐｄ－１調節之ｉｌ－２免疫結合物及其用途
|
|
CN121511261A
(zh)
|
2023-05-17 |
2026-02-10 |
国家健康与医学研究院 |
抗组织蛋白酶-d抗体
|
|
WO2024248867A1
(en)
|
2023-05-31 |
2024-12-05 |
Genentech, Inc. |
Methods of treating tgf beta-related disorders with anti-transforming growth factor beta 3 antibodies
|
|
AU2024304180A1
(en)
|
2023-06-13 |
2026-01-08 |
Adcentrx Therapeutics, Inc. |
Methods and compositions related to antibodies and antibody drug conjugates (adcs) that bind nectin-4 proteins
|
|
CN119143869A
(zh)
|
2023-06-16 |
2024-12-17 |
复旦大学 |
乙肝病毒表面抗体及其应用
|
|
CN121335619A
(zh)
|
2023-06-16 |
2026-01-13 |
瑞泽恩制药公司 |
载体、经基因修饰的细胞和包含其的经基因修饰的非人动物
|
|
WO2024263761A1
(en)
|
2023-06-22 |
2024-12-26 |
Genentech, Inc. |
Antibodies and uses thereof
|
|
TW202504929A
(zh)
|
2023-06-22 |
2025-02-01 |
美商建南德克公司 |
用於癌症治療之方法及組成物
|
|
WO2025010424A1
(en)
|
2023-07-06 |
2025-01-09 |
Vir Biotechnology, Inc. |
Antibodies against staphylococcus antigens and methods of using the same
|
|
WO2025012417A1
(en)
|
2023-07-13 |
2025-01-16 |
Institut National de la Santé et de la Recherche Médicale |
Anti-neurotensin long fragment and anti-neuromedin n long fragment antibodies and uses thereof
|
|
WO2025015321A1
(en)
|
2023-07-13 |
2025-01-16 |
Vir Biotechnology, Inc. |
Broadly neutralizing antibodies against rsv and mpv paramyxoviruses
|
|
CN121568964A
(zh)
|
2023-07-19 |
2026-02-24 |
里珍纳龙药品有限公司 |
抗因子XII/XIIa抗体及其用途
|
|
AR133384A1
(es)
|
2023-07-28 |
2025-09-24 |
Regeneron Pharma |
Anti-tfr:esfingomielinasa ácida para el tratamiento de la deficiencia de esfingomielinasa ácida
|
|
AU2024317483A1
(en)
|
2023-07-28 |
2026-01-29 |
Regeneron Pharmaceuticals, Inc. |
Anti-tfr:gaa and anti-cd63:gaa insertion for treatment of pompe disease
|
|
US20250136688A1
(en)
|
2023-08-07 |
2025-05-01 |
Janssen Biotech, Inc. |
Stabilized cd3 antigen binding agents and methods of use thereof
|
|
WO2025034715A1
(en)
|
2023-08-07 |
2025-02-13 |
Janssen Biotech, Inc. |
Gucy2c antibodies and uses thereof
|
|
WO2025032158A1
(en)
|
2023-08-08 |
2025-02-13 |
Institut National de la Santé et de la Recherche Médicale |
Method to treat tauopathies
|
|
WO2025049524A1
(en)
|
2023-08-28 |
2025-03-06 |
Regeneron Pharmaceuticals, Inc. |
Cxcr4 antibody-resistant modified receptors
|
|
WO2025049591A1
(en)
|
2023-08-28 |
2025-03-06 |
Regeneron Pharmaceuticals, Inc. |
Anti-cxcr4 antibodies and uses thereof
|
|
WO2025045251A2
(en)
|
2023-09-03 |
2025-03-06 |
Kira Pharmaceuticals (Us) Llc |
Multispecific constructs comprising anti-factor d moiety
|
|
WO2025064761A1
(en)
|
2023-09-22 |
2025-03-27 |
Regeneron Pharmaceuticals, Inc. |
Kras10-18 g12d off-target peptides and uses thereof
|
|
WO2025064738A1
(en)
|
2023-09-22 |
2025-03-27 |
Regeneron Pharmaceuticals, Inc. |
Dntt 250-258 off-target peptides and uses thereof
|
|
AR133909A1
(es)
|
2023-09-25 |
2025-11-12 |
Hoffmann La Roche |
ANTICUERPO QUE SE UNE A C3bBb
|
|
WO2025073890A1
(en)
|
2023-10-06 |
2025-04-10 |
Institut National de la Santé et de la Recherche Médicale |
Method to capture circulating tumor extracellular vesicles
|
|
US20250171516A1
(en)
|
2023-11-03 |
2025-05-29 |
Regeneron Pharmaceuticals, Inc. |
Peptide acids as a glp1r agonist and antibody-drug conjugates thereof
|
|
WO2025106474A1
(en)
|
2023-11-14 |
2025-05-22 |
Genentech, Inc. |
Therapeutic and diagnostic methods for treating cancer with anti-fcrh5/anti-cd3 bispecific antibodies
|
|
WO2025117384A1
(en)
|
2023-12-01 |
2025-06-05 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Broadly neutralizing influenza hemagglutinin stem-directed antibodies
|
|
TW202540200A
(zh)
|
2023-12-01 |
2025-10-16 |
美商基利科學股份有限公司 |
抗ｆａｐ－ｌｉｇｈｔ融合蛋白及其用途
|
|
WO2025125386A1
(en)
|
2023-12-14 |
2025-06-19 |
F. Hoffmann-La Roche Ag |
Antibodies that bind to folr1 and methods of use
|
|
WO2025133042A2
(en)
|
2023-12-22 |
2025-06-26 |
F. Hoffmann-La Roche Ag |
Activatable fusion proteins and methods of use
|
|
WO2025151806A1
(en)
|
2024-01-11 |
2025-07-17 |
Regeneron Pharmaceuticals, Inc. |
P75 neurotrophin receptor (p75ntr)-binding proteins and p75ntr-mediated delivery to the nervous system
|
|
TW202540428A
(zh)
|
2024-01-26 |
2025-10-16 |
美商雷傑納榮製藥公司 |
使用漿細胞耗乏劑及／或ｂ細胞耗乏劑遏制宿主抗ａａｖ抗體反應且實現ａａｖ轉導及重複給藥的方法及組成物
|
|
US20250263471A1
(en)
|
2024-01-30 |
2025-08-21 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating allergy using anti-bet v 1 antibodies
|
|
WO2025166042A1
(en)
|
2024-01-31 |
2025-08-07 |
Alector Llc |
Cd98hc antigen-binding domains and uses therefor
|
|
WO2025166040A1
(en)
|
2024-01-31 |
2025-08-07 |
Alector Llc |
Multi-specific binding proteins that bind to gpnmb and a blood brain barrier target and methods of use thereof
|
|
WO2025166045A1
(en)
|
2024-01-31 |
2025-08-07 |
Alector Llc |
β-GLUCOCEREBROSIDASE ENZYMES, FUSION PROTEINS AND COMPLEXES COMPRISING THE SAME, AND METHODS OF USE THEREOF
|
|
WO2025166077A1
(en)
|
2024-01-31 |
2025-08-07 |
Alector Llc |
Compositions comprising progranulin and uses thereof
|
|
WO2025171307A1
(en)
|
2024-02-08 |
2025-08-14 |
Regeneron Pharmaceuticals, Inc. |
Vectors, genetically modified cells, and genetically modified non-human animals comprising the same
|
|
WO2025171411A1
(en)
|
2024-02-09 |
2025-08-14 |
Herophilus, Inc. |
Compositions and methods related to modulating macrophage migration inhibitory factor (mif)-cd74 signaling and related treatments for neuroinflammatory conditions
|
|
WO2025179282A1
(en)
|
2024-02-23 |
2025-08-28 |
Flatiron Bio, Llc |
Antibodies targeting epstein-barr virus proteins and methods of use
|
|
WO2025194126A1
(en)
|
2024-03-15 |
2025-09-18 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Respiratory syncytial virus (rsv) g and f antibodies with high rsv-neutralizing potency
|
|
WO2025196639A1
(en)
|
2024-03-21 |
2025-09-25 |
Seagen Inc. |
Cd25 antibodies, antibody-drug conjugates, and uses thereof
|
|
WO2025202147A1
(en)
|
2024-03-27 |
2025-10-02 |
F. Hoffmann-La Roche Ag |
Interleukin-7 immunoconjugates
|
|
US20250388685A1
(en)
|
2024-04-15 |
2025-12-25 |
Sanofi Biotechnology |
Methods for treating chronic rhinosinusitis without nasal polyps by administering an il-4r antagonist
|
|
WO2025226808A1
(en)
|
2024-04-24 |
2025-10-30 |
Genentech, Inc. |
Compositions and methods of treating lupus nephritis
|
|
WO2025224297A1
(en)
|
2024-04-26 |
2025-10-30 |
Institut National de la Santé et de la Recherche Médicale |
Antibodies having specificity to tgfbi and uses thereof
|
|
WO2025235388A1
(en)
|
2024-05-06 |
2025-11-13 |
Regeneron Pharmaceuticals, Inc. |
Transgene genomic identification by nuclease-mediated long read sequencing
|
|
WO2025240335A1
(en)
|
2024-05-13 |
2025-11-20 |
Regeneron Pharmaceuticals, Inc. |
Fgfr3 binding molecules and methods of use thereof
|
|
WO2025250495A1
(en)
|
2024-05-28 |
2025-12-04 |
Regeneron Pharmaceuticals, Inc. |
Acceleration of human hepatocyte engraftment in humanized liver animals by supplementing paracrine ligands or agonists that activate human liver regeneration signals
|
|
US20260056209A1
(en)
|
2024-06-14 |
2026-02-26 |
Gilead Sciences, Inc. |
Anti-ccr8 antibodies and uses thereof
|
|
WO2025264572A1
(en)
|
2024-06-17 |
2025-12-26 |
Alector Llc |
Transferrin receptor antigen-binding domains and uses therefor
|
|
WO2025264533A1
(en)
|
2024-06-17 |
2025-12-26 |
Adcentrx Therapeutics Inc. |
Methods and compositions related to antibody drug conjugates (adcs) that bind steap-1 proteins
|
|
US20260000758A1
(en)
|
2024-06-28 |
2026-01-01 |
Regeneron Pharmaceuticals, Inc. |
Bispecific antigen binding molecules that bind gdf8 and activin a and uses thereof
|
|
WO2026006724A1
(en)
|
2024-06-28 |
2026-01-02 |
Regeneron Pharmaceuticals, Inc. |
Prame off-target peptides and uses thereof
|
|
WO2026006734A1
(en)
|
2024-06-28 |
2026-01-02 |
Regeneron Pharmaceuticals, Inc. |
Off-target peptide-mhc complex conformation modeling systems and methods for antigen-recognition molecule development
|
|
WO2026030464A1
(en)
|
2024-07-30 |
2026-02-05 |
Genentech, Inc. |
Dosage regimen for reducing cytokine release syndrome (crs) with anti-fcrh5/anti-cd3 bispecific antibodies in multiple myeloma therapy
|
|
WO2026030428A2
(en)
|
2024-08-01 |
2026-02-05 |
Regeneron Pharmaceuticals, Inc. |
Prostate-specific antigen peptides and uses thereof
|
|
WO2026035843A2
(en)
|
2024-08-06 |
2026-02-12 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals having modified immunoglobulin heavy chain constant region locus and uses thereof
|
|
WO2026039661A1
(en)
|
2024-08-15 |
2026-02-19 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals with humanized fc epsilon receptors that lack functional alpha-1, 3-galactosyltransferase (ggta1)
|
|
WO2026055183A1
(en)
|
2024-09-03 |
2026-03-12 |
Vir Biotechnology, Inc |
Antiviral compositions and methods of using the same
|
|
US20260070995A1
(en)
|
2024-09-09 |
2026-03-12 |
Marcella Ruddy |
Methods for treating bullous pemphigoid by administering an il-4r antagonist
|